

Beaumont Hospital Clinical Directorate of Laboratory Medicine

Guide to Use of Laboratory Services for GP/Nursing Home Users

Document Number: LP-GEN-0014 **Revision**: 15 **Active Date:** 25th April 2025 **Authorised By:** Prof. P. Thornton, Clinical Director of Laboratory Medicine

DEPARTMENTAL INFORMATION

<u>DEPARTMENT</u>	Information
Blood Transfusion	Clinical Guidelines Laboratory Information
Haematology & Coagulation & Flow Cytometry	Clinical Guidelines Laboratory Information
Chemical Pathology	Clinical Guidelines Laboratory Information
Immunology	Clinical Guidelines Laboratory Information
Microbiology	Clinical Guidelines Laboratory Information
Histopathology, Cytology, Neuropathology	Clinical Guidelines Laboratory Information
NHISSOT	Clinical Guidelines Laboratory Information

See next page for detailed table of contents.

1	INT	RODUCTION	6
	1.1	UPDATES OF USER'S HANDBOOK	6
2	TES	TING GUIDELINES	7
_	2.1	BLOOD TRANSFUSION & HAEMOVIGILANCE	
	2.2	HAEMATOLOGY	
	2.2.1	Thrombophilia Screening	
	2.2.2	Referral of Thrombophilia samples from an External Hospital	
	2.2.3	EŠR	
	2.2.4	Blood Film Examination	10
	2.2.5	Haematology Molecular Tests	10
	2.2.6	Clinical Advice & Laboratory Test Interpretation	11
	2.3	CHEMICAL PATHOLOGY	12
	2.4	Immunology	
	2.4.1	Rheumatoid Factor	
	2.4.2	Anti-Cyclic Citrullinated Peptide antibodies (CCP)	
	2.4.3	Connective Tissue Disease (CTD) Screen	
	2.4.4	Anti-Nuclear Antibodies (ANA) by immunofluorescence	
	2.4.5		
	2.4.6	Anti-Liver-Kidney Microsomal (LKM) Antibodies	
	2.4.7	\mathcal{F}	
		Anti-Gastric-Parietal Cell Antibodies (Anti-GPC)	
	2.4.9		
		Anti- Tissue Transglutaminase Antibodies (anti-tTG)	
		IgA Anti-Endomysial Antibodies (EMA)	
		Allergen Specific IgE	
		R Acute Allergic Reaction Investigation – Beaumont GP Service only	
		Anti-Streptolysin-O Titre (ASOT)	
		MICROBIOLOGY	
	2.5.1	General Sample Collection Guidelines	
	2.5.2	Guidelines for Routine Specimens	
	2.5.3	Serological Investigations	
	2.6 2.6.1	Current Best Practice for Renal Biopsies	
	2.6.2	· · · · · · · · · · · · · · · · · · ·	
	2.6.3	Handling of Tissue after Biopsy has been taken	
	2.0.3	NHISSOT	
3		SORATORY SERVICES PROVIDED	
	3.1	GENERAL INFORMATION	
	3.1.1	Location of Department	
	3.1.2	Contacting the Department/Telephone Numbers	
	3.1.3	Department Opening Hours	
	3.1.4	Consent	
	3.1.5	Specimen Collection Guidelines & Order Of Draw	5 /

	3.1.6	Specimen Labelling	64
	3.1.7	Specimen Request Forms	66
	3.1.8	Specimen Acceptance Criteria	68
	3.1.9	Specimen Tubes & Containers	70
	3.1.10	Delivery of Specimens for Analysis	72
		Specimen Reception Process	
	3.1.12	Test Results	73
	3.1.13	Telephoning GP/Results Out of Hours	76
		Attendance at Phlebotomy:	
	3.1.15	Specimen Referral	77
	3.1.16	Specimen Transportation Guidelines	78
	3.1.17	Specimen Storage Conditions	79
		Data Protection Policy	
	3.1.19	Placing Patient Information in the Public Domain	81
	3.1.20	Time Limits for Requesting Additional Examinations	81
	3.1.21	Repeat Examination due to Analytical Failure	81
	3.1.22	Uncertainty of Measurement (MOU)	82
	3.1.23	Accreditation/Quality Standards	82
		Complaints	
	3.1.25	Open Disclosure	83
3	.2	HAEMATOLOGY	84
	3.2.1	Repertoire of Haematology Tests	84
	3.2.2	Repertoire of Coagulation Tests	86
	3.2.3	Repertoire of Haematology Molecular Tests	90
	3.2.4	Requests for Additional Analysis	92
	3.2.5	Critical Values	92
3	.3	CHEMICAL PATHOLOGY	. 94
	3.3.1	Services Offered	94
	3.3.2	Contact Details for Medical / Clinical Advice	94
	3.3.3	Requests for Additional Tests	94
	3.3.4	Therapeutic Drug Monitoring (TDM) samples	95
	3.3.5	Tumour Marker Analysis	
	3.3.6	Externally Referred Tests	95
	3.3.7	Fertility Clinics	96
	3.3.8	Critical phoning limits	96
	3.3.9	Urinary Catecholamines and Metabolites Reference Ranges:	117
	3.3.10	Plasma Metanephrine Reference Ranges 1	118
		rinology Reference Ranges1	
3	.4	IMMUNOLOGY	120
	3.4.1	Clinical Service	120
		Laboratory Service	
	3.4.3	Repertoire of Tests & Test Profiles	121
3	.5	<u>. </u>	125

	3.5.1	Repertoire of Test Services (currently outsourced to Biomnis Eurofins	for
		Microbiological examination)	. 125
	3.5.2	General Notes	. 130
	3.5.3	Key Factors Affecting Turn Around Times:	. 130
	3.5.4	Samples sent to External Laboratories e.g., NVRL for analysis	. 131
	3.5.5	Abbreviations Used on Microbiology Reports	
	3.5.6	Time Limits for Requesting Additional Tests:	. 131
3.	6	HISTOPATHOLOGY/CYTOPATHOLOGY/NEUROPATHOLOGY	. 132
	3.6.1	Frozen Sections	. 132
	3.6.2	Other Urgent Specimens	. 133
	3.6.3	Reports	. 133
	3.6.4	Specimen Requirements For Histopathology	. 133
	3.6.5	REQUIREMENT FOR EXTERNAL CENTRES	
	3.6.6	Factors Affecting Fresh/Unfixed Tissue Specimens	. 136
	3.6.7	Turn Around Time for Results	
	3.6.8	Cytopathology Specimen Requirements	
	3.6.9	Specimen Requirements for Renal Pathology	
	3.6.10	Renal Pathology Requirements for External Centres	
		Urgent Renal Biopsies for Rapid Processing	
		Electron Microscopy	
		Specimen Requirements for Neuropathology	
		Autopsy Services (Post Mortems)	
3.		NHISSOT	
	3.7.1	How to Order Tests	
	3.7.2	Repertoire of Tests	
	3.7.3	HLA Typing of Patients for Solid Organ Transplantation	
	3.7.4	Antibody Screening	
	3.7.5	Solid Organ Transplant Pools Work-Up	
		Deceased Donor Work-up and Potential Recipient List Generation	
		Matchability Scores	
	3.7.8	Living Donor Work-Up	
	3.7.9	Crossmatching for Solid Organ Transplantation	
		Post Transplant Monitoring	
	3.7.11	HLA Typing for Partners of Recipients	. 160
		ABO blood group typing	
		Out of Hours services (On-Call)	
		Data Protection Act and freedom of information	
		Reports Issued/Expected Turn Around Times (TAT)	
		Abbreviations on H&I Reports and Printouts	
		RENAL/PANCREATIC TRANSPLANT POOL PRINTOUT ABBREVIATIONS	
		1 Crossmatch Codes	. 163 163

Document Number: LP-GEN-0014

I INTRODUCTION

This user guide is designed to enable Laboratory users to obtain the maximum benefits from the services provided by the Clinical Directorate of Laboratory Medicine in Beaumont Hospital.

The information provided is a broad guideline to the use of more commonly used tests. However the Consultant Pathologists and staff of the individual Laboratory Departments are always happy to discuss the service & individual patients in more detail.

1.1 UPDATES OF USER'S HANDBOOK

This Handbook is available on the Hospitals Internet site, and will be updated on a regular basis. If you have any suggestions for improvements please contact the Laboratory Manager or Quality Manager.

Please note the most up to date version of this manual will be available online. It is policy within the Clinical Directorate of Laboratory Medicine to notify external users of updates to this manual by email.

Changes between revisions of the user guide will be highlighted in grey text to alert users of changed information.

2 TESTING GUIDELINES

2.1 BLOOD TRANSFUSION & HAEMOVIGILANCE

Beaumont Hospital Blood Transfusion Department is fully licensed by the Health Products Regulatory Authority (HPRA). The Blood Transfusion Department is also accredited to ISO 15189 by the Irish National Accreditation Board (INAB). It incorporates the Blood Transfusion Laboratory, the Haemovigilance Office and Traceability functions.

The department supplies blood components and blood products on site to patients and red blood cells to off-site Beaumont Hospital patients in St Joseph's Raheny. It also supplies red cells to St Francis Hospice (Raheny & Blanchardstown) and to St Luke's Radiation and Oncology Centre on Beaumont Hospital campus.

NOTE: Specimens from external sources such as G.P's and nursing homes do not satisfy National Blood Users Group guidelines for minimum patient identification of three unique identifiers' for positive patient identification. It is only patients in attendance of Beaumont Hospital that may have blood group requests processed. It may be possible to have a blood group request processed by the Irish Blood Transfusion Service (IBTS) or by a private company (e.g Claymon Laboratories). Please refer to these services directly.

Service provision hours and contact details:

- Routine hours: 8am to 5pm Monday to Friday, 9am to 1pm Saturday. Ext: 2705
- Emergency out of hours: 5pm to 8am Monday to Friday, 1pm Saturday to Monday 8am. Bleep: 252

Contact details:

 Consultant Haematologist: Dr Philip Murphy Email: philipmurphy@beaumont.ie

• Chief Medical Scientist: Janice O Shaughnessy. Ext: 2705 Email: janiceoshaughnessy@beaumont.ie

• Haemovigilance. Ext: 2034

Email: haemovigilance@beaumont.ie

2.2 HAEMATOLOGY

2.2.1 Thrombophilia Screening

Beaumont Hospital's specialist coagulation laboratory has a test repertoire which includes **Inherited Thrombophilia Screens**, **Lupus Anticoagulant**, **Clotting Factor Assays and von Willebrand Screens**. In the majority of cases, patients do not meet the clinical criteria for testing.

When there is a clinical indication for testing, specialist interpretation is required so that patients can be counselled appropriately, and the ability to interpret these tests correctly requires knowledge of the clinical scenario.

The Hematology Department has introduced a demand management protocol to limit access to these specialised tests.

From 1St May 2023 onwards General Practitioners will no longer be able to request the following tests directly:

- Inherited Thrombophilia Screen (Antithrombin, Protein C, Protein S,
- Activated Protein C Resistance (+/-Factor V Leiden Mutation if required)
- Lupus Anticoagulant

Testing will be reserved for specific patients who are deemed to meet the clinical criteria after being reviewed and sanctioned by the Haematology team.

If you believe your patient meets the criteria for testing, they should be referred to the relevant specialist, e.g.:

- If you suspect your patient has a bleeding disorder or an inherited thrombophilia, they can be referred to Dr Karl Ewins' Specialist Coagulation Clinic (Department of Haematology).
- If the patient has a family member with a known bleeding disorder who already attends the National Coagulation Centre (NCC) in St James's Hospital, they should be referred directly to the NCC for family screening.
- Please note that Antiphospholipid Syndrome is <u>not</u> an inherited disorder, so family screening is not required.
- Please note that recurrent miscarriage is <u>not</u> an indication for inherited thrombophilia testing and such requests will not be processed.

If you believe your patient warrants <u>urgent</u> investigation, please contact the Haematology Registrar on consults via Beaumont Hospital switch 01-8093000.

The current national thrombophilia laboratory testing guideline can be accessed at:

https://www.hse.ie/eng/about/who/cspd/ncps/pathology/resources/national%20laboratory%20handbook.html

WHAT SAMPLES ARE REQUIRED IF APPROVED?

- Complete the Request Form with the Patient's name, DOB, unique Number, Ward/Location and Thrombophilia Screen requested
- Include patient relevant clinical information on the form
- Include anticoagulant status.
- Date and sign
- Take FOUR 2.9 mL Tri-sodium citrate 9NC (green) samples and
- Take ONE 2.6 mL EDTA (pink) sample
- Send the samples to the Coagulation Laboratory
- **Please note:** Anti Cardiolipin Antibodies are processed by Immunology and are not part of this screen.
- If a patient is on anticoagulation at the time of testing, certain assays within the Thrombophilia profile may be rejected, see above.

2.2.2 Referral of Thrombophilia samples from an External Hospital

If sending Separated Samples:

Plasma samples must be separated by a double centrifugation procedure according to the following instruction in order to prepare platelet poor plasma (plt< 10×10^9 /L).

• Frozen samples must be sent in appropriate frozen transport containers. All samples must remain in these containers.

2.2.3 *ESR*

ESR

The clinical Haematology team have listed the following conditions as the only times an ESR is indicated. In all other cases, C - reactive protein (CRP) is the preferred test.

- Giant cell arteritis, Temporal arteritis
- Polymyalgia rheumatica.
- 'Suspected myeloma'
- Hodgkins Lymphoma
- Prosthetic joint infection,

- Osteomyelitis,
- Rheumatoid Arthritis

2.2.4 Blood Film Examination

All FBCs are screened to see if a blood film will be of benefit to the patient/clinician. If the FBC results and instrument flags obtained meet the criteria required for blood film examination as set down by the Haematology Consultants, a film will be examined irrespective of whether one was ordered or not.

All FBCs with results/flags which do not meet these criteria will not have a blood film added on unless clinical details are provided. The following comment will be added in such instances 'Due to the volume of FBC and blood film requests received form GP practices, blood film requests will no longer be processed unless they meet the laboratory criteria for blood film examination as set down by the Haematology Consultant.'

2.2.5 Haematology Molecular Tests

- <u>All requests</u> for Haematology Molecular testing will not be processed unless accompanied by the fully completed request form, <u>Thrombophilia</u> <u>Request form HAEMC-LF-023</u> or Haemochromatosis Genetic Screening request form HAEMC-LF-077 available on the intranet.
- Changes to genetic consent for all haematology molecular tests (HFE, Fator V Leiden and PT mutation). From the 04/07/2022, the laboratory will no longer take receipt or store the form containing patient genetic consent. It is the responsibility of the ordering clinician to obtain and file a copy of genetic consent in the patient's record.
- A new form HAEMP-LF-003 "Haematology Genetic Consent Form" is available on the Beaumont Hospital Internet/Intranet site and must be printed and kept in the patient's record by the ordering clinician.

If this form is received in the lab it will be disposed and not returned to the sender.

2.2.5.1 Haemochromatosis Testing

Due to the significant increase in orders for Haemochromatosis HFE genotypes, the Haematology Department is introducing a demand management protocol to address unnecessary ordering of this test. From the 04/07/2022 all HFE test requests **must** fulfill the following criteria:

- Testing of adult siblings (brothers and sisters) and <u>adult</u> offspring of **p.C282Y homozygotes** is recommended owing to increased risk of p.C282Y homozygosity and related increased morbidity. **Please indicate** on the form if there is a First Degree Relative (SIBLING/PARENT) with p.C282Y homozygosity. Stating both relationship and genotype.
- The results of iron studies: Iron, Ferritin and Transferrin Saturation (%) are available and meet certain criteria. <u>In particular</u>, the Transferrin Saturation should be raised (> 45%).
- It is required to confirm elevated Transferrin Saturation on <u>two</u> occasions before HFE genetic diagnosis testing.
- Note: if Transferrin Saturation <45% and/or no first degree relative with p.C282Y homozygosity, the sample will not be processed.
- Samples must be sent to the laboratory with the updated form *HAEMC-LF-077* "Haemochromatosis Genetic Screening Request Form" Version 3. If any form other than this version is sent to the laboratory, the samples will be rejected and not processed.

Note: these guidelines are formed in line with Best Practice Guidelines "EMQN best practice guidelines for the molecular genetic diagnosis of hereditary haemochromatosis (HH) European Journal of Human Genetics (2016) 24, 479–495".

2.2.6 Clinical Advice & Laboratory Test Interpretation

Interpretation of Laboratory Tests / procedures may be obtained by phoning any of the telephone numbers in section 3.1.2 and asking for the Chief Medical Scientist or by requesting a senior member of staff 09:00- 17:00 Mon-Fri excluding Bank Holidays

Document Number: LP-GEN-0014	Revision 15
2.3 CHEMICAL PATHOLOGY	
See section 3.3 below	

2.4 IMMUNOLOGY

Information on the tests available to order via Healthlink by Beaumont GPs is given below. Other tests performed in the Immunology department may be ordered by GPs once pre-approved by a named Beaumont Consultant. This must be noted on the Healthlink request form in order for the sample to be processed. The Immunology laboratory does not offer a referral service for GPs for tests not performed in-house. The assays available on Healthlink are:

Order Name	Components	
Acute Allergic Reaction Investigation	As per clinical details provided by clinician.	
Specific IgE: House dust mite (d1)	n/a	
Specific IgE: Grass Pollen Mix 1	n/a	
Specific IgE: Tree Pollen Mix	n/a	
Specific IgE: Cat dander	n/a	
Specific IgE: Dog dander	n/a	
Anti-Tissue Transglutaminase Antibodies (IgA)	n/a	
Connective Tissue Disease Screen (CTD)	n/a	
Anti-Streptolysin O Titre	n/a	
Rheumatoid Arthritis Antibodies	Anti-Cyclic Citrullinated Peptide Antibody	
	Rheumatoid Factor	
Pernicious Anaemia Antibodies	Anti-Gastric Parietal Cell Antibodies	
	Anti-Intrinsic Factor Antibodies	
Liver Disease Associated Antibodies	Anti-Nuclear Antibodies	
	Anti-Smooth Muscle Antibodies	
	Mitochondrial Antibodies	
	Anti-Liver Kidney Microsomal Antibodies	

2.4.1 Rheumatoid Factor

INDICATIONS

- Inflammatory arthritis
- Suspected vasculitis
- Interstitial lung disease
- Pleural/pericardial effusions

INTERPRETATION OF RESULTS

<u>Negative rheumatoid factor, <14 IU/mL:</u> A negative Rheumatoid factor makes diagnosis of Rheumatoid disease less likely, however as 10% of patients are RF negative, it does not exclude this diagnosis. Where there is a strong clinical suspicion of Rheumatoid Disease anti-CCP should be ordered.

Weak positive, 14-70 IU/mL: Some patients with Rheumatoid Disease will be only weakly positive and will fall into this range. However at this level Rheumatoid Factor is not specific for a diagnosis of Rheumatoid disease and a number of patients with weakly positive Rheumatoid Factor will have other inflammatory conditions. Anti-CCP will automatically be ordered and this will give more specific information. We generally suggest that you repeat the test in approximately 3-6 months time if clinical symptoms have persisted and only RF is positive. In Rheumatoid disease the assay should remain consistently positive, or may even be more strongly positive. However infection induced Rheumatoid Factor usually clears within weeks following successful treatment of the infection.

<u>Significantly positive rheumatoid factor, 71-250 IU/mL:</u> In an appropriate clinical setting a significantly positive Rheumatoid Factor is consistent with diagnosis of Rheumatoid disease. Anti-CCP will automatically be ordered.

Strongly positive rheumatoid factor, >250 IU/mL: Strongly positive Rheumatoid Factor is suggestive of Rheumatoid disease. The presence of a high level of Rheumatoid Factor at presentation is considered an adverse prognostic marker. Patients with Sjogren's syndrome may have very high levels of RF despite only minor joint symptoms. Occasionally a similar level may be seen in patients with cryoglobulinaemia and if features suggestive of this disorder are present an appropriate sample should be sent to the Proteins Laboratory in Clinical Chemistry. Anti-CCP will automatically be ordered.

Serial measurement of Rheumatoid factor is generally not useful in monitoring the response to therapy. Measurement of acute phase reactants e.g. CRP is more useful.

2.4.2 Anti-Cyclic Citrullinated Peptide antibodies (CCP)

INDICATIONS

- Inflammatory Arthritis
- Interstitial lung disease
- Suspected extra-articular rheumatoid disease

INTERPRETATION OF RESULTS

If result is <7 U/ml = Negative CCP

Anti-CCP has a sensitivity of 80% for detection of Rheumatoid arthritis (RA). It appears less sensitive for detection of extra-articular disease. If RA is strongly suspected, RF should be measured, as at least 10% of RA patients are negative for CCP, but positive for RF.

If result is 7 - 10 U/ml = Equivocal

If patient has evidence of an inflammatory arthropathy, suggest referral to Consultant Rheumatologist.

If result is >/= 11 U/ml = Positive CCP

Anti-CCP antibodies appear to be relatively specific for rheumatoid disease (Specificity 96%). Suggest referral to Consultant Rheumatologist

To date it is unclear whether monitoring changes in anti-CCP antibody levels is helpful. However, given that the half-life of IgG is 3 weeks, we do not recommend repeat testing more frequently than 3-monthly.

2.4.3 Connective Tissue Disease (CTD) Screen

INDICATIONS

- Inflammatory arthritis
- Suspected vasculitis/ connective tissue disease
- Photosensitive/other typical skin rash
- Pleural/pericardial effusions.
- Query autoimmune haemolytic anaemia, ITP, leucopenia
- Renal impairment, proteinuria, haematuria
- Unexplained CNS disease

The CTD Screen by EliA was introduced in February 2014 as an alternative method for the detection of anti-nuclear antibodies (also referred to as ANA). The CTD screen tests for anti-DNA and clinically relevant anti-ENA such as anti-Ro, anti-La, anti-Sm, and anti-RNP. For assessment of liver autoimmune diseases, the liver antibodies panel is recommended and the ANA component of this panel will remain tested using immunofluorescence (IIF) method in the Liver Disease Associated Antibodies panel In patients with negative CTD screen but strong clinical suspicion please liaise with lab as ANA by immunofluorescence is available if clinically indicated.

In most cases, a positive CTD screen result would also yield a positive result for anti-DNA and/or anti-ENA. The lab will automatically test for anti-DNA and anti-ENA on all equivocal & positive CTD screen results.

Once a diagnosis of connective tissue disease has been made, repeated measurement of CTD screen is rarely helpful in monitoring disease activity.

INTERPRETATION OF CTD RESULTS

If CTD screen is negative, connective tissue disease is unlikely.

If CTD screen is positive or equivocal, follow on testing for anti-ENA and anti-DNA will be done.

2.4.4 Anti-Nuclear Antibodies (ANA) by immunofluorescence

INDICATIONS

- Autoimmune liver disease
- Suspected vasculitis/ connective tissue disease**

ANA (also known as anti-nuclear antibody) is one of the main serological markers for autoimmune hepatitis and most data in the literature is based on the immunofluorescence method. Therefore we have retained the immunofluorescence method (using Hep2 cells as substrate) as the ANA method in the Liver Disease Associated Antibodies panel.

**From February 2014, we introduced the CTD screen by EliA as the method for the detection of anti-nuclear antibodies for connective tissue disease and vasculitis screens. Please refer to section above for information on CTD screen.

INTERPRETATION OF RESULTS

<u>Negative ANA:</u> ANA is the commonest autoantibody found in autoimmune hepatitis but a negative ANA does not exclude the diagnosis.

<u>Positive ANA (titre >1:80)</u>: A positive ANA is one of the serological markers for autoimmune hepatitis. Results should be interpreted within the context of clinical history, imaging and other laboratory parameters.

PATTERNS OF ANA

Both the homogenous and the speckled pattern are commonly seen in patients with autoimmune hepatitis. Anti-nucleolar pattern which is typically associated with scleroderma, is also frequently seen in autoimmune hepatitis.

Anti-Centromere antibody pattern is seen in about 13% of patients with primary biliary cirrhosis (also known as primary biliary cholangitis/PBC). Anticentromere antibody is also typically found in CREST syndrome (Calcinosis, Raynaud's phenomenon, Oesophageal dysmotility, Sclerodactyly & Telangiectasia).

2.4.5 Anti-Smooth Muscle Antibodies

INDICATIONS

- Persistently abnormal Liver Function Tests
- Other signs of chronic liver disease
- Investigation of hypergammaglobulinaemia

INTERPRETATION OF RESULTS

Negative: Normal result

<u>Weak Positive 1/40:</u> Weak positive anti-smooth muscle antibody is of doubtful clinical significance. Common in the elderly or in patients with infection/inflammation of any cause.

Positive 1/80: Weak positive value, not specific for autoimmune hepatitis.

<u>Positive 1/160:</u> Moderate positive value is consistent with but not specific for autoimmune hepatitis. Other causes of liver disease should be excluded.

Strong Positive 1/320 or greater: Strongly positive value is suggestive of autoimmune hepatitis.

2.4.6 Anti-Liver-Kidney Microsomal (LKM) Antibodies

<u>Note:</u> When IIF results demonstrate an anti-LKM antibody, the specificity of this result is confirmed by an immunoblotting system using the specific antigen cytochrome P450.

INDICATIONS

- Persistently abnormal Liver Function Tests
- Other signs of chronic liver disease
- Investigation of Hypergammaglobulinaemia

Type II autoimmune hepatitis (associated with LKM antibodies) can progress rapidly. The history is often considerably shorter than with Type I autoimmune hepatitis, which is much more common and associated with the presence of antismooth muscle antibodies.

INTERPRETATION OF RESULTS

Negative: No serological evidence of type II autoimmune hepatitis.

<u>Positive IIF, Positive Immunoblot:</u> The presence of anti-LKM antibodies is associated with type II autoimmune hepatitis or hepatitis C. The titre of the

antibody is not helpful in distinguishing these disorders, and hepatitis serology should be performed.

<u>Positive IIF, Negative Immunoblot:</u> There are a small number of antibodies which generate a pattern (positivity) on IIF which is indistinguishable from LKM antibodies, but the staining is due to binding to antigens other than cytochrome P450. Such antibodies include anti-endoplasmic reticulin antibodies. The clinical significance, if any, of such antibodies is uncertain.

Serial measurement of anti-LKM titre can be useful in monitoring a patient's response to therapy.

Because of the rapidity with which Type II autoimmune hepatitis progresses, it is departmental policy to telephone clinicians when a new positive result is detected and contact details are available.

2.4.7 Anti-Mitochondrial Antibody & M2 subtyping

All newly detected anti-mitochondrial antibodies are tested for reactivity to pyruvate dehydrogenase (M2 subtype) using an ELISA system. M2 type anti-mitochondrial antibodies are highly specific for primary biliary cirrhosis (also known as primary biliary cholangitis/PBC).

INDICATIONS

- Persistently abnormal Liver Function Tests
- Other signs of chronic liver disease
- Investigation of hypergammaglobulinaemia
- Pruritis

Interpretation Of Results

Negative: Normal value

<u>Positive IIF, Positive M2:</u> Suggestive of PBC. Occasionally may be seen in undifferentiated connective tissue disease. The titre of the anti-mitochondrial antibody is usually high (1/320 or greater). However even when the antimitochondrial antibody titre is lower, detection of the M2 subtype is suggestive of PBC. Occasionally M2 positive anti-Mitochondria can be seen in undifferentiated Connective Tissue Disease

<u>Positive IIF, Negative M2:</u> The IIF pattern of staining is frequently atypical (less granular than an M2 type, and with different staining of tissues). This combination of results is not specific for PBC, and may be seen in a wide variety of conditions including undifferentiated connective tissue disease, antiphospholipid syndrome, infections and other inflammatory conditions.

Note: When an anti-mitochondrial antibody is present granular staining of mitochondria in the liver, kidney tubules and gastric parietal cells is seen. In the presence of a strong anti-mitochondrial antibody, it is not possible to exclude the presence of an anti-gastric-parietal cell antibody, which is obscured.

2.4.8 Anti-Gastric-Parietal Cell Antibodies (Anti-GPC)

INDICATIONS

- Low B12
- Macrocytic anaemia
- Suspected subacute combined degeneration of the spinal cord

Interpretation Of Results

Negative: Normal value

<u>Positive</u>: Anti-GPC antibodies are present in about 90% of people with atrophic gastritis or pernicious anaemia, however these antibodies are relatively non-specific. Anti-GPC antibodies are present in 20% of relatives of patients with pernicious anaemia, 20% of patients with other autoimmune endocrine disease, as well as 25% of patients with iron deficiency anaemia. They are also present in 16% of females over the age of 60 years. It is recommended that vitamin B12 levels be checked. Sera in which anti-GPC antibodies are found are automatically tested for antibodies to intrinsic factor.

<u>Obscured:</u> When an anti-mitochondrial antibody is present granular staining of mitochondria in the liver, kidney tubules and gastric parietal cells is seen. In the presence of a strong anti-mitochondrial antibody, it is not possible to exclude the presence of an anti-gastric-parietal cell antibody, which is obscured. If pernicious anaemia is suspected, an anti-intrinsic factor antibody should be requested.

2.4.9 Anti-Intrinsic Factor Antibodies

INDICATIONS

- Low B12
- Macrocytic anaemia
- Suspected subacute combined degeneration of the spinal cord

INTERPRETATION OF RESULTS

In September 2020 we changed the method for anti-intrinsic factor antibodies from ELISA to EliA. The Intrinsic Factor assay will continue to be reported qualitatively with the introduction of an equivocal range in addition to negative & positive. Interpretative comments will be added on all reports.

<u>Negative</u>: Negative anti-Intrinsic Factor antibody does not exclude a diagnosis of pernicious anaemia, as this antibody is only found in approximately 60% of subjects with pernicious anaemia.

<u>Equivocal</u>: The clinical significance of intrinsic factor results that fall in the equivocal range is uncertain. Correlation with clinical history and B12 level is advised.

<u>Positive</u>: Positive result is suggestive of pernicious anaemia, and measurement of vitamin B12 is recommended. Patients with a normal vitamin B12 may have latent pernicious anaemia, and follow-up with at least annual measurement of Vitamin B12 level is recommended.

2.4.10 Anti- Tissue Transglutaminase Antibodies (anti-tTG)

Please note that anti-tTG is the appropriate screening test for coeliac disease. Equivocal or positive sera will be automatically tested for anti-endomysial antibodies. Our assay and reference ranges have been extensively validated internally, to ensure that an appropriately low threshold for triggering anti-endomysial antibody testing is in place.

INDICATIONS

- Suspected coeliac disease
- Malabsorption (including low iron, Vit B12 or albumin)
- Anaemia
- Gastrointestinal symptoms
- Trisomy 21 syndrome (increased risk of coeliac disease)
- IDDM (increased risk of coeliac disease)
- Dermatitis Herpetiformis
- Osteoporosis & Osteomalacia

- Peripheral Neuropathy
- Unexplained Infertility
- Unexplained weight loss

In addition to classical presentations with GI symptoms and malabsorption, coeliac disease is found in about 3.4% of those with osteoporosis, 12% of those with Type I diabetes mellitus and up to 1% of the general population.

tTG has been identified as the target antigen against which anti-EMA is directed. The anti-tTG EliA is used as an initial screening test and all equivocal/positive sera will be further tested for EMA antibodies. IgA deficiency is excluded by using the background reading on the EliA or measurement of total IgA. Total IgA is measured on all children with a negative TTG. In cases of IgA deficiency, IgG EMA testing or other IgG serological testing is performed. Anti-tTG has a high sensitivity for untreated coeliac disease, while the anti-endomysial antibody is more specific. Sequential testing offers optimal diagnostic utility.

Please refer to NCPP Serological Testing for Coeliac Disease Guideline from National Laboratory Handbook for further guidance available on www.beaumont.ie.

INTERPRETATION OF RESULTS

<u>Negative (<4 U/ml):</u> Coeliac disease unlikely if the patient is on a normal diet. If clinical suspicion is high, should be repeated in 3-6 months, ensuring that the patient is on a diet with a normal gluten content.

<u>Equivocal 4-10 U/ml:</u> All equivocal results will be further tested for IgA anti-EMA.

<u>Positive >10 U/ml:</u> Suggestive of Coeliac Disease. However false positives may occur therefore all samples with positive anti-tTG by EliA will be further tested for EMA antibodies by indirect immunofluorescence.

2.4.11 IgA Anti-Endomysial Antibodies (EMA)

INDICATIONS

- Positive anti-tTG (automatically added as reflex test)
- Biopsy suggestive of coeliac disease, despite negative tTG**
- Strong clinical suspicion of coeliac disease, despite negative tTG**

** Discussion with clinical team essential to have test performed for these indications.

In patients with normal levels of IgA, IgA anti-endomysial antibodies are more than 90% sensitive (up to 98% sensitive in some studies) and relatively specific

(>95%) for coeliac disease. When an anti-endomysial antibody request is received in this laboratory, we also measure IgA levels to exclude IgA deficiency. If IgA deficiency is identified serum is sent to the Proteins Laboratory in Clinical Chemistry for further assessment of immunoglobulins.

IgA deficiency is present in about 1:30 patients with coeliac disease (and about 1:600 of the general population). When IgA deficiency is present serology is less helpful in assessing the likelihood of coeliac disease. However in patients with IgA deficiency we perform an IgG anti-endomysial antibody which if strongly positive is suggestive of coeliac disease.

INTERPRETATION OF RESULTS

<u>Negative IgA anti-endomysial antibodies:</u> Coeliac disease is unlikely if patient is on a normal diet. However false negative results may be seen in IgA deficiency, and also in patients on a gluten free diet. The clinical significance of a negative EMA in a patient with a positive anti-tTG is uncertain, however an expert GI opinion should be sought in this situation, as biopsy may still be indicated.

Positive IgA anti-endomysial antibodies: Suggestive of coeliac disease

<u>Negative IgA anti-endomysial antibodies, Low IgA:</u> In this setting, negative anti-endomysial antibody does not exclude coeliac disease. If there is a high clinical suspicion of coeliac disease, or if the IgG anti-endomysial antibody is strongly positive, biopsy is indicated.

Negative IgA and IgG anti-endomysial antibodies, Low serum IgA: The negative predictive value of serology in this setting is not well established, and if there is a strong clinical suspicion of coeliac disease, biopsy is necessary to exclude coeliac disease.

If a low IgA is detected, serum is sent to the Proteins Laboratory in Clinical Chemistry for immunoglobulins and SPEP. This is to exclude a more extensive hypogammaglobulinaemia. However patients with isolated IgA deficiency are at risk of infections, allergy and autoimmune disease. You may wish to arrange for a Clinical Immunology appointment for further assessmen

Document Number: LP-GEN-0014	Revision 15

2.4.12 Allergen Specific IgE

INDICATIONS – ALLERGEN SPECIFIC IGE

- Known allergic disease, to identify allergens
- Suspected allergic bronchopulmonary aspergillosis (ABPA)

National & international guidelines state that testing for allergen specific IgE (sIgE) should be based on an allergy focussed clinical history.

Specific allergens which are directly orderable on Healthlink are listed below. For other additional allergens which might be clinically indicated please order Acute Allergic Reaction Investigation (AARI) on Healthlink ensuring all relevant clinical information is provided associated with the episode(s).

If allergen specific IgE is positive, Total IgE will automatically be ordered to aid the interpretation of results.

Order Name	
Specific IgE: House dust mite (d1)	
Specific IgE: Grass Pollen Mix 1	
Specific IgE: Tree Pollen Mix	
Specific IgE: Cat dander	
Specific IgE: Dog dander	

2.4.13 Acute Allergic Reaction Investigation - Beaumont GP Service only

<u>INDICATIONS – Clinical symptoms suggestive of acute allergy. (Service provided to Beaumont GPs only).</u>

Despite advances in testing, allergy remains a clinical diagnosis, based on an allergy focussed history, supported by evidence of allergic sensitisation. Recent national and multiple international guidelines emphasise the need for allergy testing to only be performed as indicated by the allergy focussed history.

Specific IgE blood tests (when available to the allergen in question) can be helpful to indicate allergic sensitisation. However as specific IgEs are only markers of sensitisation, not necessarily a clinical allergy; results require interpretation within the context of the clinical history. Sensitised patients may be clinically

allergic OR may be sensitised and tolerant, with on-going tolerance depending on on-going exposure. Unfortunately we continue to see patients that have had their diet restricted solely based on specific IgE test results; some of whom have lost tolerance as a result.

Since 1st of March 2020 we changed the pathway for requesting specific IgE testing, to facilitate the implementation of the recommendations of these guidelines, align with MedLIS requesting and contribute to improving patient safety.

Since MedLIS GoLive in August 2024, Acute Allergic Reaction Investigation (AARI) is available to order directly on Healthink. Since February 2025 it is only available to order electronically, there is no need for the old AARI paper request form.

Specific IgEs to inhalants e.g. grass and tree pollens, cat, dog, house dust mite remain available for direct ordering (i.e. no AARI test required for these). AARI requesting pathway is only required to request specific IgEs to other allergens not listed above. If further clinical details are required, you may be contacted by a member of the Immunology team. If we are not successful in making contact, you will receive a report requesting that you make contact for discussion of clinical details. The sample will be stored for 2 weeks pending this discussion.

Reference:

https://www.hse.ie/eng/about/who/cspd/lsr/resources/indications-for-measurement-of-total-ige-in-general-practice-and-non-specialist-settings.pdf
https://www.hse.ie/eng/about/who/cspd/lsr/resources/indications-for-measurement-of-allergen-specific-ige-in-general-practice-and-non-specialist-settings.pdf

The Acute Allergic Reaction Investigation will be resulted to you in one of the following ways:

- 1. Based on clinical details provided, relevant specific IgEs have been requested. Report to follow.
- 2. Specific IgE test is not available for the suspected allergen based on the provided clinical details. If there are any queries regarding this, please contact us at immunologylab@beaumont.ie (quoting the patient's accession number and AARI in the subject line). For patient confidentiality, please ensure that only a secure healthmail email account is used. Sample will be stored for 2 weeks from date of receipt.

- 3. Specific IgE not indicated based on clinical details provided. If there are any queries or updates of the clinical information please contact us at immunologylab@beaumont.ie (quoting the patient's accession number and AARI in the subject line). For patient confidentiality, please ensure that only a secure healthmail email account is used. Samples will be stored for 2 weeks from date of receipt.
- 4. Incomplete clinical information provided in the accompanying request form. Please email us at immunologylab@beaumont.ie (quoting the patient's accession number and AARI in the subject line) to confirm contact details and suitable times between Tuesdays and Thursdays for clinical discussion. For patient confidentiality, please ensure that only a secure healthmail email account is used. Serum sample will be stored for 2 weeks pending this discussion. If no email is received within the next 2 weeks, it will be assumed that specific IgE testing is no longer required and serum will be discarded.
- 5. Further discussion of the clinical details is required to guide specific IgE testing if appropriate. We have not been successful in making contact using provided details. email the contact Please us immunologylab@beaumont.ie (quoting the patient's accession number and AARI in the subject line) to confirm contact details and suitable times between Tuesdays and Thursdays for clinical discussion. For patient confidentiality, please ensure that only a secure healthmail email account is used. Serum sample will be stored for 2 weeks pending this discussion. If no email is received within the next 2 weeks, it will be assumed that specific IgE testing is no longer required and serum will be discarded.
- 6. Please note that a separate AARI request is not required to order specific IgEs to the common inhalant allergens i.e. cat dander, dog dander, grass pollen, tree pollen and house dust mite. These can be requested directly. Please see results of the individual specific IgE to these inhalants.
- 7. No specific allergen identified in clinical history provided and frequent urticaria episodes noted. Please consider the possibility of spontaneous urticaria which is an allergy mimic but not allergic in nature. More information regarding spontaneous urticaria is available on the Clinical Immunology homepage on the Beaumont Hospital website.

Interpretation Of Results

Interpretation of allergen-specific IgE is linked with the level of total IgE, as well as the class of allergen specific IgE. Interpretation of both types of tests are considered below.

<u>Normal Total IgE</u>: Excludes atopy. However, a normal IgE does not exclude sensitisation to individual allergens. As a general rule even weakly positive allergen-specific IgE may be clinically relevant in patients with a low normal IgE. However the relevance of allergen specific IgE must be carefully assessed in the context of the clinical history.

Raised Total IgE: Consistent with atopy. Atopy denotes a genetic susceptibility to make IgE responses. This does not imply that atopic disease is present. The possible role of atopy in the patients clinical presentation should be carefully assessed. False positive results for allergen-specific IgE, particularly of class 1 & 2 become more common the higher the total IgE. In patients with a raised IgE >1000kUA/L, even class 3 allergen-specific IgEs may be false positives. The clinical relevance of allergen-specific IgE measurements must be considered in the clinical context. If uncertain, you may consider referring the patient to the immunology clinic. Raised IgE may also be due to parasitic infection (eosinophilia usually also present) and Churg-Strauss syndrome.

<u>Total IgE > 5000kUA/L</u>: If patient has infections consider the Hyper-IgE syndrome. If this is a diagnostic possibility, please contact the Immunology Department to arrange accurate quantification of level (and clinical consultation if required).

Values of IgE > 5000kUA/L are not uncommon in patients with atopic eczema alone. In such patients allergen-specific IgE results must be assessed with extreme caution.

2.4.14 Anti-Streptolysin-O Titre (ASOT)

INDICATIONS

- Suspected current or recent streptococcal infection
- Possible rheumatic fever
- Glomerulonephritis & acute renal failure
- Reactive arthritis

Anti-streptolysin-O antibodies may be produced following infection with Group A Streptococci. Only a proportion of the subtypes of group A Strep can cause rheumatic fever or glomerulonephritis in genetically susceptible individuals, usually with an onset 2-4 weeks after the infection. The ASOT does not distinguish between nephritogenic and non-nephritogenic strains – a positive result merely indicates current or recent infection with streptococcus.

If rheumatic fever is suspected, evidence of recent streptococcal infection is required for diagnosis. If cultures and ASOT are negative, it may be of value to measure anti-DNAase, an additional antibody which may be produced following a Streptococcal infection.

INTERPRETATION OF RESULTS

In October 2020 we changed the method for ASOT from Nephelometry to Immunoturbidimetry. There was no change in reference range.

<u>Negative ASOT (<200 IU/mL):</u> Negative result does not exclude Group A Streptococcal infection as this antibody is present in only 80-85% of patients with Streptococcal pharygitis. A smaller proportion of patients with skin infection are antibody positive.

<u>Positive ASOT (>200 IU/mL):</u> Indicates current or recent infection with Group A Streptococci.

2.5 MICROBIOLOGY

2.5.1 General Sample Collection Guidelines

As per MEMO-MIC-0375 circulated in 2024 on 08/11/20242, due to a national shortage of medical scientists, courier delivered samples from General Practitioners and Nursing Homes for microbiological investigations other than virology bloods are currently being outsourced to Eurofins Biomnis Ireland for processing until further notice. Practices will be provided with purple bags. All samples for Microbiology must be placed directly into this bag. Drivers will take the samples directly to Eurofins Biomnis in Sandyford. There will be no change to practice with samples for NVRL, please continue to package separately and place with blood samples.

- Collect specimens aseptically in appropriate CE-marked leak-proof containers and transport in sealed plastic bags.
- A sufficient volume of material must be submitted (See Section 3.6)
- Swabs in transport media are acceptable for throat, eye, ears, vaginal and urethral specimens. Otherwise, pus, fluid or tissue is preferable to a swab.
- Swabs with special transport media are available where applicable, e.g., for viral and chlamydia investigation.
- If a diagnosis of a viral haemorrhagic fever (Lassa, Ebola, Marburg, Congo-Crimean fever), or CJD is suspected, the consultant microbiologist must be informed before any specimens are collected.
- If a potentially cytotoxic specimen is being sent, the chief or senior medical scientists in microbiology must be informed.
- Samples must be delivered to the hospital for transport to Eurofins Biomnis laboratory as soon as possible to prevent samples becoming compromised and rejected. If this is not possible, store specimens in fridge until they can be transported.

2.5.2 Guidelines for Routine Specimens

See table 2 and 3 below for specimen acceptance and rejection

<u>Pus</u> (This sample is currently outsourced to Biomnis Eurofins for Microbiological examination)

Pus sent in sterile containers give the best results for both Gram stain and culture and is essential for the diagnosis of TB or actinomycosis. If a swab is taken, it should be sent in transport medium after it has been thoroughly soaked in the pus or exudate.

<u>ULCERS</u> (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

For the best results, ulcers should be cleaned with sterile saline to remove surface contamination, prior to obtaining the sample.

<u>EYES</u> (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

- Discharging eyes should be swabbed for bacterial culture in the usual way.
- When viral conjunctivitis or corneal lesions are suspected, a swab must be collected using viral transport medium.
- If fungal or amoebic infections are suspected, please contact the clinical microbiology team.

THROAT SWABS (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

- Even though viruses account for over 70% of sore throats, the most common bacterial cause of sore throat in this country is group A β -haemolytic streptococcus.
- Throat swabs should be taken from the tonsillar region.
- If a throat swab is being taken for other pathogens e.g. *C. diphtheriae*, *N. gonorrhoea* or *N. meningitidis*, it must be clearly requested.
- If whooping cough (pertussis) is suspected, please send a nasopharyngeal swab.
- Specimens for virology should be taken early in the course of a suspected viral illness. Virus transport medium should be used.

<u>FAECES - ENTERIC PATHOGENS</u> (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

- Testing for enteric pathogens is not part of a routine septic screen and faeces specimens should only be sent when gastrointestinal infection is suspected.
- Faeces investigation for enteric pathogens is only performed on specimens which take the shape of the container. (www.hpsc.ie)
- Faecal culture assay now includes *Cryptosporidium parvum/hominis and Giardia lamblia* as standard.
- It is important that clinical details or suspected diagnoses are included on the request form. Relevant information includes: travel history, prolonged diarrhoea, antibiotic use and suspected outbreak. Investigations for pathogens such as *Yersinia*, *Vibrio*, *or Aeromonas* etc. are only performed if indicated by clinical details.
- Specimen may be passed into a clean, dry, disposable bedpan or similar container and transferred into an appropriate CE-marked leak-proof container and place in sealed plastic bags.
- Please note the possibility of Norovirus infection and state whether vomiting is a feature or whether an outbreak is suspected. Please send a separate

specimen for Norovirus testing, as this test is performed by an external laboratory.

<u>FAECES – OVA AND PARASITES</u> (This sample is currently outsourced to Biomnis Eurofins for Microbiological examination)

- The patient's travel history or other relevant clinical details must be provided.
- Three specimens should be collected over no more than a 10-day period. It is recommended that specimens are collected every other day.
- Unless the patient has severe diarrhoea or dysentery, no more than one specimen should be examined within a single 24-hour period, as shedding of cysts and ova tends to be intermittent.
- If *E. histolytica* suspected and the first three samples are negative, ideally four additional samples should be submitted at weekly intervals.

FAECES – CLOSTRIDIOIDES DIFFICILE (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

- Testing for *Clostridioides difficile* is performed on all faecal samples except in the following cases:
 - ➤ Patients less than 2 years of age
 - > Specimens that do not take the shape of the container
 - ➤ If specimen was positive for *C. difficile* within the last 14 days,

These criteria are in compliance with national guidelines (www. hpsc.ie)

<u>FAECES - HELICOBACTER PYLORI</u> (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

- Freshly collected samples should be sent to the laboratory for testing.
- *H. pylori* testing is not carried out on blood samples in the laboratory.

When to send a stool specimen: Send a stool specimen to the laboratory when there are ≥ 3 liquid or very loose stools per day. There may be other symptoms suggestive of infectious diarrhoea e.g., abdominal pain or discomfort, nausea, faecal urgency, tenesmus, fever, blood or mucus in stools.

<u>How many samples to send</u>: One stool specimen is normally all that is required for routine testing. As microscopy for parasites is less sensitive, please send 3 specimens (but no more than 3) on different days, as some parasites are excreted intermittently. If a worm is excreted, please send the worm and faeces sample.

<u>How much to send</u>: Please fill the specimen container to between ¼ and ½ full. Please do not fill to the brim.

<u>Urine Specimens</u> (This sample is currently outsourced to Biomnis Eurofins for Microbiological examination)

In the elderly (>65 years):

- Do not send urine for culture in asymptomatic elderly patients with a positive dipstick.
- Only send urine for culture if signs of urinary tract infection, especially dysuria, fever >38°C or new incontinence. A change in colour or odour of urine is not a sufficient indication for sending urine in the absence of clinical symptoms
- Do not treat asymptomatic bacteriuria in the elderly, as it is very common. Treating it does not reduce mortality nor prevent symptomatic episodes, but increases the risk of antimicrobial side effects, antibiotic resistance and *C. difficile* infection.
- Rapid transport, or measures to preserve the sample aid reliable laboratory diagnosis. Delays and storage at room temperature allow organisms to multiply, which generate results that do not reflect the true clinical situation

What type of specimen should you send?

Send a mid-stream specimen of urine (MSU) where possible. Patients should be instructed to pass a little urine into the toilet first, then pass enough urine into the specimen container.

Urines for culture and sensitivity and pregnancy testing are now collected via the The Sarstedt NFT (Needle Free Transfer) system. This consists of a <u>100ml</u> NFT primary container (Sarstedt Product Reference 75.562.900) and a 10mL Monovette tube (Sarstedt Product reference 10.252)

This system allows for the spill free collection and transfer of urine samples to the required 10mL Monovette tube (SeeTable 1 below).

- The 10mL Monovette **tube** is to be sent to the Microbiology lab for microbiology urine investigations (URCULT).
- ONLY 10mL Monovette tubes will be accepted and other container types will be rejected
- Both products are available from the Stores Department, Beaumont Hospital

Specimens should be processed within 4 hours. If transport to the laboratory has to be delayed, the specimen can be stored at 4°C for up to 24 hours.

Table 1. Approved urine specimen collection containers.

Department	Test	Container
Microbiology	Urine culture and sensitivity Urine hCG	Uring Z
Microbiology	Non-Urine Samples: Eg: Sputum Stool samples: H.pylori or culture and sensitivity Microbiology Urine (C/S) Sputum (C/S) Stools (C/S) H pylori	Can Room Manufather
Select C/S <u>or</u> <i>H pylori</i> only		

Biochemistry	Urines for	
	ACR PCRs etc	(E
	T CKS Cit	(S)

Urine specimens for TB (This sample is currently outsourced to Biomnis Eurofins for Microbiological examination)

Urine specimens should be collected in the early morning on three consecutive days in a CE-marked leak-proof container (that does not contain boric acid), and placed in a sealed plastic bag. If there are no appropriate containers for a whole Early Morning Urine (EMU) sample, a midstream EMU sample is an acceptable, but not ideal alternative.

RESPIRATORY SPECIMENS (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

Sputum for culture and sensitivity:

- A good quality purulent or mucopurulent sputum specimen should be obtained, preferably before antimicrobial therapy, although antimicrobial therapy should not be delayed unnecessarily while awaiting a sputum specimen.
- The specimen should be transported to the laboratory within 2 hours.
- Salivary specimens are unsuitable and as such are not processed.
- If transport is delayed up to 24 hours, refrigeration is preferable to storage at ambient temperature. Specimens are not processed if they are >48hours old at time of receipt in laboratory

Sputum for investigation of *Mycobacterium* spp.:

- Sputum specimens should be relatively fresh (less than 1 day old) to minimise contamination. Purulent specimens are best.
- Two to three samples of ≥5mL should be collected approximately 8-24 hours apart with at least one from early morning

- Samples taken early morning (that is, shortly after patient waking) have the greatest yield.
- When the cough is dry, physiotherapy, postural drainage or inhalation of nebulised saline ('sputum induction') before expectoration may be helpful.

HIGH VAGINAL SWABS (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

Obtain a high vaginal swab by use of a speculum and a Trans swab and submit to the laboratory.

CERVICAL / ENDOCERVICAL SWABS (THIS SAMPLE IS CURRENTLY OUTSOURCED TO BIOMNIS EUROFINS FOR MICROBIOLOGICAL EXAMINATION)

Use a speculum without lubricant. Wipe the cervix clean of vaginal secretions and mucus. Gently insert a swab into the endocervical canal and rotate to obtain any exudate and submit to the laboratory.

MOLECULAR TESTING:

for Chlamdia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis

Samples should be collected in the APTIMA unisex Swab Specimen Collection Kit for endocervical and male urethral swab specimens and the Urine Collection kit for male and female urine specimens as per instructions on www.nvrl.ie.

All are available from the NVRL on request and the test is referred to Eurofins Biomnis Ireland for processing by the NVRL Swab and urine specimens are stable at room temperature for 60 and 30 day post collection respectively.

2.5.3 Serological Investigations

Serology/virology samples from General Practitioners and nursing homes are referred to external laboratories from the Microbiology laboratory

All test requests to be ordered via the Health link system

All reports available electronically

HIV- VIRAL LOADS AND HEPATITIS C PCR.

- For HIV viral load, blood should be collected in an EDTA blood collection tube as per instructions on www.nvrl.ie.
- For hepatitis C PCR, a serum sample is required as per instructions on www.nvrl.ie.

- Hepatitis C PCR and HIV viral load investigations should be sent to the laboratory immediately for processing. **The serum must be frozen within 6 hours of taking the patient's blood,** as per instructions on www.nvrl.ie.
- Specimens are transported at -20°C by courier each Friday to the NVRL.

ANTIBODY DETECTION.

- In order to establish a diagnosis of acute or recent viral infection by serology, viral specific IgM needs to be detected as per instructions on www.nvrl.ie.
- Before laboratory investigations are performed, paired sera must be submitted. The first should be taken as early as possible in the illness, and the second 14-21 days later and a four-fold rise in titre is required to confirm recent infection.
- A single specimen of serum is required to determine immune status or past infection.
- For serological investigations, a serum specimen of more than 1ml is required. One container of clotted blood should be sent to Beaumont Microbiology department for transport to the NVRL.
- For results enquiries, please phone the NVRL 01-7161354.
- Results are available electronically via Healthlink

VIRAL SCREENING

- Samples for routine viral investigations are referred to the NVRL and transported to the NVRL thrice daily by courier: 10.30am, 12.30pm and 2.30pm
- Please order test on Healthlink
- Clotted blood is the specimen of choice for most other external investigations.
- Please include relevant clinical details, travel history (including destinations visited and travel dates), complete demographics and inform laboratory if urgent.
- For serology referral tests, when an aliquot is required for sending out, the following is adhered to:
- -Sufficient sample available
- -Appropriate container for aliquot
- -Labelling criteria (same information as original sample) See section 2.1.6
- -Stability and storage conditions correct

Table 2: Specimen acceptance criteria

Test ordered	Container	Volume	Stability	Comments
Urine culture with microscopy	10 ml Monovette tube,	2 mls	4 hours at room temperature48 hours at 4 ℃	
HCG Pregnancy	10 ml Monovette tube60 ml sterile container	2 mls	4 hours at room temperature48 hours at 4 ℃	
TB culture	60 ml sterile container	10 mls	24 hours at room temperature, If delay store at 4 °C	
Ova and Parasites	60 ml sterile container	10 mls	1 hour without the addition of undiluted formalin	
C diff and Enteric Path	60 ml sterile container	1-2 ml/g	48 hours at 4℃	Liquid or semi- formed samples only processed
Enteric Path	60 ml sterile container	1-2 ml/g	48 hours at 4℃	Liquid or semi- formed samples only processed
Rotavirus/Adenovirus combi test	60 ml sterile container	1-2 ml/g	48 hours at 4℃	Children <5 years
Ova and Parasites	60 ml sterile container	1-2 ml/g	24 hours at room temperature	Travel details essential or CMT Request
Helicobacter pylori antigen	60 ml sterile container	1-2 ml/g	48 hours at 4 °C	
Norovirus	60 ml sterile container	1-2 ml/g	48 hours at 4 °C	Dispatched to NVRL
Respiratory culture	60 ml sterile container	15 mls	48 hours at 4℃	
TB culture	60 ml sterile container	1 ml	24 hours at room temperature, If delay store at 4 °C	
Fungal culture	Dermapak	As much as possible	Several months stored at room temperature	Any hair specimens must contain root of
(Skin scrapings/Nail clippings/Hair)	60 ml sterile container			the hair
MRSA Screen Culture	Charcoal Transswab, (Nasal, Groin or Wound site)	N/A	24 hours at room temperature 72 hours at 4 °C	

Test ordered	Container	Volume	Stability	Comments
Swab/Wound/Eye/Ear/Thro at/Mouth/Nasal/Pus culture	Charcoal Transswab	N/A	24 hours at room temperature	
	(Wound, Eye, Ear, Throat, Mouth, Nasal, Pus),NT swab (orange)For ear, nose, throat only		72 hours at 4 °C	
Genital culture	Charcoal Transswab	N/A	24 hours at room temperature	
	(Cervical/Endocer vical/Urethral/ Throat/Rectal/Pus or Discharge from penis		72 hours at 4 °C	
HVS Culture	Charcoal Transswab	N/A	24 hours at room temperature	
	(HVS)		72 hours at 4 °C	
Fluid/Aspirate culture	60 ml sterile container	Minimum of 1 ml in 60 ml sterile	24 hours at room temperature	
		container	48 hours at 4 °C for 60 ml sterile container	
TB culture	60 ml sterile container	1 ml	24 hours at room temperature,If delay store at 4 °C	
Pus culture	60 ml sterile container	1 ml	24 hours at room temperature	
			If delay store at 4 °C 72 hours at 4 °C	
Cryptococcal antigen	CSF	100 μ1	Longer at -20 °C	
Cryptococcal antigen	White Topped Serum Tube	7.5 ml	72 hours at 4 °C,Longer at -20 °C	
Amikacin levels	White Topped Serum Tube	7.5 ml	Separated at 4 °C within 48 hours	Dispatched to Biochemistry MMUH
Adenovirus PCR	EDTA tube (pink top)	2.6 ml	Separated at -20 °C within 24 hours	
CMV PCR	EDTA tube (pink top)	2.6 ml	Separated at -20 °C within 24 hours	Dispatched to
EBV Serology	EDTA tube (pink top)	2.6 ml	Separated at -20 °C within 24 hours	NVRL State clearly on
Hep B Viral Load/PCR/DNA	White Topped Serum Tube	7.5 ml	Separated at -20 °C within 24 hours	label Serum or Plasma

Test ordered	Container	Volume	Stability	Comments
Hep C PCR/Genotype/DNA/Viral Load	White Topped Serum Tube	7.5 ml	Separated at -20 °C within 24 hours	
HIV Viral Load/PCR	White Topped Serum Tube	7.5 ml	Separated at -20 °C within 24 hours	
HIV Viral Load/PCR	EDTA tube (pink top)	2.6 ml	Separated at -20 °C within 24 hours	
Beta-D-glucan	White Topped Serum Tube	7.5 ml	Separated at 4 °C for 15 days	Dispatched to Southmead, Bristol
			Separated at -20 °C for 27 days	
Norovirus	60 ml sterile container	1-2 ml/g	48 hours stored at 4℃	
Parvovirus PCR	White Topped Serum Tube	7.5 ml	Separated at -20 °C within 24 hours	Dispatched to NVRL,State clearly on label Serum or Plasma
Teicoplanin levels	White Topped Serum Tube	7.5 ml	Separated at 4 °C within 48 hours	Dispatched to Eurofins Biomnis
Tobramycin levels	White Topped Serum Tube	7.5 ml	Separated at 4 °C within 48 hours	Dispatched to Biochemistry SVUH
Voriconazole levels	White Topped Serum Tube	7.5 ml	Separated at -20 °C within 24 hours	Dispatched to MMUH

Table 3: Specimen rejection criteria

Specimen	Label	Test ordered	Container	Volume	Stability	Comments
				<u>Urine</u>		
Specimen unlabelled or mislabelled with incorrect patient details	Urine	Incorrect Healthlink order Specimen with request form, not	Sarstedt "Urine NFT" primary sample container	< 2 ml (manual microscopy & culture will be performed)	> 4 hours at room temperature > 48 hours at 4 °C	
Leaking specimen	HCG TB,	ordered on Healthlink	60 ml sterile container without red sticker on lid	< 2 ml	241 A.P.T.	
	O&P			< 10 mls	24 hours at RT > 48 hours at 4 °C	
			Faeces			

Specimen	Label	Test ordered	Container	Volume	Stability	Comments
Specimen	C diff toxin & Enteric Path	Incorrect Healthlink order	Sarstedt "Urine NFT" primary sample container 10 ml Monovette	< 1 ml/g	>48 hours at 4°C	Formed samples & < 2 years old for C.diff
unlabelled or mislabelled with incorrect patient details	C diff toxin PCR	Specimen with request form, not ordered on	tube Sarstedt "Urine NFT"	< 1 ml/g	>48 hours at	Will only be processed for Crypto/Giardia
Leaking specimen	EntericPath	Healthlink	primary sample container	< 1 ml/g	4°C	if no travel details have been received or no request from CMT
	ROT/ADV		Monovette tube	< 1 ml/g		nom en r
	O&P		tube	< 1 ml/g	> 48 hours at 4°C without addition of 10% formalin-water	
	H. pylori Ag			< 1 ml/g	> 48 hours unless stored at -20 °C	
			Respiratory			
Specimen unlabelled or mislabelled with incorrect patient details	Respiratory/Sputum/ CF Resp	Incorrect Healthlink order Specimen with request	Sarstedt "Urine NFT" primary sample container	< 15 mls	> 48 hours stored at 4 °C except CF specimens	Salivary samples (except CF) are rejected.
Leaking specimen	ТВ	form, not ordered on Healthlink	Sarstedt "Urine ,FT" primary sample container	< 1 ml (Culture only)	> 24 hours at room temperature	
			<u>Fungal</u>			
Specimen unlabelled or mislabelled with incorrect patient details Leaking specimen	Fungal	Incorrect Healthlink order, Specimen with request form, not ordered on Healthlink	Non sterile container	No visible sample present Culture only performed on insufficient sample	Stored at 4 °C > Several months	
		·	Screens	<u> </u>		
Specimen unlabelled or mislabelled	MRSA	Incorrect Healthlink order	Viral swab (pink)ENT swab	N/A	> 24 hours at room temperature	

Specimen	Label	Test ordered	Container	Volume	Stability	Comments
with incorrect patient details			(orange)Pert ussis swab (blue)Liquid Amies eSwab		> 72 hours at 4 °C	
			<u>Swabs</u>			
Specimen unlabelled or mislabelled with incorrect	C Swab/C Wound/C Eye/C Ear/C Throat/C Mouth/C Nasal/C Pus	Incorrect Healthlink order Specimen with request	Viral swab (pink) Pertussis swab (blue)	N/A	> 24 hours at room temperature > 72 hours at 4 °C	
patient details	Genital	form, not ordered on Healthlink	liquid Amies eSwab,ENT swab (orange) for any site other than ear, nose, throat	N/A	> 24 hours at room temperature > 72 hours at 4 °C	
	GC		Agar plate other than VCAT	N/A	N/A	
	HVS		Viral swab (pink),ENT swab (orange),Pert ussis swab (blue),Liqui d Amies eSwab	N/A	> 24 hours at room temperature > 72 hours at 4 °C	
			<u>Fluids</u>			
Specimen unlabelled or mislabelled with incorrect patient details Leaking specimen, (If possible clean & process)	Fl/Asp	Incorrect Healthlink order Specimen with request form, not ordered on Healthlink	Non sterile container	< 1 ml in 60 sterile container	> 24 hours at room temperature > 48 hours at 4 °C for 60 ml sterile container	
	ТВ		Non sterile container	<1 ml (Culture only performed on insufficient volume)	> 24 hours at room temperature If delay store at 4 °C	
			<u>Pus</u>			
Specimen unlabelled or mislabelled with incorrect patient details	Pus	Incorrect Healthlink order	Non sterile container	< 1 ml	> 24 hours at room temperature	If < 1 ml charcoal swab can be processed
patient details		Specimen with request			> 48 hours at 4 °C	

Specimen	Label	Test ordered	Container	Volume	Stability	Comments	
Leaking specimen,		form, not ordered on					
		Healthlink					
	<u>Tips</u>						
			1103				
		Virology	(External labor	atories)			
	4 '1D				N		
	AmikR	Specimen with request	Blood bottle other than	Visibly no blood in bottle	Not separated at 4 °C within 48		
Specimen unlabelled		form, not ordered on	white topped serum tube		hours		
with MedLIS label or	ADVADNA VRL	Healthlink)	Blood bottle				
mislabelled with incorrect	ADVDNAL VRL		other than EDTA tube				
patient details	CMVDNA VRL		(pink top)				
Leaking specimen	EBV DNA VRL						
	HBVL VRL		Blood bottle				
	HBGER VRL		other than white topped serum tube				
	HCVGE VRL						
	HCVVL VRL						
		-					
	HIVGER VRL	-					
	HIV1VL VRL		Blood bottle other than	Visibly no blood in bottle	Not separated at 4 °C within 24		
			EDTA tube (pink top)		hours		
	B-D GLUCAN		Blood bottle	Visibly no	Not separated at		
			other than white topped	blood in bottle	4 °C for 15 days,not		
			serum tube		separated at -20 °C for 27 days		
	NORXPERT VRL		Non sterile	Visibly no	> 48 hours at 4		
			container	faeces	°C		
	PARVDNA VRL		Blood bottle other than	Visibly no blood in bottle	Not separated at 4 °C within 24		
	Teicoplanin Level		white topped serum tube		hours		
	Tobra Trough	_					
	Voriconazole						

2.6 HISTOPATHOLOGY/CYTOPATHOLOGY/NEUROPATHOLOGY

As per communication previously circulated, due to a national shortage of medical scientists, the Histopathology laboratory is currently outsourcing some paraffin embedded blocks to Hibernian Testing Services Ltd. for Histopathological staining and cutting as documented in the quality management system documentation.

2.6.1 Current Best Practice for Renal Biopsies

Two cores of tissue should be taken to ensure that there are sufficient numbers of glomeruli for examination — not less than 10 for light microscopy and immunofluorescence. This applies to native and allograft kidneys. Both cores can be placed in the same container.

2.6.2 Handling of Tissue after Biopsy has been taken.

Tissue must be fresh in order to allow immunological assessment to be performed. In Beaumont Hospital biopsies are carried out in the X-Ray Dept. by one of the Radiologists. The biopsy cores are placed in a universal container which is at least half full of normal saline. The container is placed in a biohazard bag and the Renal Biopsy Request form which should have been filled in by the Nephrology team on the ward prior to transfer of the patient to X-Ray is placed in the outer pouch of the bag.

2.6.3 Coroners's Post Mortem

In all cases the Information Sheet on Post-Mortem Examination (Lab 360A) should be given to families. (http://dms.beaumont.ie/sections/medical/procedures-formedical1263)

Circumstances where a death should be reported to the Coroner are listed below.

If an autopsy is required, the clinical staff must inform the Anatomical Pathology Technician at extension 2679 or Mortuary Service Co-Ordinator at extension 8180. Information relating to consent is available on request.

For "consented" autopsies (so called non-Coroners or "House Cases") it is the responsibility of the individual who requests the autopsy to ensure the completed consent form (LAB 358B), patient case notes and a concise clinical summary are delivered to the Mortuary/Pathology in order for the autopsy to be performed. Case should be discussed with Pathologist where possible. (Ext 2638)

In the case of deaths outside normal working hours, the individual who obtained consent for autopsy must ensure that the relevant documentation is given to the Anatomical Pathology Technician or Autopsy/Mortuary Manager (Ext 8354) the following morning.

In Coroner's cases it is the responsibility of the clinical team to notify the Coroner and to ensure that the Coroner Autopsy Post Mortem Examination Form (LAB 357B) is completed.

DEATHS WHICH MUST BE REPORTED TO THE CORONER

- (a) Deaths occurring at home or other place of residence:
 - Where the deceased was not attended by a doctor during the last illness;
 - Where the deceased was not seen and treated by a doctor within one month prior to the date of death;
 - Where death was sudden or unexpected;
 - Where death may have resulted from an accident (regardless of length of time
 - between injury and death), suicide or homicide;
 - Where the cause of death is unknown or uncertain:
 - Where concerns are expressed by any person in relation to a death.
 - Where the cause of death is suspected to be CJD.
- (b) Deaths occurring in hospital:
 - Deaths occurring in the accident and emergency department and individuals dead on arrival at hospital;
 - Deaths occurring within 24 hours of admission;
 - Where a patient dies before a diagnosis is made and the general practitioner is also unable to certify the cause;
 - When death occurred while a patient was undergoing an operation or under anaesthesia or within 24 hours of same;
 - Where death occurred during or as a result of any procedure;
 - Where any question of negligence or misadventure arises in relation to the treatment of the deceased;
 - Where death resulted from an industrial disease;
 - Where death was due to neglect or lack of care (including self neglect);
 - Where death occurred in a Mental Hospital;
 - Where death may have resulted from an accident (regardless of length of time
 - between injury and death), suicide or homicide.
 - Where a patient has MRSA, C. Diff. or VRE if this is a contributing factor
 - Where a patient is resident in a long stay unit or nursing home (e.g. Rockfield Unit)
 - Where the cause of death is suspected to be CJD.

- (c) A death is reported to the coroner by a member of the Garda Siochana:
 - Where death may have resulted from an accident, suicide or homicide;
 - Where death occurred in suspicious circumstances;
 - Where death is unexpected or unexplained;
 - Where a dead body is found;
 - Where there is no doctor who can certify the cause of death.
- (d) Other Circumstances
 - Sudden infant deaths;
 - Where a body is to be removed out of Ireland.

A detailed list of reportable deaths is available in the "The Role of the Coroner in Death Investigation", a copy of which is available on request.

It is the responsibility of the most senior member of the medical staff attending the patient to ensure that the death is reported to the Coroner.

2.7 NHISSOT

The National Histocompatibility and Immunogenetics Service for Solid Organ Transplantation (NHISSOT) provides a nationwide transplant immunology service for solid organ transplantation, including HLA typing and crossmatching of both donors and recipients, HLA antibody screening for post transplant monitoring and HLA typing for disease association.

NHISSOT or H&I (Histocompatibility & Immunogenetics) is an accredited laboratory awarded by The European Federation for Immunogenetics (EFI). EFI is a European organisation that focuses on immunogenetics, tissue typing and transplantation. The EFI Accreditation Programme provides an internationally recognised accreditation scheme for laboratories providing Histocompatibility & Immunogenetics testing services in support of solid organ transplantation.

The H&I Department is committed to providing and maintaining a service of the highest quality by strictly adhering to policies and procedures that are in place to ensure the EFI standards are being maintained and updated.

We actively participate in well established external and internal quality control programmes to ensure best practice is being followed. We are continuously implementing ways to improve the service by assessing and validating new assays and techniques to provide the best level of service for our patients.

The NHISSOT provides H&I support for:

- The National Kidney Transplant Services at Beaumont Hospital
- The National Liver /Pancreas Transplant Services at St Vincent's University Hospital
- The National Heart/ Lung Transplant Services at the Mater Misericordiae University Hospital
- Organ Donation Transplant Ireland

This document is intended as a guide to the services and tests available in the H&I Department. It provides details of the tests available, their specimen requirements, as well as appropriate background information.

3 LABORATORY SERVICES PROVIDED

3.1 GENERAL INFORMATION

3.1.1 Location of Department

The Clinical Directorate of Laboratory Medicine is located between the lower ground and ground floors of Beaumont Hospital.

The postal address of the Directorate is:

Clinical Directorate of Laboratory Medicine

Beaumont Hospital

PO Box 1297

Beaumont Road

Dublin 9

D09 V2N0

Visitors to any laboratory should go to the Pathology Reception Desk on the Lower Ground Floor. Staff at pathology reception will contact the Department and a member of staff will accompany them to the relevant Laboratory.

3.1.2 Contacting the Department/Telephone Numbers

FUNCTION	CONTACT	TELEPHONE/EMAIL
Beaumont Hospit	al Switchboard	01-8093000/8377755
Reception		
Directorate	Clinical Director	01-8092644
Management	Laboratory Manager	01-7977925
	Business Manager	01-8092508
Quality Management	Quality Manager	01-8092978

FUNCTION	CONTACT	TELEPHONE/EMAIL
Appointments	Phlebotomy Appointements	01-7974675
I	BLOOD TRANSFUSION & HAE	EMOVIGILANCE
Medical Enquiries	Prof. Philip Murphy	01-8093382
	Prof. John Quinn	01-8092664
	Prof Patrick Thornton	01-8092664
	Dr. Siobhan Glavey	01-8092664
	Haematology Registrar	Bleep 276
	SP Registrar	Bleep 887
	For Out-Of- Hours Service	Contact Switch Board
Scientific Enquiries	Chief Medical Scientist	01-8094733
	Senior Medical Scientists	01-8094734
	Senior Scientist	01-8094734
	Routine Laboratory	01-8092705
	On Call	Bleep 252
Haemovigilance	Haemovigilance Officers	01-8093334/2034 /
Enquiries		Bleep 649
	HAEMATOLOGY DEPA	RTMENT_
General Enquiries	HaematologyOffice-	01-8092655
	secretary/general enquiries	haemtologyadmin@beaumont.ie
		01-8093914/2674/2669/4075
	Central Reception	
Results	Phone number for the	01-8092690
	GP/External Lab Results	
	Line	

FUNCTION	CONTACT	TELEPHONE/EMAIL
Medical Enquiries	Prof. Philip Murphy	01-8093382
	Prof. John Quinn	01-8092664
	Prof. Patrick Thornton	01-8092644
	Prof. Siobhan Glavey	01-8092664
	Dr Karl Ewins	018528832
	Dr Jeremy Sargent	01-8092150/2622
	Dr Elizabeth Smyth	01-8092150/2622
Clinical Advice and	Coleman. K. Byrne Unit	01-8092150/2622
Laboratory Test	Haematology Registrars	'Contactable through switch'
Interpretation	Haematology Senior House	'Contactable through switch'
	Officers	
	Chief Medical Scientist	01-8092662
Clinic	Coleman. K. Byrne Unit	01-8092150/2622
	Warfarin Clinic	01-8092083/3982
Scientific Enquiries	Chief Medical Scientist	01-8092662
	Seniors office	01-8093952
	Haematology Laboratory	01-8092703
	Coagulation Laboratory	01-8092656
	Flow Cytometry Laboratory	01-8092763
	Morphology	01-8093226
	Special Haematology	
	IMMUNOLOGY DEPAR	TMENT_
General Enquiries	Departmental Secretary	01-8093026
	Secretary to Prof. Keogan/	01-8092652
	Dr Khalib/Dr Cox	
	Specialist Registrar	Bleep 797

FUNCTION	CONTACT	TELEPHONE/EMAIL
Appointment	Secretary to Prof. Keogan/	01-8092652
Information	Dr Khalib/Dr Cox	
Clinical Advice and	Specialist Registrar	immunologydepartment@beaumont
Laboratory Test		<u>.ie</u>
Interpretation		Bleep 797
Lab Enquiries	Lab Reception	01-809 3914/2674/2669/4075
Results	Pathology Reception	01-8092690
Scientific Enquiries	Chief Medical Scientist	01-8093174
	Immunology Laboratory	01-8092635/2421
		immunologylab@beaumont.ie
	CHEMICAL PATHOLOGY D	EPARTMENT_
General Enquiries	Pathology Reception	01-8092507
Test Results	Pathology Reception	01-8092507
Medical Enquiries	Dr.Shari Srinivasan	01-8092676
	Dr. Clodagh Loughrey	01-8092035
	Specialist Registrar	01-8092666 Bleep 332
Scientific Enquiries	Chief Medical Scientist	01-8092670
	Chief Medical Scientist	01-7977811
	General Clinical	01-8092704/2668/2671
	Biochemistry	01-8528675
	Proteins	01-8092305
	Mass Spectrometry	01-8092351 or 01-7977333
	Laboratory	
Out of Hours	Via Switchboard	Bleep 251 or DECT 8727
	MICROBIOLOGY DEPA	RTMENT
All Enquiries	Microbiology office	01-8092646

FUNCTION	CONTACT	TELEPHONE/EMAIL
Results	Microbiology office	01-8092646
Medical Enquiries	Prof. B. Dinesh	01-8092646
	Prof. F. Fitzpatrick	01-8092646
	Prof. K. Burns	01-8092646
	Dr. Ciara O' Connor	01-8092646
	Dr. Sinead O' Donnell	01-809 2646
	Dr. Helene McDermott	01-809 2646
	Registrars	01 -8093320/3321/2667
	Out of Hours	Through Switchboard
Scientific Enquiries	Chief Medical Scientist	01-8092645
	Main Laboratory	01-8092647
HISTO	PATHOLOGY & CYTOPATHO	DLOGY DEPARTMENT
General Enquiries	Department Office	01-8092636/2353
	Department Email	histo@beaumont.ie
Medical Enquiries	Dr. Clíona Ryan	01-80922284
	Dr. Marie Staunton	01-8092997
	Dr. Brian Pierce	01-8094240/ Bleep 322
	Prof. Brendan Doyle	01-8092636
	Dr. Anne Marie O'Shea	01-8093910
	Dr. Maeve Redmond	01-8092998
	Dr. Helen Barrett	01-8092641
	Dr. Christian Gulmann	01-8092078
	Dr. Keith Pilson	01-8093986
	Dr. Clive Kilgallen	01-8092284
	Dr. Odharnaith O'Brien	01-8094218
	Dr. Laura Mc Kenna	01-8093286

FUNCTION	CONTACT	TELEPHONE/EMAIL	
	Registrars Office	01-8092638/3435/ Bleep 448	
Scientific Enquiries	Chief Medical Scientist	01-8092555	
•	Main Laboratory	01-8092353	
	Specimen Reception	01-8092659	
	Cytology Laboratory	01-8092640	
Reports	Histopathology Office	01-8092636/2632/3919/3150/2154	
RENAL PATHOLOGY			
Medical Enquiries	Dr. Brian Pierce	01-8094240/ Bleep 322	
	Prof. Brendan Doyle	01-8092636	
Scientific Enquiries	Renal Pathology	01-8528633 (dect phone)	
_	Laboratory	_	
General Enquiries	Renal Pathology Secretary	01-8092008	
	NEUROPATHOLO	<u>GY</u>	
Medical Enquiries	Dr Jane Cryan	01-8093973	
	Dr. Francesca Brett	01-8093143/ Bleep 324	
	Dr. Alan Beausang	01-8092615	
	Dr. Abel Devadass	01- 8097775	
	Specialist Registrar	01-8092706	
Scientific Enquiries	Senior Medical Scientist	01-8092633	
-	Senior Medical Scientist	01-8092633	
	(CJD)		
	Research Scientist	01-8092706/ 3798	
	Brain Bank	01-8092706	
	Molecular Neuropathology	01-8098452/8453	
Reports	Neuropathology Office	01-8092631/2072	
	<u>NHISSOT</u>		

FUNCTION	CONTACT	TELEPHONE/EMAIL	
General Enquires	Main Laboratory	01-8092650	
	Chief Medical Scientist	01-8092661	
Scientific Enquiries	Main Laboratory	01-8092650	
	Molecular	01-8093955	
	Scientists Office	01-8093238/2960	
	Reporting Room	01-8092651/4246	
	Antibody Screen	01-8094248	
Email Addresses	General enquires	crossmatch@beaumont.ie	
	Patient enquires	transplantlab@beaumont.ie	
	Post transplant enquires	posttransplant@beaumont.ie	
On-Call	Medical Scientist on duty	087-2615112	
Clinical Enquiries	Consultant Immunologist	01-8092652	
	Out of Hours	Through Switchboard	
Renal Transplant	Office	01-8092759	
Co-Ordinators	E-Mail	transplantcoordina@beaumont.ie	
Beaumont Hospital	Urgent Call via Switch	01-809300/8377755	
	MOLECULAR PATHO	DLOGY	
General Enquiries	Chief Medical Scientist	01-8092856	
Email Address	General enquiries	molecular@beaumont.ie	
	HEALTHLINK SYS	TEM	
General Enquiries/Tes	stProject Manager	01-8825720	
Result Issues		<u>info@healthlink.doh.ie</u>	

3.1.3 Department Opening Hours

The Clinical Directorate of Laboratory Medicine is open 8am to 8pm, Monday to Friday. There is no routine Saturday/Sunday/Bank Holiday service.

- > Immunology laboratory hours are from 9.00 am to 5.00pm, on Monday to Friday.
- ➤ Blood Transfusion laboratory routine hours are 8am -5pm Monday to Friday and 9am-1pm on Saturday contactable on Ext. 2705. An Emergency On –Call service from 5pm -8am Monday to Friday and 1pm 8am Saturday to Monday contactable on Bleep. 252
- ➤ Haematology Laboratory routine hours 8am to 8pm, Monday to Friday. There is a routine Saturday, 09.00 13.00. An Emergency On –Call service from 8pm -8am Monday to Friday and 1pm 8am Saturday to Monday. Contactable on Bleep. 852. A reduced service is offered between Christmas, New Year and Easter
- ➤ Chemical Pathology Laboratory routine hours 8am to 8pm, Monday to Friday and Saturday, 09.00 13.00. An Emergency On –Call service from 8pm -8am Monday to Friday and 1pm 8am Saturday to Monday. Contactable on Bleep #251. A reduced service is offered between Christmas, New Year and Easter
- ➤ Only a limited Histopathology/Cytopathology/Neuropathology service is provided between 5pm to 8am and scientists on call can be contacted through switch.
- ➤ Microbiology laboratory hours are from 08:00am to 8.00pm, Monday to Friday and 9:00am to 1.00pm on Saturdays. After 8pm on weekdays, and from 1pm Saturday until 8:00am Monday morning, Microbiology provides emergency on-call service only.
- ➤ NHISSOT Laboratory hours are from 8:00am to 600pm Monday to Friday. After 6pm, it is an emergency on call service. The laboratory is closed on Saturday, Sunday and Bank Holidays

➤ Molecular Pathology Laboratory hours are from 8am to 5pm Monday to Friday. The laboratory does not operate at weekends/bank holidays.

There is no clerical support outside Mon-Fri 09:00-17:00

Please ensure samples arrive in the laboratory as early as possible in the working day.

Arrangements are put in place each year regarding the specific services available over the Easter, Christmas and New Year periods and issued to service users with reports.

3.1.4 *Consent*

The laboratory shall obtain the informed consent of the patient for all procedures carried out on the patient. For most routine procedures, consent can be inferred when the patient presents himself or herself with a request form and willingly submits to the collecting procedure e.g. venepuncture. Patients in a hospital bed should normally be given the opportunity to refuse.

Special procedures, including more invasive procedures, or those with an increased risk of complications to the procedure, may need a more detailed explanation and, in some cases, recorded consent.

If obtaining consent is not possible in emergency situations, the laboratory may carry out necessary procedures, provided they are in the patient's best interest

The requirement for consent for individual tests performed is outlined in the relevant departmental sections of this laboratory manual.

3.1.5 Specimen Collection Guidelines & Order Of Draw

3.1.5.1 Patient Preparation

Patients should adhere strictly to any conditions which are required prior to and during primary sample collection. Caregivers and phlebotomists should ensure that patients are informed of the procedure required for specialist primary sample collection and that they have the required equipment e.g. 24hr urine collection containers. For further information on patient preparation for primary sample collection, please contact the relevant laboratory using the contact details provided in section above.

3.1.5.2 Venepuncture Instructions

The collection of a venous sample means the identification of the best vein to source the sample. The arm veins are normally the first choice for a phlebotomist. The most commonly used veins are the cephalic, medial cubital or basilic veins.

- 1. The Limb should be supported on a pillow or armrest of a phlebotomy chair.
- 2. Apply the tourniquet 2-3 inches above the selected site.
- 3. Wear your disposable gloves, cleanse the patients skin with a mediswab.
- 4. Anchor the vein using manual traction below the site of entry. The vein should feel firm and slightly bouncy.
- 5. Insert the needle with the bevel facing upwards and the needle at 15° angle.
- 6. There should be a flashback of blood to denote a vein has been accessed.
- 7. The needle should be held firmly between your thumb and fingers to allow the change of the different tubes onto the needle.
- 8. When all blood specimens have been obtained, release the tourniquet, detach the last tube and now remove the needle smoothly and quickly.
- 9. Apply pressure to the venous site for as long as required. This avoids a haematoma forming.
- 10.Dispose of the used needle immediately into the sharps bin. Do not recap the needle

The blood bottles must now be labelled correctly and any special requirements adhered to.

3.1.5.3 Blood Sample Order of Draw

Samples must be drawn in the order as tabulated below, to avoid any cross contamination of samples.

Never pour blood from one tube into another. The preservative in the first tube could contaminate the second tube; this can greatly affect results and potentially compromise patient care.

Refer to the Test Library for information on sample requirements and the number of tubes required. Tubes CANNOT be used / shared across different platforms because of the risks involved in sample re-labelling.

The brown and white cap samples must be stood upright to clot as soon as the bottles are filled to ensure that the clot forms in the base of the tube and not the lid. The yellow and pink bottles must be inverted gently to ensure complete mixing. Place all the labelled samples into the bio-hazard bag attached to the patient request form and seal.

Please note: The order of draw is in line with approved standards. Please refer to test information available under relevant department guidelines below.

Colour Code	Tube type and Order of Draw	Investigations
	Stand UPRIGHT ONCE DRAWN	4.9ml Chemical Pathology (specific tests only, see label) 4.9ml Immunology
Brown		
	2nd Serum STAND UPRIGHT ONCE DRAWN	4.9ml Chemical Pathology (specific tests only, see label) Virology (Serological testing) 4.9ml WHITE on
White		ICE
	3rd Sodium Citrate Coag	10ml required for HLA27 / Tissue Typing 2.9ml / 1.8ml for Coagulation Tests Under-filled or over-filled tubes will be rejected
Green	4th	Troponin only
	Lithium Heparin 4.9ml	Under-filled tubes will be rejected
Orange	5th	4.9ml Chemical Pathology (specific tests only)
	Lithium Heparin 4.9ml	4.9ml orange on ice Metal-free available from Specimen Reception (using special metal-free needle)
Orange		

	6th K-EDTA	2.6ml Pink FBC (Haematology tests),HbA1C Molecular Tests Virology (Molecular Investigations eg EBV,CMV,HIV molecular)
Pink	7th	4.9 ml EDTA for Type and Screen
	K-EDTA Blue 4.9ml with BTD label	4.9 ml EDTA for Type and Screen 4.9 ml EDTA for ACTH/PTH/Aldosterone/Renin
Blue		
	8th Sodium Fluoride	Glucose Alcohol
Yellow		
Purple	9th Sodium Citrate	ESR Under-filled tube will be rejected

3.1.5.4 24-Hour Urine Collection: General Information for Patients:

You will receive

- A large plastic container in which to store urine.
- A request form with your details on it.
- A plastic bag in which to return your collection and request form.
- 1. You may need more than one storage container to contain all of your urine for the 24-hour period.

Revision 15

- 2. Make sure each storage container is labelled with your full name and hospital number written on it. If your container is not labelled properly, you may be asked to repeat the 24-hour collection.
- 3. Keep your storage container cool throughout the 24-hour collection period until you bring it back
- 4. For certain collections, a blood sample may need to be taken within the 24 hour collection period; you will be informed if this is the case.

How to collect your sample.

- 1. Start the 24-hour urine test by urinating directly into the toilet. Do not save this urine.
- 2. After you urinate, write the date and time on your storage container, **this is the start of your test.** Write this time & date on the container.
- 3. For the next 24 hours, collect all your urine into your storage container.
- 4. Exactly 24 hours after you started the test, urinate one last time and place the urine in your storage container. **This is the end of your test.** Write the date and time the test ended on your storage container.
- 5. If you need to use more than one container during the 24-hour period, use one container at a time. When it is full, collect your urine in the next container.
- 6. Please bring the urine to the hospital as soon as possible. To prevent leaks, make sure the lid is on tightly, and that the container is transported upright inside a plastic bag.
- 7. If you are an inpatient, your nurse will tell you what time to begin and end the collection and will set up more containers, as needed. If you have questions about the procedure, please ask.

3.1.5.5 24-Hour Urine Collection (Acidified): Information for Patients

HCl can cause burns and irritate the respiratory system. It is designated harmful and corrosive and bears the following hazard warnings.





Harmful

Corrosive

You will receive

- A large plastic container with acid in which to store urine.
- A request form with your details on it.
- A plastic bag in which to return your collection and request form.
- 1. You may need more than one storage container to contain all of your urine for the 24-hour period.
- 2. Make sure each storage container is labelled with your full name and hospital number written on it. If your container is not labelled properly, you may be asked to repeat the 24-hour collection.
- 3. Keep your storage container in a cool place throughout the 24-hour collection period and until you return it to the laboratory.
- 4. For certain collections, a blood sample may need to be taken within the 24 hour collection period; you will be informed if this is the case.

How to handle acid safely.

- 1. Your storage container is supplied with a small volume of acid, do not throw this out.
- 2. You should open the container in a well ventilated area as fumes may escape from the acid.
- 3. Do not urinate directly into an acidified container.
- 4. Pour the urine slowly down the inside wall of the container, trying not to splash the acid.
- 5. Close the lid and swirl the container gently, to mix the acid and the urine.
- 6. Repeat steps 2~4 each time you add urine to the container.
- 7. Should you spill any acid on your skin, wash it off at once with plenty of running water.
- 8. If you experience soreness or reddening of your skin, as a result of a splash, consult your doctor & take these instructions with you.
- 9. Keep the container in a safe place and out of the reach of children at all times.

How to collect your sample.

1. Start the 24-hour urine test by urinating directly into the toilet. Do not save this urine.

- 2. After this urination, write the date and time on your storage container, this is the start of your test.
- 3. For the next 24 hours, collect all your urine into your storage container.
- 4. Exactly 24 hours after you started the test, urinate one last time and collect this urine in your storage container. **This is the end of your test.** Write the date and time the test ended on your storage container.
- 5. If you need to use more than one container during the 24-hour period, use one container at a time. When it is full, collect your urine in the next container.
- 6. Please bring the urine to the hospital as soon as possible. To prevent leaks, make sure the lid is on tightly, and that the container is transported upright inside a plastic bag.
- 7. If you are an inpatient, your nurse will tell you what time to begin and end the collection and will set up more containers, as needed. If you have questions about the procedure, please ask.

3.1.5.6 Mid-Stream Urine

Male: Clean the glans penis with soap and water. Commence micturition and when a few ml of urine has been passed, introduce a widemouthed container into the stream

Females: If the patient is able to collect urine without assistance from the nursing staff, instruct them as follows:

- 1. Separate the labia and with cotton wool or a sponge moistened with water, wipe the vulva from the front to the back. Disinfectants must not be used.
- 2. With the labia still separated allow some urine to pass into the toilet, and then, without stopping, allow some to pass into a sterile container.
- 3. Pass the remaining urine into the toilet.

3.1.5.7 Swabs

Collect the specimen by passing the swab twice over the relevant area. Label and send to the laboratory as soon as possible after collection

3.1.5.8 Endocervical Swab for GC Culture

Clean the cervical os with a large sterile swab and discard. Insert a new swab into the endocervix and rotate 360 degrees.17 Swab the external os 360 degrees if os stenosed

3.1.5.9 **Sputum**

Instruct the patient to remove dentures, rinse mouth and gargle with tap water and not with antiseptic mouthwash. Instruct the patient to expectorate saliva or postnasal discharge and discard, before expectorating a deep lung sputum sample into a specimen container. Specimens must be submitted in a wide-mouthed container and sent to the laboratory without delay.

3.1.5.10 Stool Samples

Stool specimens should be collected in a clean container with a secure lid, labeled, and sent to the laboratory as soon as possible after collection

3.1.5.11 Disposal of Materials Used

Dispose of all clinical waste must be in accordance with National Guidelines.

- Universal precautions must be adhered to at all times.
- Gloves must be worn at all times.
- Gloves must be changed after each patient.
- Needles must not be recapped after use.
- Dispose of sharps in a suitable sharps container.
- Dispose of all clinical waste into yellow bag.

3.1.6 Specimen Labelling

The following details must be recorded clearly on specimen containers:


- Name
- Date of Birth
- Medical Record Number where available
- Date and time of specimen collection
- For 24 hour urine collections the date and time that the collection commenced and finished
- For Histopatholoy/Cytopathology/Neuropathology, anatomical location of specimen. If multiple specimens on the patient are taken, the specimen containers must be individually labelled as to the site of origin.
- For Microbiology, nature and site of specimen

3.1.7 Specimen Request Forms

All orders are to be electronically ordered where the system is available to the GP practice. Full training has been provided to users on implementation of the GP eOrdering system. The requesting clinician is responsible for the ordering of specimens including addition of all relevant clinical details and are responsible for correct labelling of specimens. Specimens must be accompanied by a fully completed electronic request.

Where electronic ordering is not available in your GP practice or in the rare event that the system is down, the below request form may be used on instruction from Beaumont Hospital.

Approved request forms are distributed by First Direct Couriers on behalf of Beaumont Hospital. The Hospital does not have supplies of request forms. An example is shown below.



When ordering, submit separate samples for each laboratory department. Refer to the individual sections of this manual to ascertain number of specimens required for each sub-laboratory area. If there any problems please contact the department for clarification.

The following details <u>must</u> be recorded on the request:

- Name of Patient
- Date of Birth
- Hospital/Practice Name/Address
- Requesting Clinician
- Tests requested
- Contact number also an out-of hours contact number.
- Clinical details (where appropriate/relevant and including details of recent antimicrobial therapy) NOTE: For ESR requests, full clinical details are required
- Specimen Type for Histopathology/Cytopathology/Neuropathology
- Nature and exact body site and source of the specimen for Microbiology

The following details should be recorded on the request:

- Patients Address (and previous address where applicable)
- A current Episode number or medical record number if available
- Gender (this may have a bearing on a reference range)
- Date of collection/time
- Drawing doctor's or phlebotomist's signature
- When requesting a thromboexact specimen to be tested, please indicate on the request form that this sample needs to be processed in addition to the FBC.

Note: It is imperative that contact details of the requesting doctor and/or location of the patient are attached to the test request so that critical results can be phoned immediately. NHISSOT request and consent forms for HLA typing and HLA Antibody screening can be obtained by emailing crossmatch@beaumont.ie

3.1.8 Specimen Acceptance Criteria

The name on the request and accompanying specimen(s) must match e.g. do not use Pat on one and Patrick or Patricia on other. Please ensure that writing is legible - BLOCK CAPITALS. The requesting clinician is responsible for the correct labelling of specimens and requests. Incorrectly or inadequately labelled specimens are not accepted by the laboratory and will be returned to the source of origin.

Where additional samples are received and are not required to process the tests requested, these samples will be discarded without notification on the day of receipt.

Specimens/request will be rejected in the following situation

- Electronic request not received
- Electronic request does not match the details on specimen
- Unlabelled / Incorrectly labelled specimens i.e. without two unique patient identifiers
- Name or date of birth missing on specimen
- Specimen illegible
- Leaking or improperly sealed containers.

- Overfilled specimens
 - ESR samples where blood is collected into the lid of the container.
 - Coagulation containers where the blood is filled beyond the marking on the label.
- Underfilled specimens:
 - ESR samples must be 85mm full. 2.7 ml
 - FBC and Retic samples must have a minimum of 1mL of blood. 1.8 ml samples should have at least 500µL for FBC Coagulation samples must be filled to the marking on the label
- No suitable sample received for test requested
- Sample not suitable for analysis (e.g. vomit or MRSA on axilla)
- Incorrect transport media/container used (e.g. viral swab sent for C&S, MRSA requested on Chlamydia swab)
- Specimen Clotted, Underfilled, Overfilled or Haemolysed
- ESR requested with lack of clinical details
- Inherited Thrombophilia and Lupus requests if the patient is on anticoagulation.
- Factor V Leiden sample, if the screening test APCR is not also requested. Exceptions allow for family history,
- Obvious inadequacy of specimen for the test(s) required i.e. only one coagulation specimen for a Thrombophilia screen.
- If a patient is on anticoagulation at the time of testing, certain assays within the Thrombophilia profile may be rejected.
- Haematology Molecular testing cannot be performed unless patient consent has been obtained and HAEMG-LF-084 Request form has been completed in full
- HbA1c is analysed in the Biochemistry Laboratory. Patients requiring a FBC and HbA1c will require 2 EDTA 2.6mL samples sent with the test request.
- Aged Specimens:
 - o Coagulation samples must be <4 hours old. In samples greater than 4 hours old. The clotting factors begin to deteriorate which lead to inaccurate results, with the exception of patients on Warfarin. In such cases, samples are stable for 24 hours.
 - o D-Dimer/: Request for D-Dimer add-on, must be <8 hours old post sample collection
 - o ESRs should be < 6 hours old. Samples > 6 hours can lead to a false lowering of results.
 - o FBC: EDTA samples must be <24hours

o Blood film preparation: samples must be <8 hours old

In the case of a sample being rejected, the requesting clinician will be informed by means of a 'test not done' being added to the original test with the reason why. A written record of all discarded samples is kept in the laboratory.

3.1.9 Specimen Tubes & Containers

With the exception of swabs, specimen tubes and containers are available from Beaumont Hospital Stores Department. Contact number: 01 809 3030. All orders must be accompanied by a requisition form. These are also available from the Stores Department.

Swabs are available for collection from Pathology Reception every Friday afternoon from 2-4pm only, on a walk-in basis. Supplies of non-standard phlebotomy accessories are available to purchase from Sarstedt, 053-9144922, www.sarstedt.com.

Sarstedt brand tubes are ESSENTIAL as their size and shape are compatible with our laboratory analysers. Tubes supplied by other hospital laboratories are not compatible with the requirements of Beaumont Hospital. It is important to check expiry dates on all tubes. Tubes MUST BE FILLED to ensure the appropriate concentration of any anticoagulant. <u>Do not use</u> Paediatric tubes.

BLOOD SAMPLES

Tube colour	Anticoagulant	Volume (ml)
Orange	Lithium Heparin	4.9
Orange	Lithium Heparin For Troponin Only	2.7
Orange	Lithium Heparin in FOIL	4.9
White	White Serum ,in FOIL	4.9
Pink	EDTA wrapped in FOIL	
Random Urine	Random urine wrapped in FOIL	
Faecal Sample	Faecal Sample, foil wrapped.	

Tube colour	Anticoagulant	Volume (ml)
Brown	Plain, With Gel Separator	4.9
White	Plain, 4.9 mL volume	4,9
White	Plain	7.5
White On Ice	Plain White	7.5
Orange On Ice	Lithium Heparin	4.9
Pink	Potassium EDTA	2.6
Pink on ICE	Potassium EDTA on ICE	2.6
Yellow	Sodium Fluoride	2.7
Pink- Large	Potassium edta	7.5
N/A	plain	
**Orange	Special Metal Free Tube & Needle	7.5
N/A	Plain	
N/A	Pre-Acidfied	
N/A	CSF Plain	
CSF – Brown	Plain-Protect From Light	At least 1ml
Arterial syringe	Lithium heparin	
Purple	Tri-sodium citrate 4NC	3.5 mL
Pink	EDTA-KE (Tri-potassium	2.6 mL
	Ethylenediaminetetra-acetic acid)	1.8 mL- Paediatric
Green	Tri-sodium citrate 9NC	2.9 mL
		1.8 mL- Paediatric
Red	0.82mg Magnesium/mL	2.7mL
n/a	Salivette	

Never pour blood from one tube into another. The preservative in the first tube will contaminate the second tube; this can greatly affect results.

Revision 15

URINE SAMPLES

Both 24 hour urine collections and random spot urine samples are analysed in the laboratory.

Random spot urine samples are collected into The Sarstedt NFT (Needle Free Transfer) system. This consists of a 10ml NFT primary container (Sarstedt Product Reference 75.562.900) and a 10mL Monovette tube (Sarstedt Product reference 10.252)

• A 24 hour urine collection is either taken in a plain 3L container or an acidified 3L container, depending on the test required. Pre-acidified containers with either 50% acid or concentrated acid are available from phlebotomy. If known in advance that the patient has an unusually large output, please request 2 containers for the test. Results are normally expressed per 24 hour period. Where two tests are desired, each requiring a different container, two separate 24 hour collections must be obtained. If in doubt please contact the relevant laboratory prior to commencement of the test.

APTIMA GENPROBE COLLECTION DEVICES

Aptima GenProbe Collection Devices (swabs and urine containers) are only available from the NVRL. Contact number: (01) 7161354

3.1.10 Delivery of Specimens for Analysis

Specimens can be delivered directly to Pathology Specimen Reception or posted to the relevant laboratory department. If posting specimens, the guidelines outlined in section 3.1.16 on page 78 must be adhered to.

3.1.10.1 GP Courier Service

A courier collects samples from each GP practice within the Beaumont Hospital catchment area. The samples are brought to Pathology Reception where request forms are reviewed and scanned, labels printed and samples are labelled prior to analysis. The final courier delivery to Pathology reception is 1:30pm Monday to Friday.

3.1.11 Specimen Reception Process

Samples are received in the central pathology reception where they are distributed to the relevant laboratory department. Where appropriate, specimens are centrifuged. This process separates the cells from the serum / plasma. Samples left unseparated for a number of hours / overnight (sample 'on cells'), causes a gradual leakage of red cell contents and produces spurious results for some assays including potassium, phosphate, magnesium, transaminases, LDH and Folic Acid. Therefore accurate information on date and time of sampling is very important and saves many unnecessary phone calls to busy clinicians.

3.1.12 Test Results

Beaumont Hospital participates in the Healthlink service, which provides the secure transfer of patient results over the internet. This service is available free of charge to all GPs and is the preferred method of result transmission. Beaumont Hospital Pathology Department does not issue paper reports unless specifically requested by a GP practice. Beaumont Hospital uploads patient reports to the Healthlink service every 10minutes.

Departmental reports going outside the hospital to GPs or external agencies are included in pathology composite reports, which include all test results validated that day from all disciplines. Interpretative comments are routinely included where appropriate.

If you have any queries in relation to a report, please contact the relevant laboratory area to discuss the result. Feedback from users about difficulty with reports helps us to improve the service. Contact details are available in Section 3.1.2 of this manual.

Despite our best efforts, it is possible that an error can occur. If you have concerns about a report please draw it to our attention without delay, and we will investigate immediately.

If you are interested in accessing this service please contact The National Healthlink Project. Tel. (01) 8825606. Email info@healthlink.doh.ie

Document Number: LP-GEN-0014

PLEASE NOTE: It is the responsibility of the laboratory to ensure that tests are performed to the highest possible standard and reported in the time specified within this User Manual. It is the responsibility of the requesting clinician to follow up on the test results.

3.1.12.1 Requests for Results

A dedicated results telephone line is in place for blood sciences and a copy of a report can be emailed by administration staff to a secure email account (e.g @hse @healthmail etc.). The laboratory has previously issued details on obtaining a secure email account and this information is available at http://www.beaumont.ie/media/July20181.pdf. The dedicated results line details are as follows:

Tel: 01 809 2690 Monday to Friday 9.30-12:30 and 14:30-16:00

Please note this <u>does not</u> affect the reporting of critical results or request for clinical interpretation. Requests for clinical interpretation will be handled as outlined in section 3.1.12 above

Other useful numbers:

Microbiology reports: 01 809 2646 (lines open 9am-4pm) Histopathology reports: 01 809 2632 (lines open 9am-4pm

NVRL results: 01 716 4414 (lines open 8am-6pm)

3.1.12.2 Critical Values

Results falling outside defined alert limits will be telephoned to the appropriate GP/Nursing Home/External personnel. Given the hundreds of specimens received each day, sample analysis often continues into the 'out-of-hours' period, it is vital that the laboratory has a mobile phone contact number for each GP so that urgent results can always be phoned.

Reports that are critical to care, requiring immediate attention will be phoned to the requesting practice as soon as they are authorised. To avoid inappropriate phone calls it is essential that the time and date of sample draw is clear on both the sample

and request form. Chemical Pathology Samples that are received that were not drawn on the day of delivery to the department will have all labile tests reported as 'on cells'.

3.1.12.3 Flagged Results.

Abnormal and flagged results are highlighted on the laboratory information system. However, each GP practive management system differs on how these messages are received. As previously communicated to GP practices by the Clinical Directorate of Laboratory Medicine in Beaumont Hospital in Dec 2024 (MEMO201), during testing carried out during implementation of the new laboratory information system and its interface with GP practice management systems, some risks were identified due to differences in how results are viewed compared to previous systems. The risks for each system are highlighted below.

A full risk assessment has been completed by the Clinical Directorate of Laboratory Medicine in Beaumont and the HSE.

The risks have been highlighted to the vendors involved. Where possible these issues will be updated.

Socrates:

1. Clinical viewing of abnormal results: shows 'abnormal' tick, even if a non-abnormal result is included in battery of results

Healthone:

- 1. Abnormal results only indicated by red colour, and colour changes back to default on screen change
- 2. No header for reference ranges
- 3. Microbiology result may appear in duplicate if sent multiple times.
- 4. Microbiology results with multiple organisms and susceptibilities can look confusing in the default view.

GP Socrates, Helix & HealthOne:

- 1. Amended results don't overwrite / invalidate previous. In these cases, the result previous to amendment is also visible.
- 2. Some symbols aren't supported by the interface (mostly uncommon symbols such as $| ^ \sim$ and accented letters like á). These characters are not correctly represented and can appear as a 'question mark'

3. Results flagged on the lab system as 'critical' are only flagged as 'abnormal'. Note that abnormal results may be beyond critical limits

To minimise these risks, it is advised that the Healthlink view is always used to view results.

<u>Mapping between Healthlink and GP Practice Management Systems remains the responsibility of each GP practice, contact your GP Practice Management vendor for training if required.</u>

3.1.12.4 Turn Around Times

Turnaround times are quoted in each departmental section. Turnaround times are constantly monitored by The Clinical Directorate of Laboratory Medicine and we aim to meet the quoted turnaround times at all times. However, if the laboratory is experiencing any deays in turn around times which affect our users and patients, this will be notified to laboratory users via written communication from the laboratory management team.

3.1.13 Telephoning GP/Results Out of Hours

Where a GP is not contactable by mobile telephone, the dedicated GP Results Out of Hours telephone may be used to alert the GP by text that urgent results are awaiting them.

If a mobile number for the GP is not available, a non-conformance will be raised. It will be passed to the relevant Consultant Pathologist for signing and the scanned documentation will be emailed to the relevant GP's healthmail account. Paper copies of patient reports are available from the Pathology Office, 8092507.

Beaumont Hospital has no access to the Healthlinks service.

3.1.14 Attendance at Phlebotomy:

An online appointment system for Phlebotomy is in place for the GP phlebotomy clinic. GP patients and family members of patients can go to www.beaumont.ie and select the 'Patient Information' link to make a blood test appointment. Alternateively, GPs can go to www.swiftqueue.com/gp to make an appointment for a patient after registering using the code 'sw1ft45'.

Telephone appointments can be made between 10.30am and 12.30pm Monday to Friday at 01-2910993 (standard local call rates), for a limited period of time. Outside these times, telephone appointments can be made by calling 1517 345 333. NOTE: This is a premium rate service with calls charged at €2.03 inclusive of VAT (calls from some mobiles may be higher with a maximum cost of €2.50).

A Phlebotomy Appointments Online User Guide is available on the hospital website.

3.1.15 Specimen Referral

When we are unable to provide a clinically important assay, we will attempt to source a referral laboratory, to which specimens may be sent. We welcome input from interested clinicians in this process. The choice of laboratory is primarily based on quality grounds, with accredited laboratories being chosen preferentially. Other factors such as cost and turnaround times are also considered. A list of referral laboratories in use is available from the Directorate on request. The Directorate does not refer samples for GPs or other external units. Only samples for tests that are conducted in-house, and included in the National Clinical Pathology Programme/ Beaumont Hospital approved test catalogue will be processed. In exceptional circumstances, where a patient attends a GP for bloods on the request of a Beaumont Hospital Consultant, **AND** the Consultants name and the Test required is written legibly on the Healthlink Request form, we will process the test.

External test reports are issued on paper only via the post. They will not be available on Healthlink. The report will also be scanned into the patient's record on Powerchart where it will be available to the requesting clinician.

3.1.16 Specimen Transportation Guidelines

It is essential that all specimens are transported to the laboratory under conditions which

- Comply with the Hospital Safety Statement, as well as relevant National Postal and Health and Safety legislation and IATA regulations
- Protect postal workers, couriers, porters and laboratory staff
- Ensure the integrity of the analyte to be measured

Specimens where the external surface is contaminated with blood or other body fluids will not be accepted for analysis – another specimen must be collected.

Send specimens in the bag attached to the request form. Up to 10 specimens may be placed in the bag. It is the responsibility of referring hospitals to ensure that packaging complies with relevant legislation.

The international regulations for the transport of infectious materials by any mode of transport are based upon the recommendations of the United Nations Committee of Experts on the Transport of Dangerous Goods (UN), The Universal Postal Union (UPU), the International Civil Aviation Organisation (ICAO) and the International Air Transport Association (IATA) have also incorporated the UN Recommendations in their respective regulations.

The specimen should be placed in watertight containers containing 10% Neutral Buffered Formalin (volumes larger than 125ml should not be transported by post but hand delivered to the laboratory), the lid must be securely closed to avoid leakages. Patient's details entered on container and request form as above. Specimens <u>must</u> be packaged in a UN-approved packaging system (UN3373/4GU/Class 6.2/05 GB) which consists of three layers:

1. Primary Receptacle: a labeled primary watertight, leak-proof receptacle containing the specimen. The receptacle is wrapped in enough absorbent material to absorb all fluid in case of breakage.

- 2. Secondary Receptacle: A second durable, watertight leak-proof container to enclose and protect the primary receptacle(s). Several wrapped primary receptacles may be placed in one secondary receptacle. Sufficient additional absorbent material must be used to cushion multiple primary receptacles
- 3. Outer Packaging: The secondary container is placed in an outer shipping package which protects its contents from outside influences such as physical damage and water while in transit.
- 4. Both the recipient's and the sender's name and address must be shown on the packaging so that contact can be made in the event of a leakage.

Specimens should be addressed to the laboratory, and never to an individual member of staff. If there have been prior discussions the form (not the envelope) should state which member of staff should be informed of the specimen's arrival.

If a specimen arrives in a condition which places staff at risk, we regret that it cannot be processed. Where contact details are provided the requesting clinician will be informed, however we can take no responsibility for delays which occur due to the lack of contact details.

If diagnostic specimens in 10% formalin are posted the following guidelines and instructions must be adhered to:

Please note: Glass specimen tubes are not acceptable due to Health and Safety regulations. Please refer to page 70 for correct specimen tubes to be used.

3.1.17 Specimen Storage Conditions

- Store blood samples at room temperature, unless otherwise specified. Note that blood samples stored in a refrigerator may have falsely elevated results e.g. potassium. The exception to this is FBC samples which may be stored in a refrigerator for up to 24 hours (however, should there be a delay in an FBC reaching the laboratory the sample must be <24 hours old in order for it to be processed)
- 24 hour urine collections should be refrigerated throughout the collection and brought to the laboratory ASAP.
- Samples for auto antibody crossmatches for NHISSOT should reach the laboratory within 24 hours' and **should not** to be refrigerated.

- Addition of test requests to existing samples is not recommended due to issues of sample integrity. Contact individual laboratory for advice and to book in the samples for testing.
- Malaria tests must be examined within 2 hours of sample collection. Therefore, it is recommended that patients attend the Phlebotomy Department in Beaumont Hospital for sample collection.
- In most cases, if delays are unavoidable, microbiology specimens can be preserved by refrigeration at 2-8°C in a designated specimen fridge, as this maintains the viability of the pathogens present and prevents the overgrowth of non-pathogenic bacteria. This is of particular importance if quantitative or semi-quantitative culture is required, for example during microbiological analysis of sputum and urine.

Exceptions to this include:

- 1) Blood cultures should be promptly brought to the laboratory by a porter or sent via chute
- 2) CSF should be held at room temperature.
- 3) Samples specifically for the isolation of *Neisseria gonorrhoea*. (i.e. cervical or urethral specimens) should be stored at room temperature.

3.1.18 Data Protection Policy

The Clinical Directorate of Laboratory Medicine complies with the policy of the HSE regarding the legislation pertaining to the rights of the patient and staff and to act in an ethical and responsible manner in maintaining the security and integrity of all personal information

The Directorate retains the following information in relation to each test request received, for a minimum of 30 years, in order to ensure patient history is maintained and that sufficient information is available to staff responsible for the interpretation and reporting of results from the laboratory:

- 1. Patient full name
- 2. Patient Address
- 3. Patient medical record number/episode number
- 4. Patient date of birth
- 5. For each specimen: date/time of collection, date/time of receipt in the laboratory and date/time of report, specimen type, priority.

- 6. Clinical information provided by clinicians
- 7. The results and where appropriate, interpretation of each test requested.
- 8. Requesting clinician and address

3.1.19 Placing Patient Information in the Public Domain

It is laboratory policy that information obtained or created during the performance of laboratory activities is not placed in the public domain unless agreed by the patient. If the laboratory is required by law or authorised by contractual arrangements to do so, the patient's clinician will be informed and they will inform the patient (unless this is prohibited by law). Further details are outlined in the relevant departmental standard operating procedures.

Information about the patient from a source other than the patient (e.g. complainant, regulator) is kept confidential by the laboratory. The identity of the source is kept confidential by the laboratory and is not shared with the patient, unless agreed by the source.

3.1.20 Time Limits for Requesting Additional Examinations

Please note that verbal requests for any examinations must be followed by a fully completed request, by email request in order for results to be issued. Request forms must be received within the timeframe outlined for each department below. Requests for Chemical Pathology add-on tests must be e-mailed to: chemicalpathology@beaumont.ie. Requests for Haematology add-on tests must be e-mailed to: Haematology@beaumont.ie

3.1.21 Repeat Examination due to Analytical Failure

In the event of an analytical failure, if the system returns to normal within the test cut-off time, the samples are processed accordingly. However, if this time exceeds the test cut-off limit, the users are notified and repeat samples are requested, where applicable

3.1.22 Uncertainty of Measurement (MOU)

Every measurement, including a laboratory result, is subject to a level of uncertainty. For example blood pressure measured a few times within a single clinical visit may vary. This variation is made up of biological variation together with the uncertainty of measurement (and may be compounded further if any error is made). Systems in the laboratory are designed to minimise error – however if you are concerned that an error has occurred please contact us to let us investigate this. Even when error is eliminated, uncertainty of measurement affects all results.

When interpreting the results of a laboratory test the uncertainty of measurement (UM) of that result needs to be considered. UM is a numerical value & is an expression of the magnitude of uncertainty of a result. It characterizes the dispersion of values reasonably attributed to measurement. If not understood may lead to over interpretation of results.

e.g. If the UM is 10% & the result is 100, then the true result probably lies between 90-110. Therefore is the result obtained due to clinical changes in the patient or imprecision of the test method itself?

Uncertainty is not error. Error tells us the difference between the true value & the measured value. Error can be corrected, uncertainty cannot. UM is the quantitative expression of doubt (uncertainty) & spread of a particular measurement. It is an estimate of the confidence in the result produced by the laboratory.

Uncertainty is a parameter associated with every result & is specific to each result. The uncertainty associated with any assay performed in the laboratory is available on request.

3.1.23 Accreditation/Quality Standards

Beaumont Hospital Clinical Directorate of Laboratory Medicine's current scope of Accreditation to ISO15189 is available from the INAB website, https://www.inab.ie/FileUpload/Medical-Testing/Beaumont-Hospital-225MT.pdf The H&I Department is accredited by EFI (European Federation for Immunogenetics).

Specimens referred out from Beaumont Hospital are not covered by the scope of Beaumont Hospital ISO15189 accreditation.

3.1.24 *Complaints*

Beaumont Hospital is committed to responding to patient and user feedback both positive and negative. The hospital endeavors to respond to concerns and identify and manage any deviation from high quality care.

Complaints and feedback may be given directly to any member of staff in the laboratory or through the Patient Advisory Liaison Service (PALS) In any case, there may be a resolution at point of contact or the case may be of a serious nature that requires further action. All complaints (verbal or written) are recorded directly onto Q-Pulse, and are classified as per Nonconformity procedure. The medical significance of each complaint is decided upon by the departmental Consultant Pathologist. The Head of Department or Laboratory Manager may deal with the complaint depending on its severity. Records of complaints are maintained for periods as defined in schedule for record retention.

If a complaint cannot be resolved at local level it will be forwarded to the hospital's Patient Liaison officer.

The laboratory actively seeks feedback from its patients, users and personnel which is used to analyse and improve the laboratory management system, activities and services provided to users as demonstrated below. This is achieved through regular user satisfaction surveys, complaints and compliments that are received and through it's annual management review. All of these contribute to the laboratory continual improvement process.

3.1.25 Open Disclosure

Beaumont Hospital follows the HSE National Policy for Open Disclosure. Open Disclosure is a requirement of the HIQA National Standards for Safer Better Healthcare. Open Disclosure "an open, consistent approach to communicating with patients when things go wrong in healthcare. This includes expressing regret for what has happened, keeping the patient informed, providing feedback on investigations and the steps taken to prevent a recurrence of the adverse event." Open Disclosure should happen when a service user has experienced an "adverse event" but also when a service user experiences a "no harm event" or is exposed to a "near miss event".

3.2 HAEMATOLOGY

Same day turnaround times refer to results being available to the requesting clinician on the same working day. Results are available on ward look-up or on Healthlink. Clinicians receiving results by post will incur an added delay.

3.2.1 Repertoire of Haematology Tests

Test	Specimen	Minimum/ Container		ult Reference	O	TAT	Test Method	Comment		
	Container			ports for Paediat	ric Kanges)					
Full	` -	k2.6ml standard	Parameter	Male	Female	1 Working Day		7.5ml and	10ml	EDTA
Blood count	capped)		Hb	13-17.5 g/dL	11.5-16.5 g/dL			samples	are	not
					11.7-16.0 *		Lauryl	acceptable		
			PCV	0.37-0.54	0.335-0.54 L/L		Sulphate (SLS)			
				L/L	0.355-0.52*		Haemoglobin	*Fei	male	>50
			RCC	$4-6.5 \times 10^{12}/L$	$3.8-5.8 \times 10^{12}/L$		Method	year	S	
							 Calculated 			
					3.8-5.6*		Parameters			
			RDW	11-15 %			• Impedance			
			MCV	79 -96 fL			TechnologyFluorescence			
			MCH	27 -32 pg			Flow			
			MCHC	32.0-36.5 g/d	T.		Cytometry			
			PLTS	140 -400 x10						
			WBC	$4.0 - 11.0 \times 10^{-1}$						
			Neut	$2.0 - 7.5 \times 10^9$						
				$1.0 - 4.0 \times 10^{9}$						
				$0.2 - 1.0 \times 10^{9}$						
				0.04- 0.4 x10						
			Baso	$0.01 - 0.1 \times 10^{\circ}$	7/L					

Test	.	Minimum/ Container Volume	Adult Reference Range (See Reports for Paediatric Ranges)	TAT	Test Method	Comment
Platelet Check (Thromboexact)	0.82mgMg^2		140 -400 x10 ⁹ /L	1 Working Day	 Sysmex XN Impedance Technology Fluorescence Flow Cytometry 	Arrange in advance with laboratory to obtain sample tube. Please write on the request form that a platelet count from a Thromboexact tube is required
	Trisodium citrate 4NC /3.5 (purple)	3.5 ml must be filled to the line	Male Female 1- 12 mm/hr 1-20 mm/hr		Sarstedt Desaga S2000 Sedimentation of RBC's	Only indicated for the following • Giant cell arteritis, • Polymyalgia rheumatica. • 'Suspected myeloma' • -Hodgkins Lymphoma • Prosthetic joint infection, • Osteomyelitis, • Rheumatoid Arthritis
Infectious mononucleosis Screen	EDTA (pink capped)	2.6ml standard	Negative	1 Working Day	Manual Immunoassay	

3.2.2 Repertoire of Coagulation Tests

Test	Specimen Container	Number of Samples	Minimum Volume	Reference Range	TAT	Test Method	Comment
Coagulation Screen Prothrombin Time Activated Partial Thromboplastin Time	Trisodium citrate 9 NC/2.9 mL (green capped)	1	to the line	PT: 10-13.2 seconds INR should only be used for monitoring Warfarin therapy. Refer to local treatment algorithm. APTT: 24 – 36 seconds	Day	Coagulometric(turbidimetric) Calculated parameters	Sample must be <4 hours old
INR	Trisodium citrate 9 NC/2.9 mL (green capped)		Must be filled to the line	The INR should only be used for monitoring Warfarin therapy. Refer to local treatment algorithm.	Day	turbidimetric)	INR only requests are stable for 24 hrs Warfarin Office contact no. 01- 8092083
D-Dimer	Trisodium citrate 9 NC/2.9 mL (green capped)		Must be filled to the line	Under 50 yrs<0.5 µg/ml Then increases in 5 year increments by 0.5. i.e 55- 60 (<0.6) and 85-90 (<0.9)	Day	Immuno- turbidimetric	Sample must be <8 hours old

Test	Specimen	Number of	Minimum	Reference Range	TAT	Test Method	Comment
	Container	Samples	Volume				
Fibrinogen	Trisodium citrate	1	Must be filled	1.9 – 3.5 g/L	1 working	Clotting	Sample must be <4 hours old
	9 NC/2.9 mL		to the line		Day	(Clauss)	For patients on Argatroban a Clauss
	(green capped)						Fibrinogen test is not appropriate &
							will be reported as follows:
							"Fibrinogen result is unavailable as
							the patient is on Argatroban which
							may cause a false low fibrinogen
							result in the Clauss fibrinogen assay.
							Please discuss with the Haematology
							team".

Test	Specimen	Number of	Minimum	Reference Range	TAT	Test Method	Comment
	Container	Samples	Volume				
Thrombophilia	Trisodium citrate	4	Must be filled	See individual requests		APCR ,	
screen	9 NC/2.9 mL		to the line	APCR, PC, Prot S Act,,			From 1 St May 2023 onwards General
	(green capped)			Antithrombin and LA.		turbidimetric)	Practitioners will no longer be able to
						PC	request the following tests directly:
						PC Antithrombin	• Inherited Thrombophilia Screen (Antithrombin, Protein C, Protein S,
						Chromogenic	Activated Protein C Resistance (+/-
						Cinomogenie	Factor V Leiden Mutation if
						Prot s	required)
						Immuno-	•
						turbidimetric	Testing will be reserved for specific
							patients who are deemed to meet the
							clinical criteria after being reviewed and
							sanctioned by the Haematology team. If sanctioned then a
							Thrombophiliarequest form
							HAEMC-LF-023 MUST fully
							be completed. This form can be
							obtained from the Beaumont
							Hospital website, under
							Haematology Dept.
							Batch tested.
							The Inherited Thrombophilia
							screen (Thr philia) includes
							the following tests: PT,
							APTT, FIB-C,
							ATPC, Prot S Act, APCR
							5LEIDEN*. A Lupus screen is not on
							this profile.

Document Number: LP-GEN-0014

Test	Specimen	Number of	Minimum	Reference Range	TAT	Test Method	Comment
	Container	Samples	Volume				
Lupus anticoagulant	Trisodium citrate 9 NC/2.9 mL (green capped)		to the min	DRVVS < 1.17 DRVVTR: <1.23 SCT TR < 1.14	4 weeks	Coagulometric(turbidimetric)	 From 1st May 2023 onwards General Practitioners will no longer be able to request the Lupus Anticoagulant directly: Testing will be reserved for specific patients who are deemed to meet the clinical criteria after being reviewed and sanctioned by the Haematology team. If sanctioned then a Thrombophiliarequest form HAEMC-LF-023 MUST fully be completed. This form can be obtained from the Beaumont Hospital website, under Haematology Dept. Batch tested. Patients must not be on any anticoagulation as they interfere with the interpretation of the assay.

3.2.3 Repertoire of Haematology Molecular Tests

Test	Specimen Container	Number of Samples	Minimum/ Container Volume	Reference Range	TAT	Test Method	Comment
Factor V Leiden mutation (5Leiden) And APCR	EDTA sample (pink) Trisodium citrate 9 NC/2.9 mL (green capped)	1	2.6ml Standard Must be filled to the line		6 weeks	Coagulometric(Only tested if the Activated Protein C (APCR) is positive or a family history is indicated on the request form. For APCR sample requirements see previous table. Thrombophilia request form HAEMC-LF-023 MUST fully be completed. This form can be obtained from the Beaumont Hospital website, under Haematology Dept. If genetic consent is not obtained the molecular test will be rejected. The laboratory will no longer take receipt or store the form containing patient genetic consent. It is the responsibility of the ordering clinician to obtain and file a copy of genetic consent in the patient's record.

Test	Specimen	Number of	Minimum/	Reference Range	TAT	Test Method	Comment
	Container	Samples	Container Volume				
HFE Haemo-	EDTA (PINK	1	2.6ml	Not detected	4weeks	Real-time	Must be accompanied by completed
chromatosis	cap) Whole blood					PCR	Haemachromatosis Genetic Screening Request Form (HAEMC-LF-077) This form can be obtained from the Beaumont Hospital website, under Haematology Dept. If genetic consent is not obtained the molecular test will be rejected. The laboratory will no longer take receipt or store the form containing patient genetic consent. It is the responsibility of the ordering clinician to obtain and file a copy of genetic consent in the patient's record.

3.2.4 Requests for Additional Analysis

Verbal requests for additional examinations from GPs will be reviewed on a case-by-case basis and are dependent on suitable specimen availability and the appropriateness of the test request. GP verbal requests accepted by phone will then need to be emailed to haematologyadmin@beaumont.ie for the additional test.

Refer to table below for test cut-off times when requested to add a test to a sample already received in the Laboratory. Processing an additional request depends on the sample having the correct anti-coagulant, not too old for analysis, correct storageand not discarded.

3.2.4.1 Test Cut-Off Times

Document Number: LP-GEN-0014

Test	Test Cut-off Times
FBC	<24 hours
Blood Film preparation	<8 hours
Platelet Exact for platelet clumping	<24 hours
Malaria	< 2 hours (test should be performed within 2 hours of phlebotomy hence patient should present themselves to the Phlebotomy Department or AE with a request for a "malaria screen")
IM	<24 hours
Sickle Screen	<14 days if stored @ 2-8°C
PNH	< 48 hours if stored at @ 2-8°C
Lymphoproliferative Panel, T-Panel, Lymphoid Screening Tube	All EDTA samples must be <48 hours old.
Acute Screen, Acute Leukaemia Panel, Blast Count	Sodium Heparin (orange capped - BMA) with 1ml RPMI must be < 48 hours old
Coagulation Samples	< 4hours
D-dimer	<8 hours
INR	<24 hours
Factor V Leiden, PT mutation	<28 days once stored at 2-8°C

In cases where the Haematology consultants have reviewed a blood film, these are reported under 'HBFC. 'Bld film F' and 'HBFC can only be ordered in the Laboratory.

3.2.5 Critical Values

- GP results are available on Healthlink.
- Results falling outside defined alert limits are telephoned to the appropriate personnel.

- It is imperative that the mobile phone number of the requesting doctor is on the request form so that critical results can be phoned when surgeries are closed.
- If a mobile phone number is not available or contact number unanswered, the critical alert value will be telephoned the following day.

The following are the different catagories as defined by

theCommunication of Critical Results for Patients in the Community, National Laboratory Handbook, HSE National Clinical Programme for Pathology

- <u>Category A</u>: Result MUST be telephoned that day as soon as possible resort to Ddoc if all else fails <u>Consider all results on this list Category A unless</u> stated otherwise
- <u>Category B</u>: Every attempt to be made to telephone result on same day but if not possible do not contact Medical SHO and instead wait for next day(if next day is weekend or bank-hol, need to contact MED-SHO after all other avenues have been exhausted.

The Following Table is a list of these results that will be phoned:

Test	OPD(except CKB) GP/ Nursing Homes/ External Hospitals
Hb	<7.0 g/dL N/N* Normochromic/ Normocytic
	5-7 g/dL H/M* (Category B)
	>20.0 g/dL
PLT	<30 x 10 ⁹ /L
	31-50 x 10 ⁹ /L (Category B)
	>1000 x 10 ⁹ /L
WCC	>30 x 10 ⁹ /l (Category B)
Neutrophils	$<0.5 \times 10^9/L \& >50 \times 10^9/L (1^{st} time)$
FBC	Results indicating possible leukaemia i.e. numerous flags (especially blast),
	increase WCC, DIFF vote-out or very abnormal, plt<100 and low Hb. Phone
	ward/clinical team responsible for the patient and to bring these results to
	their attention.
INR/	>5.0
Fibrinogen	<1.5 g/l
Flow	New Acute Leukaemia/PNH patients
Cytometry	CHB Blast counts >5%, contact Prof. Thornton/Dr Quinn directly
Morphology	New Acute Leukaemia
	ТТР/МАНА

3.3 CHEMICAL PATHOLOGY

3.3.1 Services Offered

The Chemical Pathology Department provides a comprehensive suite of routine and specialised tests including;

- General biochemistry, including test profiles for renal, liver, bone, cardiac, muscle, lipid disorders and glucose homeostasis.
- Immunoassay tests of thyroid, gonadal, adrenal and pituitary function, haematinics, therapeutic drug monitoring.
- Urine tests for total protein and albumin, calcium, phosphate, magnesium and uric acid.
- Biochemical tests for phaeochromocytoma, neuroblastoma and carcinoid tumours including Plasma Free Metanephrines, urinary fractionated catecholamines, metanephrines and 5HIAA.

3.3.2 Contact Details for Medical / Clinical Advice

For test results please contact the dedicated results telephone line on (01) 8092690.

For medical advice contact:

Consultant Chemical Pathologist; Dr. Shari Srinivasan on (01) 8092676 Consultant Chemical Pathologist: Dr. Clodagh Loughrey on (01) 8092053

During working hours medical advice can also be obtained by contacting; Chemical Pathology Specialist Registrar; (01) 8092666 or 8093000 Bleep #332

During working hours scientific advice can be obtained by contacting;

Chief Medical Scientist; Alison Griffin (01) 8092670 Chief Medical Scientist; Miriam Shinners (01) 7977811 For information on test requirements please see below.

3.3.3 Requests for Additional Tests

To request additional tests please contact the relevant laboratory.

Samples are retained in the Department for 72 hours and are validated for testing only up to this time. Requests for additional analysis must be made to the laboratory within this validity period. The laboratory will advise on the suitability of the sample for additional testing if appropriate and if agreed an e-mail outlining the request must then be sent to Chemical Pathology chemicalpathology@beaumont.ie for the attention of the relevant chemical pathology staff member following the discussion.

Table D: Routine Profiles and their Components

Description	Mnemonic	Tests
Renal Profile	Renal	Urea, Na, K, Cl, Creatinine, eGFR
Liver Profile	Liver	Bilirubin, ALT, ALK, γGT, AST,
		ALB, TP, Globulin
Lipid Profile - Fasting	FHDL	Cholesterol, Triglyceride, HDL,
Lipid Profile - Non-fasting	HDL	Calculated LDL, non HDL
		Cholesterol
Bone Profile	Bone	Ca, ALB, Phosphate, Ca Adjusted,
		ALK
Thyroid Function Test	TFT	FreeT4 and TSH

3.3.4 Therapeutic Drug Monitoring (TDM) samples

- All samples must be drawn into a white cap serum tube, 4.9mL.
- Samples should be taken immediately prior to next dose trough sample.
- **Digoxin:** samples must be taken pre-dose or at least 6 hours post-dose.
- **Lithium:** samples must be collected 12 hours post dose.

3.3.5 Tumour Marker Analysis

Tumour markers should not be used to diagnose disease. Their use is to monitor / follow-up known disease states. If a patient is attending Beaumont Public Hospital for Oncology treatment, we can accept samples for Tumour marker analysis, at the request of the attending clinician and this MUST be indicated on the request form — or a copy of the Consultants request included.

Patients that are being treated and followed-up at other facilities must have tumour markers analysed at that laboratory as there can be very significant variations in results between assay platforms.

Please refer to relevant NCCP guidelines.

3.3.6 Externally Referred Tests

Samples from General Practitioners or other external service users are not referred to external laboratories. Beaumont Hospital is not funded to provide this service.

If a clinician of Beaumont <u>Public Hospital</u> requests a GP to organise a test not provided in Beaumont Hospital this will be facilitated <u>if</u> the request from the clinician is sent with the test request form or noted very clearly on the request form.

3.3.6.1 Reports from External Laboratories

External test reports are issued on paper only via the post. They will not be available on Healthlinks. The report will also be scanned into the patient's record on Powerchart where it will be available to the requesting clinician.

3.3.7 Fertility Clinics

Chemical Pathology does not provide testing services for patients attending fertility clinics.

3.3.8 Critical phoning limits

- Results falling outside defined alert limits will be telephoned to the requesting GP or referring laboratory.
- Note: If it is not possible to contact the relevant GP out of hours the result will be communicated to the nominated out-of-hours service.
- It is the responsibility of the healthcare professional who requests a laboratory test to ensure that the result is reviewed and appropriate action taken.
- Results apply to the current episode number.
- **Urgency A** rapid communication of results within 2 hours.
- **Urgency B** results require communication within 24 hours, and preferably on the same working day. This would also apply to outpatients. For outpatients if there is no facility to phone on a Saturday then discuss with the on-call senior to determine the urgency.
- **Urgency** C- communication of these results on the next working day is deemed satisfactory.

RESULTS FOR URGENT COMMUNICATION							
	Units	A	Urgency	Ref.	Comments		
Analyte		Lower	Upper				
Sodium	mmol/L	120	155	A	1		

	RESULTS FOR URGENT COMMUNICATION									
	Units	A	ction Limits	Urgency	Ref.	Comments				
Analyte		Lower	Upper							
		130 if< 16 yrs		A	2	Note different phoning limits for in-patients and GP/OPD				
		125 GP/OPD		A	3	31,312				
Potassium	mmol/L	2.5	6.5 6 GP/OPD	A A	2	Check for haemolysis, age of sample & EDTA contamination.				
		2.7 GP/OPD		A	3	Note different limits for in-patients and GP/OPD				
Urea	mmol/L	-	30	A	1	017012				
			10 if< 16 yrs	A	2					
			35 CKD patients	A	3					
Creatinine	μmol/L	-	354	A	1,2					
			200 if < 16 yrs	A	2					
			800 CKD patients	A	3					
Glucose	mmol/L	2.5	25	A	1,2,3					
			30 GP/OPD/known diabetics	A	2					
			15 if < 16 yrs	A	2					
Calcium Adjusted	mmol/L	1.8*	3.5	A	1,2	*report with Albumin				
(Total Calcium if no			3 GP/out-patients	В	1	Request and perform U&E.				
calculation available)			3.2 CKD patients	A	3	All calcium results above upper action limit to be phoned regardless of previous critical result.				
Phosphate	mmol/L	0.3	-	A	2					
		0.45 GP/OPD		В	1					
Magnesium	mmol/L	0.4		A	1,2					
Creatine	U/L	-	5000	A	1,2					
Kinase			400 if <16 yrs	A	3					
Amylase	U/L	-	500	A	1,2					
CRP	mg/L	-	300	A	1,2					
AST	IU/L	-	500 female	A	1,2					
			600 male	A	1,2					

		RESULTS	FOR URGENT COM	MMUNICAT	ΓΙΟΝ	
	Units	A	Urgency	Ref.	Comments	
Analyte		Lower	Upper			
ALT	IU/L	-	500 female	A	1,2	
			600 male	A	1,2	
Cortisol		50	-	A	1	Unless part of dexamethasone suppression test Do not assume a dexamethasone test has been undertaken.
Cortisol	nmol/L	250		A	2	As part of short
(SST)	1 /T	10		4	2	synacthen test
	mmol/L	10	400	A	2	Excluding ICU patients
Ethanol	mg%		400	A	2	
CCC 1	(mg/dL)	1 .	All levels in <16 yrs	A	3	
CSF results			sults to be phoned	A	3	
Paracetamol :		All results	D 5	A	2	
Digoxin	ug/L		2.5	A inpatients B GP/OPD	2 1,2	Check timing > 6 hrs from last dose. Give U&E results also. More urgent if K+< 3 mmol/L. Phone immediately to GP/OPD requestor if overdose suspected or K+ low
Carbamazepi ne	mg/L		15	A inpatients B GP/OPD	3	IX IOW
Phenobarbito ne	mg/L	-	70	A inpatients B GP/OPD	3	
Phenytoin	mg/L	-	25	A inpatients B GP/OPD	2,3 1,2,3	
Valproate (Valproic acid)	mg/L	_	120	A inpatients B GP/OPD	3	
Theophylline	mg/L		25	A inpatients B GP/OPD	2 2	
Lithium	mmol/L	-	1.5	A inpatients B GP/OPD	2 1,2	
Salicylate	mg/L	-	300	A	2	
Triglycerides	mmol/L	-	20	В	1	If specimen lipaemic, measure and report direct ISE Sodium and Potassium.

		RESULTS	FOR URGENT COM	MMUNICA'	ΓΙΟΝ	
	Units	A	ction Limits	Urgency	Ref.	Comments
Analyte		Lower	Upper			
Haem 4+	Phone al	l URGENT ha	nem 4+	A	3	
samples	(this will	include all E	D)			
PSA	ng/mL	_	40	С	3	If no previous critical result
Ferritin	ng/mL	_	5000	C	3	
TSH	mU/L		30	C	3	
fT4	pmol/L	-	50	С	1,3	
Prolactin	mU/L	-	2000	C	3	
Testosterone	nmol/L	-	5	C	3	
female						
Gamma-	g/L	IgG<3		C	1	With low IgA and IgM
globulins						
Serum FLC		-	>100	C	3	First time detection
Ratio						
Paraprotein	g/L	Any IgE/IgD		C	1	First time detection
			IgA>10			
			IgM>10			
		Monoclonal f	ree light chain- any	C	3	First time detection
		size, whether	or not with intact			
		paraprotein				

3.3.8.1 Reference Intervals

All reference intervals and/or clinical decision values apply only to non-pregnant adults unless specifically stated otherwise.

3.3.8.2 Interference in Laboratory Tests

Many laboratory tests are subject to interference by endogenous or exogenous factors which may alter the true concentration of a substance within the body, or cause an analytical interference giving a potentially erroneous or misleading result.

All samples are routinely checked for Haemolysis, Lipaemia and Icterus which can interfere with laboratory tests to varying extents. Significant levels of any of these may affect the quality of some test results which will be highlighted and/or removed from the individual report.

Test results should be interpreted in conjunction with clinical findings and if interference is suspected please contact the laboratory where further information on each test method is available.

Drug interferences are also commonly encountered, a summary list is available at http://www.beaumont.ie/media/Interference in Laboratory Tests1.pdf.

3.3.8.3 Repertoire of Test Services - Routine Chemistry

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
~~~~	Required	Container	Volume	Unit of Measurement	10 11	70.1
5HIAA	24 hour Urine collection	Pre-acidified (50% acid)	N/A	2.5 - 50 μmol/24hr	12 working days	If the patient is <15 years old, please contact the laboratory (01-7977333) for information regarding sample collection.  Age-related reference ranges will accompany results for paediatric samples.
Alpha1 Antitrypsin	Plasma	Orange Cap	4.9ml	0.9 - 2.0  g/L	72 hours	Surrigios.
Adrenocortico- trophic Hormone (ACTH)	EDTA PLASMA on Ice	Blue Cap	4.9mL	7.2-63.3 pg /mL	10 days STAT- Contact laboratory	Patient must attend Beaumont Hospital phlebotomy for sample collection. Sample is labile, must be sent to lab immediately on ice for separation.
Adrenaline	24 hour Urine collection	Pre-acidified (50% acid)	N/A	See Table Below		If the patient is < 15 years old, please contact the laboratory (01-7977333) for information regarding sample collection.  Age-related reference ranges will accompany results for paediatric samples
Alanine aminotransferase (ALT)	Plasma	Orange Cap	4.9 mL	Female: < 33 IU/L Male: < 41 IU/L	24 hours	
Albumin	Plasma	Orange Cap	4.9 mL	35 – 52 g/L	24 hours	
Albumin Creatinine Ratio	Spot urine sample	Plain MSU	N/A	mg/mmol Creatinine Males: <2.5 Females: <3.5	96 hours	

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
Aldosterone	Whole blood	EDTA (Blue Cap)	4.9ml	Female: 0 – 1179pmol/L Male: 0 - 670pmol/L	20 days	Patient must be seated for 10mins prior to sample draw. Sample must be spun and separated immediately.
Alkaline Phosphatase (Total Alk Phos)	Plasma	Orange Cap	4.9 mL	Female 35 – 104 IU/L Male 40 – 129IU/L	24 hours	
Amylase	Plasma	Orange Cap	4.9mL	28 - 100 IU/L	24 hours	
Amylase Urine	Spot urine sample	Plain MSU container	N/A	M: 16 – 491IU/L F: 21 – 447 IU/L	24 hours	
Aspartate aminotransferase (AST)	Plasma	Orange Cap	4.9mL	Female < 32 IU/L Male < 40 IU/L	24 hours	
B12 (Vitamin)	Plasma	Orange Cap	4.9mL	197 – 771 ng/L	3days	
B2M	Plasma	Orange Cap	4.9mL	<60yrs 0.8 − 2.4mg/L >60yrs ≤3.0mg/L	72 hours	
bНСG	Serum	Brown Cap	4.9mL	Non-pregnant,pre-menopausal women: <1 Postmenopausal women: <7	72 hours	For preganacy testing purposes only.
Bicarbonate (TCO2)	Plasma	Orange Cap	4.9mL	22 – 29 mmol/L	24 hours	Fresh sample required – patient should attend Beaumont Hospital phlebotomy for sample collection.
Bilirubin - total	Plasma	Orange Cap	4.9mL	< 21 μmol/L	24 hours	
Bilirubin Direct	Plasma	Orange Cap 22 wrapped in foil to exclude light	4.9mL	<5.0μmol/L	72 hours	Only analysed if total bilirubin is elevated. Patient must attend Beaumont Hospital phlebotomy so that a fresh sample can be taken and protected from light.

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
BNP (Nt-Pro BNP)	Plasma or serum	Orange Cap or White Cap	4.9ml	35y-45y M 0-115 35y-45y F 0-237 45y-55y M 0-173	24hrs	
				45y-55y F 0-284 55y-65y M 0-386 55y-65y F 0-352 65y-75y M 0-879		
CRP	Plasma	Orange Cap	4.9ml	65y-75y F 0-623 0 – 5mg/L	24hrs	
C Reactive Protein		orange cap	11,71111			
CA 12-5	Serum	Brown Cap	4.9ml	<35 kU/L	72 hours	Refer to Ovarian Cancer GP Referral For Symptomatic Women May 2016
Caeruloplasmin	Plasma	Orange Cap	4.9ml	Male 0.15 – 0.30g/L Female 0.16 – 0.45g/L	72 hours	
Calcium	Plasma	Orange Cap	4.9mL	18-60yrs: 2.15 – 2.50mmol/L 60-90yrs: 2.20 – 2.55mmol/L >90yrs: 2.05 – 2.40mmol/L	24 hours	
Calcium Adjusted	Plasma	Orange Cap	4.9ml	2.21 – 2.52mmol/L	24 hours	Locally derived equation.
Calcium 24 Hour Urine	24 hour Urine collection	No Preservative	N/A	2.5 - 7.5 mmol/24hrs	72 hours	Container available from Phlebotomy Department
Carbamazepine	Serum	Plain (White Cap)	4.9mL	4.0 – 12.0 mg/L	24 hours	Samples should be taken immediately prior to next dose.
Catecholamines (Noradrenaline, Adrenaline & Dopamine)	24 hour Urine collection	Pre-acidified (50% acid)	N/A	See Table Below	24 working days	If the patient is <15 years old, please contact the laboratory (01-7977333) for information regarding sample collection.  Age-related reference ranges will accompany results for paediatric samples.
Chloride	Plasma	Orange Cap	4.9mL	95 – 108 mmol/L	24 hours	
Cholesterol	Plasma	Orange Cap	4.9mL	< 5.0 mmol/L	24 hours	

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
Cortisol AM (8-10AM)	Serum	Brown Cap	4.9mL	166-507 nmol/ L	24hrs	
Creatine Kinase (CK)	Plasma	Orange Cap	4.9mL	Males 39-308 IU/L Females 26 – 192 IU/L	24 hours	
Creatinine	Plasma	Orange Cap	4.9mL	Male: 59-104μmol/L Female: 45-84μmol/L	24 hours	
Creatinine Urine - 24 Hour	24 hour Urine collection	Plain	N/A	Female: 6000-13000 µmol/ 24hrs Male: 9000-19000 µmol/ 24hrs	72 hours	Container available from Phlebotomy Department
Creatinine Clearance (GFR)	24 hour Urine collection	Plain	N/A	80 – 125 mL/min (adults)	72 hours	Blood creatinine level also required for GFR calculation.
Cyclosporin A	Whole blood	EDTA (Pink Cap)	2.6mL	N/A (ng/ml)	10days	Trough level sample.
Dehydroepi- androsterone Sulphate (DHEAS)	Serum	Plain (White Cap)	4.9mL	(μmol/L)       Years     Female     Male       15-20y     1.8-10.0     1.9-13.4       20-25y     4.0-11.0     5.7-13.4       25-35y     2.7-9.2     4.3-12.2       35-45y     1.7-9.2     2.4-11.6       45-55y     1.0-7.0     1.2-9.0       55-65y     0.5-5.6     1.4-8.0       65-75y     0.3-6.7     0.9-6.8       ≥ 75y     0.3-4.2     0.4-3.3	3days	Age and gender specific ranges are applied to individual reports.
Dexamethasone overnight	Serum	Brown Cap	4.9 mL		24hrs	
Digoxin	Serum	Plain (White Cap)	4.9mL	0.6 -1.2 μg/L	24 hours	With hypokalaemia toxicity may occur within the therapeutic range

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
Estimated Glomerular Filtration Rate (eGFR)	Lithium Heparin	Lithium Heparin (Orange Top)	4.9ml	>90ml/min/1.72m ²	24 hours	Addition to Renal Profile
Dopamine	24 hour Urine collection	Pre-acidified (50% acid)	N/A	See Table Below	24 working days	If the patient is <15 years, please contact the laboratory [(01)7977333)] for information regarding sample collection. Age-related reference ranges will accompany results for paediatric samples.
Ethanol	Plasma	Fluoride oxalate (Yellow Cap)	2.7 mL	Unit: mg %	24 hours	
Ferritin	Plasma	Orange Cap	4.9mL	Female (17-60yr) 13-150ng/mL Male (20-60yr): 30-400ng/mL	3days	No reference range for >60yr.
Folate/ Folic Acid	Plasma	Orange Cap	4.9mL	3.9 – 26.8µg/L	3days	Affected by light and recent food intake. Please note, results reported as >20 µg/L.
Follicle Stimulating Hormone (FSH)	Serum	Brown Cap	4.9mL	Male: 1.5 – 12.4 U/L Female: Follicular: 3.5-12.5 U/L Mid Cycle: 4.7 – 21.5 U/L Luteal: 1.7-7.7 U/L Post Menopausal: 25.8-134.8 U/L	3days	
Free T3	Plasma	Orange Cap	4.9ml	3.1 - 6.8 pmol/L	3days	
Free Thyroxine (fT4)	Plasma	Orange Cap	4.9mL	11.9-21.6 pmol/L	3days	

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
	Plasma	Orange Cap	4.9mL	Males < 59 I.U/L	24 hours	
transferase (GGT)				Females < 39 I.U/L		
Glucose - Fasting	Plasma	Fluoride Oxalate	2.7mL	C 3	24 hours	Fast for at least 8 hours.
		(YELLOW cap)		mmol/L		See Interpretive Comment
				Impaired Fasting Glucose =		(ADA 2019)
				5.6 –6.9 mmol/L		
				Diabetes = $\geq 7.0 \text{ mmol/L}$		
Glucose- Random	Plasma	Fluoride Oxalate	2.7mL	Values >7.8 and <11.1	24 hours	See Interpretive Comment
		(YELLOW cap)		recommend Fasting Glucose		(ADA 2019)
				Values $\geq 11.1$ (with symptoms		
				of hyperglycaemia) are		
				consistent with Diabetes.		
	Serum	Brown Cap	4.9mL	N/A (ng/ml)	20 days	HGH test is most useful in
(hGH)				See Interpretive Comment		dynamic tests where states of
						hypoglycaemia or hyperglycaemia
						are induced. Samples need to be
						separated and frozen immediately.
HbA1c	Whole blood		2.6mL	IFCC: 20–42 mmol/mol	96 hours	
		(PINK cap)		Reference range for people		
				without diabetes. The target range for patients with		
				diabetes will be set by the		
				clinician.		
HMMA (VMA)	24 hour Urine	Pre-acidified		< 45 μmol/24 hr	12 working	If the patient is <15 years, please
, ,	collection	(50% acid)		(Adult)	days	contact the laboratory [(01)7977333)]
		,				for information regarding sample
						collection.
						Age-related reference ranges will
						accompany results for paediatric
						samples.

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
HVA	24 hour Urine	Pre-acidified		< 40 μmol/24 hr	12 working	If the patient is <15 years, please
	collection	(50% acid)		(Adult)	days	contact the laboratory [(01)7977333)]
						for information regarding sample
						collection.
						Age-related reference ranges will
						accompany results for paediatric
						samples.
Immmunoglobulin	Serum	Brown Top	4.9ml	IgG: 7.0 - 16.0g/L	35 days	
G, A, M				IgA: 0.7 - 4.0 g/L		
				IgM: 0.4 - 2.3 g/L		

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
IGF1	Serum	White Cap	4.9mL	(ng/ml)	20days	Sample must be spun and separated immediately.
				Years Female Male		
				0-1y 17.9-125.6 27.0-157.0		
				1-2y 19.5-132.3 29.7-166.8		
				2-3y 22.2-145.4 33.9-183.9		
				3-4y 25.9-164.2 39.0-204.5		
				4-5y 30.7-187.8 44.3-225.0		
				5-6y 26.2-214.4 50.0-245.5		
				6-7y 42.0-240.4 56.2-267.1		
				7-8y 48.6-269.6 63.4-291.9		
				8-9y 56.9-305.3 72.4-323.1		
				9-10y 67.2-349.4 83.6-361.6		
				10-11y 79.5-400.3 96.9-406.6		
				11-12y 92.6-452.6 111.6-454.	4	
				12-13y 105.3-499.1 126.1-498.	7	
				13-14y 115.9-533.4 138.6-532.		
				14-15y 123.4-552.0 147.5-551.		
				15-16y 127.4-554.2 152.2-553.	5	
				16-17y 127.9-541.5 152.9-541.	3	
				17-18y 125.3-517.3 150.6-520.	5	
				18-19y 120.5-485.8 146.2-493.		
				19-20y 114.4-450.8 140.2-462.	7	
				20-21y 107.8-416.0 133.1-430.	)	
				21-26y 92.9-342.0 115.2-354.	3	
				26-31y 78.4-270.0 97.9-281.6		
				31-36y 73.1-243.0 88.3-246.0		
				36-41y 69.0-227.0 83.4-232.7		
				41-46y 61.5-204.4 74.9-216.4		
				46-51y 56.8-194.5 66.9-205.1		
				51-56y 53.0-189.6 60.6-200.3		
				56-61y 45.6-172.4 54.3-194.2		
1				61-66y 42.2-169.0 48.8-187.7		
				66-71y 38.3-162.5 46.5-191.9		
				71-76y 36.6-164.7 40.9-179.2		
				76-81y 34.7-164.8 37.1-172.0		
				81-86y 34.4-172.4 33.8-165.4		
				86-91y 33.6-177.8 32.2-166.1		

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
Iron	Plasma	Orange Cap	4.9mL	5.8 – 34.5µmol/L	24 hours	
Lactate Dehydrogenase (LDH)	Plasma	Orange Cap	4.9mL	Males 135 – 225 U/L Females 135 – 214 U/L	24 hours	Significantly increased by haemolysis and/or if sample is left on cells overnight.
Lithium	Serum	Plain (White Cap)	4.9mL	0.6 – 1.2 mmol/L	24 hours	Therapeutic range: Up to 1.3 in acute mania. Severe Toxicity likely if level > 2.0
Lipid Profile (Fasting)	Plasma	Orange Cap	4.9ml	Cholesterol ≤ 5.0mmol/L LDL(calculated) ≤ 3.0mmol/L HDLCholesterol ≥ 1.0mmol/L Triglycrides ≤ 1.7mmol/L Non HDL Cholesterol ≤ 3.8mmol/L		Refer to National Pathology Handbook: Laboratory Testing for Lipids
Lipid Profile (Non Fasting)	Plasma	Orange Cap	4.9ml	Cholesterol ≤ 5.0mmol/L LDL (calculated) ≤3.0mmol/L HDLCholesterol ≥ 1.0mmol/L Triglycrides ≤ 2.0mmol/L Non HDL Cholesterol ≤ 3.8mmol/L		Refer to National Pathology Handbook: Laboratory Testing for Lipids
Luteinising Hormone (LH)	Serum	Brown Cap	4.9mL	Male: 1.7 – 8.6 U/L Female: Follicular: 2.4 - 12.6 U/L Ovulation: 14.0 - 95.6 U/L Luteal: 1.0 - 11.4 U/L Post-Menopausal: 7.7-58.5 U/L	3days	
Magnesium	Plasma	Orange Cap	4.9mL	0.66 – 1.07 mmol/L	24 hours	Increased by haemolysis or if sample is left on cells overnight.
Magnesium 24 Hour Urine	24 hour Urine collection	No Preservative		3.0 – 5.0 mmol/24hr	72 hours	Container available from Phlebotomy Department

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
Metanephrine	24 hour Urine	Pre-acidified		See Table Below	24 working	Container available from
(Urine Total)	collection	(50% acid)			days	Phlebotomy Department
Neuroblastoma	Spot Urine	Plain container	1-2 mLs	All results are reported in	12 days for	
Screen	Sample carefully	but sample		mmol/Mol of Creatinine	Routine	
(HMMA, HVA,	acidified to pH 4	should be			samples	
Dopamine,	or less.	protected from			1-2 working	
Adrenaline and		light			days for	
Noradrenaline).					Urgent	
					samples-	
					must be	
					discussed	
					with	
					laboratory	
Noradrenaline	24 hour Urine collection	Pre-acidified (50% acid)	N/A	See Table Below	24 working days	If the patient is <15 years, please contact the laboratory (01-
	Conection	(30% aciu)			uays	7977333) for information
						regarding sample collection.
						Age-related reference ranges will
						accompany results for paediatric
						samples.
						Samples should be taken
						immediately prior to next dose.
Normetanephrine	24 hour Urine	Pre-acidified	N/A	See Table Below	24 working	Container available from
(Urine Total)	collection	(50% acid)	1 1/1 1		days	Phlebotomy Department
Oestradiol	Serum	Brown Cap	4.9mL	Follicular: 114-332 pmol/L	3days	J .F
		1		Ovulation: 222-1959 pmol/L		
				Luteal: 222-854 pmol/LPost		
				Menopausal:18.4-505 pmol/L		
				Male: 41.4 – 159 pmol/L		
Osmolality	Plasma	(Orange Cap)	4.9mL	275 – 295 mOsm/Kg	24 hours	

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
Osmolality Urine	Spot urine sample	Plain MSU container	N/A	400 – 1000 mOsm/Kg	24 hours	Results are interpreted in conjunction with the plasma Osmolality
Paracetamol	Serum	Plain (White Cap)	4.9 mL	Units: mg/L	24 hours	In suspected overdose, take sample more than 4 hours post ingestion.
Parathyroid Hormone (PTH)	Whole blood	EDTA (Blue cap)	4.9ml	17 - 74pg/ml	3days	
Phenobarbital	Serum	Plain (White Cap)	4.9mL	10.0 – 40.0 mg/L	24 hours	Therapeutic range ill-defined due to 'tolerance'
Phenytoin	Serum	Plain (WhiteCap)	4.9mL	5.0 – 20.0 mg/L	24 hours	Severe toxicity likely if >40.0mg/L
Phosphate	Plasma	Orange Cap	4.9mL	0.81 – 1.45 mmol/L	24 hours	Can be dramatically increased if sample is left on cells overnight.
Phosphate 24 Hour Urine	24 hour Urine collection	No Preservative	N/A	13.00 – 42.00 mmol/24hr	72 hours	Container available from Phlebotomy Department
Plasma Free Metanephrines	Plasma	EDTA 7.5ml	7.5ml	See table Section 3.4.11	12 working days	Sample must be taken on ice, spun within 1hr of collection aliquoted, frozen for transport.
Potassium	Plasma	Orange Cap	4.9mL	3.5 – 5.3 mmol/L	24 hours	Greatly increased if sample is left on cells overnight or refrigerated.
Potassium 24 Hour Urine	24 hour Urine collection	Plain	N/A	30.0 – 100.0 mmol/24hr (for person on average diet)	72 hours	Container available from Phlebotomy Department
Potassium Urine	Spot urine sample	Plain MSU container	N/A	N/A See Interpretive Comment	24 hours	Reference ranges are not available for spot urine tests, results must be considered in conjunction with the age, sex and hydration status of the patient

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
Prolactin	Serum	Brown Cap	4.9mL	(mIU/L)	7 days	Bioactive prolactin is the
				Total Prolactin		biologically active form of
				Female: 102-496 mIU/L		prolactin.
				Male: 86-324 mIU/L		For further information please
						consult the National Laboratory
				Bioactive Prolactin:		Handbook- Laboratory Testing for
				Female: 75-381mIU/L		Hyperprolactinaemia 2019.
				Male: 63-245 mIU/L		
Progesterone	Brown	Brown Cap	4.9mL	Male: 0.159 - 0.474 nmol/L	3days	Note date of cycle on test request
				Female:		form.
				Follicular: 0.159 – 0.616		
				nmol/L		
				Ovulation: 0.175–13.2nmol/L	,	
				Luteal: 13.1 - 46.3 nmol/L		
				Post Menopasal: 0.159 -		
				0.401 nmol/L		
D ( (T ( 1)	DI	0 0	4.0. I	CO 00 /I	0.4.1	
Protein (Total)	Plasma	Orange Cap	4.9mL	60 – 80 g/L	24 hours	
Protein (TUP)	24 hour Urine	Plain	N/A	0.05 - 0.140  g/24  hour	72 hours	
24 Hour Urine	collection					
Protein:	Spot urine	Plain MSU	N/A	3 – 14 mg/mmol	96hours	
Creatinine Ratio	sample	container				
Protein	Serum	Brown Cap	4.9mL	N/A	35 days	
Electrophoresis				See Interpretive Comments		

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
PSA (total) Roche Method (e801)	Plasma	Orange Cap	4.9mL	Age related PSA (non-suspicious DRE) $<50 = <2ug/L$ $50 - 59 = <3ug/L$ $60 - 69 = <4ug/L$ $70+ = <5ug/$	3days	Specimens for PSA should not be drawn immediately after digital rectal examination, prostatic massage or transrectal ultrasound. PSA sampling should not be carried out for at least 6 weeks after prostatic biopsy.  Refer to National Pathology Handbook: National Prostate Cancer GP Referral Guideline
Renin	Whole blood	EDTA (Blue Cap)	4.9ml	Female: 6.1 – 62.7mIU/L Male: 9.0 – 103.5mIU/L	20 days	Sample must be spun and separated immediately.
Salicylate	Serum	Plain (White Cap)	4.9 mL	Units: mg/L	24 hours	Concern level 280 mg/L if age <5 years; Severe toxicity likely if level >700 mg/L
SHBG	Serum	Plain (White Cap)	4.9ml	Male (20-49yr): 18.3 – 54.1nmol/L Male (≥ 50yr): 20.6 – 76.7nmol/L Female (20-49yr): 32.4 – 128.0nmol/L Female (≥ 50yr): 27.1 – 128.0nmol/L	3days	No SHBG reference intervals for <20yr old.
Sodium	Plasma	Orange Cap	4.9mL	133 – 146 mmol/L	24 hours	
Sodium 24 Hour Urine	24 hour Urine collection	Plain	N/A	40.0 – 220.0 mmol/24hr	72 hours	

Test	Sample Required	Specimen Container	Minimum Volume	Reference Range/ Unit of Measurement	TAT	Comment
Sodium Urine	Spot urine sample	Plain MSU container	N/A	N/A See Interpretive Comment	24 hours	Reference ranges are not available for spot urine tests, results must be considered in conjunction with the age, sex and hydration status of the patient
Tacrolimus (FK506)	Whole blood	EDTA (Pink Cap)	2.6mL	(ngml) N/A See Interpretive Comment	72 hours	Trough level sample.
Testosterone	Serum	Plain (White cap)	4.9mL	Male: 19 - 50y: 8.6 - 29.0 nmol/L ≥50y: 6.7 - 25.7 nmol/L Female: 19 - 50y: 0.3 - 1.7 nmol/L ≥50 y: 0.1 -1.4 nmol/L	3 days	
Theophylline	Serum	Plain (White Cap)	4.9mL	10.0 – 20.0 mg/L	24 hours	Lower levels ≥ 5.0mg/L may be effective.  Concern level 14.0mg/L if age < 3months.  Severe toxicity likely if > 60.0mg/L.
Total Thyroxine (TT4)	Lithium Heparin	Lithium Heparin (Orange Top)	4.9ml	66 – 181nmol/L	72 hours	
Transferrin	Plasma	Orange Cap	4.9mL	A Fasting Transferrin Saturation > 55% in Males OR > 50% in Females indicates Iron accumulation.	24 hours	If Transferrin Saturation > 50% Please repeat on a morning fasting sample. Refer to: BCSH Guidelines.
Thyroid Stimulating Hormone (TSH)	Plasma	Orange Cap	4.9mL	0.27- 4.20 mU/L	72 hours	

Test	Sample	Specimen	Minimum	Reference Range/	TAT	Comment
	Required	Container	Volume	Unit of Measurement		
Triglycerides	Plasma	Orange Cap	4.9mL	0.5 -2.0nmol/L (Non fasting)	72 hours	Refer to National Pathology
				0.5 - 1.7mmol/L (Fasting)		Handbook: Laboratory Testing for
						<u>Lipids</u>
Troponin T (TNT)	Lithium Heparin	-	2.7mL	< 14 ng/L	1.5 hours	
Must have a		(Orange Top)				
dedicated sample						
Urate/Uric Acid	Plasma	Orange Cap	4.9mL	Males 202 - 416µmol/L	24 hours	
				Females 143 - 340µmol/L		
		Plain	N/A	1.20 – 5.90 mmol/24hr	72 hours	
24 Hour Urine	collection					
Urea	Plasma	Orange Cap	4.9mL	2.8 - 8.1  mmol/L	24 hours	
Urea 24 Hour	24 hour Urine	Plain	N/A	428.0 – 714.0 mmol/24hr	72 hours	
Urine	collection					
Valproic Acid	Serum	Plain	4.9mL	50 - 100  mg/L	24 hours	Therapeutic range ill-defined as
		(White Cap)				toxic effects shows no clear
						relationship to plasma levels.
Xanthochromia	CSF	Brown cap	1mL	N/A	24 hours	See Protocol for Sending CSF
		wrapped in foil		See Interpretive Comment	(Mon-Fri)	Samples to Beaumont for
		to exclude light				Xanthochromia Analysis
						Beaumont Hospital - Chemical
						Pathology
						Service available during routine
						working hours only.

# 3.3.8.4 Calculated / Derived Tests

Calculated Parameter	Formula	Reference Range	Units	Important Notes
Calcium Adjusted	[Ca] + (46.18 - [Alb]) * 0.01516	2.21 - 2.52	mmol/L	The calculation is unsuitable if the albumin
	(Locally derived equation)			result is $< 30g/L$ or $> 52g/L$
Estimated Glomerular Filtration Rate (Female Creatinine < 62µmol/L)	144 x (Creat/62) ^{-0.329} x (0.993) ^{Age}	>90	ml/min/1.72m ²	The calculation is not valid in patients with acute kidney injury, pateints receiving dialysis, patients under the age of 18yrs, pregnant patients, for drug dosing and/or in
				people at extremes of body type e.g patients with limb amputations, severely malnourished or very muscalr.
Estimated Glomerular Filtration Rate (Female Creatinine > 62µmol/L)	144 x (Creat/62) ^{-1.209} x (0.993) ^{Age}	>90	ml/min/1.72m ²	
Estimated Glomerular Filtration Rate (Male Creatinine < 80µmol/L)	141 x (Creat/80) ^{-0.4.11} x (0.993) ^{Age}	>90	ml/min/1.72m ²	
Estimated Glomerular Filtration Rate (Male Creatinine > 80µmol/L)	141 x (Creat)/80) ^{-1.209} x (0.993) ^{Age}	>90	ml/min/1.72m ²	
Globulin	Total Protein - Albumin	N/A	g/L	Interpret in conjunction with Total Proteim amd Albumin values.
LDL (Low Density Lipoprotein) Cholesterol	Cholesterol – HDL – (triglyceride / 2.2) (Friedwald Equation)	See Above	mmol/L	The calculation is unsuitable if the triglyceride level is > 4.5mmol/l Refer to National Pathology Handbook: Laboratory Testing for Lipids
Non-HDL Cholesterol	Total Cholesterol – HDL Cholesterol.	See Above	mmol/L.	Refer to <u>National Pathology Handbook:</u> <u>Laboratory Testing for Lipids</u>

Document Number: LP-GEN-0014 Revision 15

Calculated Parameter	Formula	Reference Range	Units	Important Notes
Transferrin saturation (TfS)	(Iron / Transferrin) * 398	See Interpretive Comment		If transferrin saturation > 50% please repeat on a morning <u>fasting</u> sample.  Refer to: BSCH guidelines.  A fasting transferrin saturation  > 55% in males <u>or</u> >50% in females indicates iron accumulation.
Unconjugated Bilirubin	Total Bilirubin – Conjugated (Direct) Bilirubin	N/A		Patient must attend Beaumont Hospital phlebotomy so that a fresh sample can be taken and protected from light.  Must be interpreted in conjunction with Total and Conjugated Bilirubin.

# 3.3.9 Urinary Catecholamines and Metabolites Reference Ranges:

Adult reference ranges:

<u>508.</u>	
Analyte	Reference Interval
Noradrenaline	< 0.900 umol/24hrs
Adrenaline	< 0.230 umol/24hrs
Dopamine	< 3.300 umol/24hrs
Metanephrine	< 1.80 umol/24 hrs
Normetanephrine	< 2.80 umol/24 hrs

<u>Paediatric Reference Ranges:</u> Units are mmol/mol Urinary Creatinine.

Age Group (yrs)	Noradrenaline	Adrenaline	Dopamine
< 1	< 0.43	< 0.08	< 1.95
1 – 3	< 0.20	< 0.08	< 1.45
3-5	< 0.19	< 0.08	< 0.95
5 – 8	< 0.18	< 0.08	< 0.85
8 – 11	< 0.17	< 0.08	< 0.75
> 11	< 0.13	< 0.08	< 0.65

# 3.3.10 Plasma Metanephrine Reference Ranges

Analyte	Reference Interval (Seated)
Plasma Free Methanephrine	0 – 510 pmol/L
Plasma Free Normetanephrine	0 – 1180 pmol/L
Plasma Free 3-Methyoxytyramine	0 – 180 pmol/L

The below table provides Supine Reference Intervals, i.e. after 30 minutes rest.

Analyte	Reference Interval (Supine)
Plasma Free Methanephrine	0 – 450 pmol/L
Plasma Free Normetanephrine	0 – 730 pmol/L
Plasma Free 3-Methyoxytyramine	0 – 180 pmol/L

Document Number: LP-GEN-0014 Revision 15

# **Endocrinology Reference Ranges**

Where age and cycle reference ranges apply to females, 50 years has been agreed by the Endocrinologists as the age to apply a post-menopausal range.

#### 3.4 IMMUNOLOGY

The Immunology Department provides both Clinical and Laboratory Services. Additionally we are keen to assist with the development of guidelines for investigations of potential immunological disorders, clinical audit and other educational activities.

#### 3.4.1 Clinical Service

There is a general immunology outpatients clinic held in Clinic A on Monday mornings and an allergy clinic held in Clinic F on Thursday afternoons. Additionally, various ANP led allergy clinics are held in the department throughout the week. The Department also has an established home therapy programme for patients on immunoglobulin replacement therapy and an ANP-led review clinics for these patients are held in the department..

Referrals are accepted from hospital teams and GPs. Self-referrals from patients cannot be accepted. Appropriate referrals include known or suspected immunodeficiency, recurrent infections, serious allergy (anaphylaxis) or angioedema, as well as difficult autoimmune disease. A detailed referral letter including current medications, previous treatments and laboratory investigations with results should be sent to Prof. Keogan/Dr Khalib/Dr Cox. Please ensure that the patients' correct address and phone number is included. Appointments are allocated on the basis of clinical urgency. Due to the long waiting time, we do not routinely offer second appointments to patients who fail to attend without cancelling their appointment.

#### 3.4.2 Laboratory Service

The Laboratory provides a large range of immunological investigations focussing on investigations for autoimmune and allergic disorders. Some immunology tests are carried out in the Protein chemistry and Haematology laboratories.

# 3.4.3 Repertoire of Tests & Test Profiles

All tests are performed on serum samples. Up to 5 tests can be performed on a 10 mL sample. However separate samples are required for some tests to facilitate optimum handling.

Test	Specimen	Minimum Volume		Reference Range	TAT	Urgent Service		Frequency of
		v olullie				Sel vice		Retesting
_	Serum Gel Brown tube		FEIA (IMMUNOCAP)	N/A	N/A		See Section	
Investigation AARI		serum plus an extra					reporting pathway	and discussed as
(Service for Beaumont GP's only)		50µl serum per specific allergen needed						per interpretive comments
Anti-CCP	Serum Gel Brown tube		EliA (IMMUNOCAP)	< 7 U/ml	8 days			3 Months
•	Serum Gel Brown tube		Indirect Immunofluorescence	Negative	8 days			>3 months
•	Serum Gel Brown tube		Indirect Immunofluorescence	Negative	8 days		Only performed when IgA deficiency	
Anti-Gastric-Parietal Cell antibodies (Anti- GPC)			Indirect Immunofluorescence	Negative	3-5 days			>3 months
Anti-Intrinsic Factor Antibodies	Serum Gel Brown tube		EliA (IMMUNOCAP)	Negative: <7 U/ml Equivocal: 7- 10U/ml Positive: >10 U/ml	8 days			>6 months

Test	Specimen	Minimum Volume	Method	Reference Range		Urgent Service	Comment	Frequency of Retesting
1	Serum Gel Brown tube		Indirect Immunofluorescence + Immunoblot if IIF positive		3-5 days			>1 month
Anti-Mitochondrial Antibody (including M2 subtyping)	Serum Gel Brown tube		Indirect Immunofluorescence + ELISA if positive		3-5 days (1 month if IIF positive)			>3 months M2 performed only once
Anti-Nuclear Antibodies	Serum Gel Brown tube		Indirect Immunofluorescence	Negative. Weak positive (1:80) are commonly seen particularly in healthy older women.	1			No more than 3 monthly
Anti-Smooth Muscle Antibodies	Serum Gel Brown tube		Indirect Immunofluorescence	Negative	3-5 days			>3 months
Anti-Streptolysin-O Titre (ASOT)	Serum Gel Brown tube		Immunoturbidimetry	<200IU/ml	3-5 days			3 weeks
Anti-Tissue Transglutaminase Antibodies (anti-tTG)	Serum Gel Brown tube	4.9 mls	EliA (IMMUNOCAP)	Negative: < 4 U/ml Equivocal: 4-10 U/ml Positive: 10 U/ml	8 days			>3 months
CTD Screen	Serum Gel Brown tube		EliA (IMMUNOCAP)	Negative	2-5 days			No more than 3 monthly
Rheumatoid Factor	Serum Gel Brown tube		Immunoturbidimetry	<14 IU/mL	3-6 days			>3 Months

Test	Specimen	Minimum	Method	Referenc	e Range	TAT	Urgent	Comment	Frequency
		Volume					Service		of
									Retesting
Specific IgE	Serum Ge	4.10 mls	FEIA	< 0.35	Class 0 Negative	15days		For GP users,	1 year for
	Brown tube	Note 200µl	(IMMUNOCAP)	0.35-0.7	Class 1 Weakly	21 days for sIgE		please order	same
		serum plus		Positive 0.7-3.5	Class 2Positive	to Drugs		using AARI	allergens
		an extra		3.5-17.5	Class 3 Positive				
		50μ1 serum		17.5-52.5	Class 4 Strongly	7			
		per specific		positive					
		allergen		52.5-100	Class 5 Strongly	7			
		_		positive					
		needed		>100	Class 6 Strongly	7			
				positive					

### 3.4.3.1 Test Profiles

To make test ordering more efficient we have set up a range of disease specific test profiles, for investigations of common potentially immunological disorders. Where screening tests are included in test batteries, positive screening tests lead

to reflex ordering of appropriate follow-up tests.

Profile	Tests Included	Indication	Comment
Rheumatoid Arthritis	RF	Isolated inflammatory	2 separate samples are
Antibodies	CCP	arthritis, in the absence	required for RA Abs
		of systemic features.	
Pernicious Anaemia	Anti-Gastric		
Antibodies	Parietal Cell Abs		
	Anti-Intrinsic		
	Factor Abs		
Liver Disease	Anti-Nuclear Abs	Suspected chronic liver	If anti-mitochondrial
Associated Antibodies	Anti-Smooth	disease.	antibody positive, M2
	Muscle Abs		subtyping will be
	Anti-		performed, on the first
	Mitochondrial Abs		occasion only.
	Anti-LKM Abs		

# 3.5 MICROBIOLOGY

# 3.5.1 Repertoire of Test Services (currently outsourced to Biomnis Eurofins for Microbiological examination)

Test	Target Pathogens	Specimen	Minimum Volume	Biological reference range	TAT	Comment
		<u>Urine</u>				
Microscopy	N/A	The Sarstedt NF (Needle Free Transfe system. 100ml NF primary contain Reference 75.562.90 and a 10mL Monovet tube reference 10.252)	r) T er 0)	WBC, RBC <1 to >100 per µL	Within 24 hours of receipt	Culture is only performed on urines which meet the appropriate laboratory and clinical criteria. 'WBC ≥50/uL OR sediMAX bacterial count of >+.  The following urines are always cultured: in pregnancy, children ≤16 years old,

Revision 15 Document Number: LP-GEN-0014

Target Pathogens	Specimen	Minimum Volume	Biological reference range	TAT	Comment
Urinary pathogens	(Needle Free Transfer system. 10ml NF: primary containe Reference 75.562.900	) [ r )	N/A	6 days	
N/A	(Needle Free Transfer system. 10ml NF: primary containe Reference 75.562.900	) [ r )	Positive 25mIU/mL HCG Preg Negative HCG Weak	,	Repeat specimen requested within 48 hrs for weak pos results
Mycobacterium spp.	Approved yellow screw-capped (Sarstedt) container	v10 mls	N/A	70days	3 consecutive EMUs needed — For diagnosis of disseminated or urinary tract mycobacterial infection only
	Urinary pathogens  N/A	Urinary pathogens  The Sarstedt NFT (Needle Free Transfer system. 10ml NFT primary containe Reference 75.562.900 and a 10mL Monovette tube reference 10.252)  N/A  The Sarstedt NFT (Needle Free Transfer system. 10ml NFT primary containe Reference 75.562.900 and a 10mL Monovette tube reference 10.252)  Mycobacterium spp.  Approved yellow screw-capped	Urinary pathogens  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 75.562.900) and a 10mL Monovette tube reference 10.252)  N/A  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 75.562.900) and a 10mL Monovette tube reference 75.562.900) and a 10mL Monovette tube reference 10.252)  Mycobacterium spp.  Approved yellow 10 mls screw-capped	Urinary pathogens  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 10.252)  N/A  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 10.252)  N/A  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 75.562.900) and NFT primary container Reference 75.562.900) and a 10ml NFT primary container Reference 75.562.900) and a 10ml Monovette tube reference 10.252)  Mycobacterium spp.  Approved yellow 10 mls N/A	Urinary pathogens  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 10.252)  N/A  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container tube reference 10.252)  N/A  The Sarstedt NFT (Needle Free Transfer) system. 10ml NFT primary container Reference 75.562.900) and NFT primary container Reference 75.562.900) and a 10ml NFT primary container Reference 75.562.900) and a 10ml Monovette tube reference 10.252)  Mycobacterium spp.  Approved yellow 10 mls  N/A  70days

Test	Target Pathogens	Specimen	Minimum Volume	Biological reference range	TAT	Comment
Enteric pathogens	1 0			N/A	3 to 6 days	Perfomed only on specimens which take the shape of the container  A negative disclaimer is added to 'Not Detected' results
C. difficile		Approved yellow screw-capped (Sarstedt) container	1-2mls	C diff tox Detected/not detected	_	Perfomed <b>only</b> on specimens which take the shape of the container and >2 years of age.
Rota/adeno virus		Approved yellov screw-capped (Sarstedt) container	/1-2g	Adeno/Rota virus Positive Adeno/Rota virus Neg	4 days	Performed routinely on children <2 years
Ova/parasites		Approved yellow screw-capped (Sarstedt) container	/1-2g		4 to 8 days	Clinical/travel details essential or discussion with CMT.
Helicobacter pylori antigen		Approved yellov screw-capped (Sarstedt) container	/1-2g	H.pylori Ag Not detected/det ected	4 days	A negative disclaimer is added to 'Not Detected' results
		<u>Sputum</u>				

Test	Target Pathogens	Specimen	Minimum Volume	Biological reference range	TAT	Comment
Routine culture	Respiratory pathogens	screw-capped (Sarstedt) container	As available	N/A	6 days	Salivary samples are unsuitable
ТВ	Mycobacterium spp.	Approved yellow screw-capped (Sarstedt) container	As available	N/A	70 days	3 consecutive morning samples
		n Scrappings/ Naii				
Microscopy	Fungal Elements	Screw capped container (as above) or Dermapak		N/A	7 days	
<u>Culture</u>	Dermatophytes, moulds & Yeasts	Screw capped container (as above) or Dermapak		N/A	40 days	Swabs are not an appropriate specimen for fungal culture. Hair must contain root
		<b>SWABS</b>				
MRSA Screen	MRSA	Charcoal Transswab	N/A	N/A	10 days	MRSA- Only from Nasal, Groin & Wound sites
Non uro-genital (e.g wound, eye, ear, nasal throat)	Pathogens appropriate to site	Charcoal Transswab	N/A	N/A	6 days	Relevant clinical details essential, e.g. surgery, post-partum
Penile/vulval	Non -STI pathogens	Charcoal Transswab	N/A	N/A	4 days	
HVS –microscopy	Bacterial vaginosis	Charcoal Transswab	N/A	N/A	4 Days	
HVS –Culture	Bacterial vaginosis	Charcoal Transswab	N/A	N/A	4 Days	

Ova & parasites only performed when specifically requested and with relevant clinical details eg. Foreign travel.
 Microscopy is prioritised over culture if insufficient sample is received.

Test	Target Pathogens	Specimen	Minimum Volume	Biological reference range	TAT	Comment
	SUSPEC [*]	TED STI SPECIMEN	REQUIREMI	ENTS		
MALE		GenProbe Collection		N/A	5 days	First void urine
Urine	Chlamydia trachomatis	Device ¹	25 mls			(FVU) required
Swab - urethral	N. gonorrhoeae ²	Charcoal Transwab or GenProbe Collection	N/A	N/A	4 days	Clinical details eg urethral
		Device ¹				disharge/ ?STI essential ¹
- rectal	N. gonorrhoeae	Charcoal Transwab or GenProbe Collection Device ¹	N/A	N/A	4 days 48-72 hours	Clinical details essential ¹
- pharyngea	al N. gonorrhoeae	Charcoal Transwab or GenProbe Collection Device ¹	N/A	N/A	4 days	Clinical details essential ¹
FEMALE Swab endocervic	N. gonorrhoeaee al	Charcoal Transwab or GenProbe Collection Device ¹	N/A	N/A	4 days	Clinical details essential ¹
	Chlamydia trachomatis	r GenProbe Collection Device ¹	N/A	N/A	5 days	Clinical details essential ¹
- cervic	alN. gonorrhoeae	Charcoal Transwab or GenProbe Collection Device ¹		N/A	4 days	Clinical details essential ¹
- urethr	alN. gonorrhoeae	Charcoal Transwab or GenProbe Collection Device ¹		N/A	4 days	Clinical details essential ¹
- HV	SBacterial vaginosis Candida and non-STI pathogens	Charcoal Transwab	N/A	N/A	4 days	Clinical details essential ¹

Document Number: LP-GEN-0014 Revision 15

Test	Target Pathogens	Specimen	Minimum Volume	Biological reference	TAT	Comment
				range		

- 1. Specimens received in Aptima Collection Devices will be sent to the NVRL for processing. The GenProbe (Aptima) collection devices (urine containers and swabs) are supplied by the NVRL.
- 2. In cases where *Neisseria gonorrhoeae* (GC) is suspected, clinical details of ?STI or 'DISCHARGE' must be provided on the request form. If not, samples will not be cultured for GC.

#### 3.5.2 General Notes

- Beaumont Hospital Microbiology Laboratory does not provide a referral service for tests carried out in other centres (other than the NVRL virology/serology tests)
- If the test you require is not on our User Guide list, we may be able to provide you with information as to possible referral centres
- If we receive a request for a test not carried out in Beaumont, the specimen will be rejected with the 'test not performed in this laboratory' comment.

#### 3.5.3 Key Factors Affecting Turn Around Times:

The main reason for extended turn-around-times in Microbiology is in follow up of positive specimens. Microbial isolation and identification can be extensive in some instances and occasionally requiring referral of an isolate to a Reference Laboratory for typing or confirmation

#### 3.5.4 Samples sent to External Laboratories e.g., NVRL for analysis

Please refer to the NVRL user manual for information on range of tests available in the NVRL, the type of specimen required and turn around time information on these tests. Information available on www.nvrl.ie

#### 3.5.4.1 Notes on Samples Sent to the NVRL

- For tests where clotted blood is required, one 10ml vial is the specimen of choice.
- Report are available electronically via the Health link system
- For results or enquiries, the NVRL can be contacted on 01 716 1354. Address: UCD National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4.
- Request forms can be printed on-line via the NVRL web site (<u>www.nvrl.ie</u>)
   at 'How do you send samples?' prompt (for tests not ordereable on Healthlink)
- Specimens that are referred out from Beaumont Hospital are not covered by the scope of Beaumont Hospital ISO15189 accreditation.

#### 3.5.5 Abbreviations Used on Microbiology Reports

CRE: Carbapenem resistant *Enterobacterales* 

CPE: Carbapenemase *Enterobacterales* 

ESBL: Extended spectrum Beta-lactamase producing Enterobacterales

MRSA: Meticillin resistant Staphylococcus aureus

VRE: Vancomycin resistant enterococci

# 3.5.6 Time Limits for Requesting Additional Tests:

The normal limit of acceptability for culture for most microbiology specimens is 48hrs, once the specimen is in an appropriate transport medium.

Fungal culture specimens (nail clippings and skin scrapings) have a longer 'shelf life', though any delay increases the risk of contamination of the primary specimen, thus possibly compromising the ability to culture a pathogen

#### 3.6 HISTOPATHOLOGY/CYTOPATHOLOGY/NEUROPATHOLOGY

The Histopathology Department provides an extensive Histopathology service, including supporting the symptomatic breast service, urology and gastrointestinal units. The department provides a diagnostic Renal Pathology service in addition to supporting the renal transplant service, including an Out of Hours service. Electron Microscopy, Cytopathology and an Autopsy service are also provided by the Histopathology laboratory. The Non-Gynae Cytopathology service includes provision of assistance and support for the Fine Needle Aspirate and endoscopic ultra sound services.

The Neuropathology section provides a diagnostic service for Neurosurgery and Neurology (including paediatric neurology and paediatric neurosurgery). A rapid intra-operative service is provided for the diagnosis of intracranial and spinal lesions including brain tumour. A range of investigations are available for the interpretation of muscle and nerve biopsies including molecular screening of common mitochondrial disorders. In addition Neuropathology is the national centre for the CJD Surveillance Unit. A Neuropathology autopsy service is also available and provides pathologic diagnosis in a variety of conditions including dementia and other neurodegenerative disorders. A CSF cytology service is also provided.

Other diagnostic services are provided on a consultative basis and include CSF analysis for 14.3.3 protein and mitochondrial genetic studies.

#### 3.6.1 Frozen Sections

A <u>frozen section</u> service is offered between 09.00 - 17.00. Twenty Four hours notice should be given to the laboratory, prior to a frozen section. Frozen sections outside usual working hours may be provided by prior arrangement with the Consultant Pathologist.

Specimens from patients with TB, HIV or Hepatitis B or C infection should not be sent for frozen section. If such a suspicion is present, the medical staff concerned must inform laboratory personnel in order to safeguard the laboratory staff from risk of infection.

In addition, if the laboratory inadvertently processes such specimens, a decontamination procedure of the equipment required for frozen sections must be carried out. Decontamination of this equipment takes 12 hours. During this time no further frozen sections can be performed.

Frozen section reports are delivered to theatre, usually via the intercom. A written report is available following subsequent routine processing of the specimen.

# 3.6.2 Other Urgent Specimens

Other urgent specimens are dealt with on an individual basis. The laboratory should be contacted directly with these requests in order to ensure that they are handled appropriately. Overuse of the urgent service will adversely affect the turnaround times for all urgent requests.

#### 3.6.3 *Reports*

Document Number: LP-GEN-0014

The Authorised report is printed and sent to the Clinical Consultant or requesting GP. Reports are available through PIPE or by phoning the Histopathology Office at 2632/2636/2687/2154, 3919 or the Neuropathology Office at 2631 or the Renal Pathology Office at 2008. Reports are not available in the laboratory. Unauthorized reports and any issues of clinical concern can be discussed with the consultant involved in the case for any clinical advice.

### 3.6.4 Specimen Requirements For Histopathology

The following is a guideline on the requirements of the various specimen types and the appropriate manner in which they should be delivered to the laboratory. This ensures the integrity of the specimen for laboratory investigations.

Tissue Type	Fixative Required	Comment
Specimen for Frozen	Send fresh to the laboratory -	24 hours notice of Frozen
Section.	immediately.	sections should be given where
		possible. Contact the
		Histopathology Lab Ext 2353.
		Details supplied with the
		specimen must include a bleep
		number or theatre intercom to
		deliver report to.
Renal biopsies	Send in saline (Dublin Hospitals)	Please inform Renal Office Ext.
	Send in Formalin/Zeus (Regional	2765 of specimen. The Main
	Centres) (full details in section	Histology Lab can be contacted
	3.6.9)	@ 2353. The EM lab on 8633.
Lymph nodes	Send fresh to the laboratory -	Please supply all relevant clinical
(for lymphoma	immediately.	details.
diagnostics)		
Solid Tumours	Send fresh to the laboratory -	Please supply all relevant clinical
(Colon, Breast, Lung	immediately.	details.
etc.)	-	
Liver biopsies*	Where possible, send two	Please supply relevant clinical
	specimens – one in 10% Neutral	

Tissue Type	Fixative Required	Comment
	Buffered Formalin and one	Referred to St. Vincents
	wrapped in saline moistened gauze.	University Hospital for copper
		analysis where required*
Oncotyping*	Paraffin Block	Referred to Genomic HealthCare
		(US) for Oncotyping
Mitochondrial	Send fresh to the laboratory -	Referred to Mitochondrial
Studies*	Immediately	Research Group in Newcastle
		University for analysis/St James
		Hospital (CMD)
CSF for RT-QuIC	CSF frozen at -70°C within 30	Volume CSF: 1 - 2ml.
Analysis	minutes of aspiration and	Sample must be clear and
	transported to the Neuropathology	colourless (not blood stained)
	Dept, Beaumont Hospital on dry	with a white cell count of
	ice.	$<10x10^6/L$ and have a total
		protein concentration of <1 g/L1.
		Red blood cells (>1250 x 10^6/L)
		inhibit the RT-QuIC response
		resulting in false negatives. High
		CSF total protein concentrations
		of >1.0 g/L and raised white
		blood cell counts can result in
		false positives.
, ,	Nasal Scraping	Referred to Southhampton
Dyskinesia*		General Hospital for analysis
Flow Cytometry*	CSF	Referred to Haematology in St.
	Or	James's Hospital Dublin for
	Lymph Node	Analysis
Amyloidosis*	Paraffin Block	Referred to National Amyloidosis
		Centre, London, University
		College London ,
PDL1* metastatic	Paraffin Block	Referred to Poundbury Cancer
breast carcinoma,		Institute, Dorchester, London
Head & Neck Cancer		HSL-Advanced Diagnostics
& metastatic		HEALTH SERVICES
oesophageal SCC.		LABORATORIES
(NCCP		(A Sonic Healthcare UK
recommendation)		laboratory) for metastatic
		oesophageal SCC.
Molecular Studies* –		Referred to Royal Victoria
MY88		Hospital, Belfast
All other tissue	Send in 10% Neutral Buffered	_
	Formalin.	in a specimen container of

Tissue Type	Fixative Required	Comment
		suitable size is essential for
		proper fixation. The volume of
		formalin used should be at least
		twice the volume of the tissue to
		be fixed. Small specimens should
		be placed in biohazard bags.
Histology Blocks 3	*	outsourcing of blocks for cutting
		& staining to HTS

^{*} Specimens referred out from Beaumont Hospital - the results of these tests are not covered by the scope of Beaumont Hospital Histopathology Department ISO15189 accreditation. The responsibility for sending specimens lies with the external centre (Sender).

Please Note: Sample acceptance criteria ensure adequate identification for Histopathology samples and request forms in order for them to be accepted by the laboratory. The requesting clinician is responsible for the correct completion of the request form and the correct labelling of the sample.

Failure to comply with the correct guidance may result in the sample not being accepted in the laboratory. Inadequately or inaccurately labelled samples or forms will not be accepted unless they are considered to be unrepeatable or reproducible. An assessment of acceptance will be made by the laboratory personnel/consultant on an individual bass. The risk to the patient of rejection/acceptance of the sample will be weighed against the risk of acceptance of a wrongly labelled sample and is specific to the examinations requested. Cellular Pathology will accept no responsibility for samples processed which initially failed to meet the acceptance criteria, any deviation from the established collection procedures clearly recorded and an appropriate comment will be included in the pathology report. The laboratory will make every effort to ensure patient requests are processed in a safe and timely manner, but it is essential that request forms and samples are labelled appropriately and legibly. Inadequate or inaccurate labelling results in delays and impacts patient care. If you have any doubts regarding this policy, please contact the lab.

Multiple samples taken from a patient MUST be labelled on the sample container with the number and stae the site of tissue on each. The request form should be labelled accordingly to allow clear specimen location to be identified,

#### 3.6.5 **REQUIREMENT FOR EXTERNAL CENTRES**

The responsibility for sending slides/blocks/material lies with the external centre (Sender). External centres may send slides/blocks/material to Pathology for review/conferences etc. Ensure that slides/blocks/material is accompanied with the appropriate request form and relevant report. When multiple slides/blocks/materials are received, all must be labelled with clear identification of case number, according to acceptance criteria. This allows for unequivabal traceability to the patient. Any discrepancies will be addressed with the relevant referring hospital.

Ensure that packaging and transportation comply with the European Agreement for the Carriage of Dangerous Goods by Road, ADR Regulations.

Address the package to:

Histopathology/Neuropathology (as appropriate to the analysis required) Beaumont Hospital,

Dublin 9

Include the Consignee address and telephone number.

#### 3.6.6 Factors Affecting Fresh/Unfixed Tissue Specimens

The techniques that are performed on fresh tissue are affected by the length of time that the tissue is removed from the patient before it is received for analysis. Therefore it is imperative that all tissue samples required to be sent fresh should be done so immediately. Fresh samples should be sent during normal working hours and the department must be informed in advance if a fresh sample is to arrive out of hours.

NOTE: Specimens from patients with TB, HIV or Hepatitis B or C infection should not be sent "fresh". If such a suspicion is present, the medical staff concerned must inform laboratory personnel in order to safeguard the laboratory staff from risk of infection

The following may be obtained from the Histopathology laboratory.

- Specimen containers various sizes.
- 10% Neutral Buffered Formalin (in polycubes with taps/5lt containers).
- Pre-filled 60ml 10% Neutral Buffered Formalin containers.
- Histopathology/ Cytopathology/ Neuropathology / Renal Request Cards
- Slides and slide containers with fixative for Fine Needle Aspirates (FNAs).
- EM fixative.
- Liquid nitrogen for the Dermatology clinics.

**SAFETY:** Formalin is a potent eye and nasal irritant and can cause respiratory distress and allergic dermatitis. Gloves, goggles and aprons should be used when

dealing with formalin. Contact the Histopathology Laboratory for any additional information that may be required and if a formalin spillage should occur.

Liquid nitrogen can cause cold burns and is dangerous to use in confined spaces as it is an asphyxiant. It can also shatter receptacles that are unsuitable for its storage. Subsequently it will only be given to Beaumont Hospital personnel and transferred into a suitable receptacle. Information on safety on any of the above may be obtained from Histopathology on request @ ext. 2353

Please note: The laboratory periodically reviews any collection sample and handling issues through feedback via MDT meetings/User feedback Survey's and any issues discussed at departmental meetings. Where compromised samples are accepted (e.g. specimen received with no specimen) the final report will indicate the nature of the problem and if applicable that caution is required when interpreting the results.

#### 3.6.7 Turn Around Time for Results

The turn around time of specimens for Histopathology will vary depending on the nature of the specimen and the complexity of the investigations required. The following is an outline of estimated turn around time for different specimen types from time of receipt in the laboratory:

Biopsies – 5-10 working days (on average)
Resections – 10 working days (on average)
Renal Biopsies –7-9weeks for Electron Microscopy

4-6weeks for Light Microscopy14 days for Immunofluorescence

CSF for RT-QuIC –10-15 working days

This is only a guideline and the complexity of a case and the requirement for further investigations may lengthen the turn around time. Results can be obtained from the Histopathology office, ext. 2636/2632/3150/3919. The Consultant/NCHDs can be contacted to discuss individual patients. TAT's are routinely monitored as part of the laboratories quality improvement programme,

# 3.6.8 Cytopathology Specimen Requirements

Specimen	Specimen requirements
Bronchial brushings	- Place material in a sterile container labelled with patient and specimen details, including the time of specimen collection.
	-
Fluids (Pleural, Ascitic etc.)	- Place material in a sterile container labelled with patient and specimen details, including the time of specimen collection.

Specimen	Specimen requirements	
	- At least 20 mls of fluid is required for diagnosis.	
Urine	- Total voided specimen is required for cytology.	
	- The first morning specimen is not suitable.	
	- Place in a container labelled with patient and	
	specimen details.	
Fine Needle	Sample from EUS/EBUS is sent to the cytology lab in	
Aspiration	cytolyt (available in the lab – Ext 2640)	
Cytology/EUS/EBUS		
Cerebrospinal Fluid	- Specimen must be collected in a sterile container	
for Cytology.	labelled with patient and specimen details and	
	delivered to the Neuropathology laboratory.	
Flow Cytometry* - Cytometry placed directly into RPMI are v		
	up to 18Hrs. (Contact Cytology on Ext. 2640)	

^{*} Specimens referred out from Beaumont Hospital - the results of these tests are not covered by the scope of Beaumont Hospital Histopathology Department ISO15189 accreditation

#### ITEMS THAT CAN BE OBTAINED FROM THE CYTOLOGY LABORATORY

- Slides
- Slide holders
- Spray fixative
- Coplin jars of alcohol (Fixing FNA smears)
- Cervical cytology request forms
- ThinPrep kits for cervical smears (Hospital Clinics only)
- Biohazard bags
- Cytolyt containers
- NOTE: EACH SAMPLE SHOULD BE ACCOMPANIED BY A HISTOPATHOLOGY/CYTOPATHOLOGY REQUEST FORM (FOUND ON ALL WARDS) PLEASE PUT AS MUCH INFORMATION AS POSSIBLE.

# **TURN AROUND TIMES FOR CYTOLOGY SAMPLES**

Non-Gynae Cytology Samples – 3-4 Days

# 3.6.9 Specimen Requirements for Renal Pathology

The Laboratory should be notified in advance when a renal biopsy is to be taken.

Contact the Renal Pathology Secretary or if she is not available the Medical Scientists in the Renal Pathology/EM/Histopatholgy Laboratories:

# **DETAILS REQUIRED FOR RENAL BIOPSIES**

The following **minimum** information must be supplied LEGIBLY:

On the body of the specimen container:

A Renal Biopsy Request Form must be filled in (use a ballpoint pen please to make details legible on all copies of the form) and sent with each biopsy:

- Name of patient
- Date of birth
- Medical record number
- Address of patient
- Name of Consultant
- Source (Ward Name/OPD/Hospital)
- Date sample taken
- Relevant clinical details
- Time sample taken (when applicable) as this can have an impact on the integrity of the results.
- Please give *as much clinical information on the form* as possible, as this will be required by the Renal Pathologist when considering differential diagnoses.
- If using addressograph labels please attach one to both flimsies and to the backing card these copies are sent with each portion of the biopsy to the three laboratories involved in the investigation.
- **Do not** attach labels, use date stamps or write in the portion marked for "**Laboratory use**" as this area is used by Beaumont Scientific staff for recording the gross description of the biopsy. If your despatch procedures require that stamps or bar codes be attached please use the reverse (blank side) of the form's card copy.

# 3.6.10 Renal Pathology Requirements for External Centres

- The Renal Pathology Department should be notified before sending biopsy via email to: electronmicroscopy2@beaumont.ie
- The responsibility for sending specimens rests with the external centre.
- The <u>minimum details</u> required are as set out above, including the use of the Renal Biopsy request form. Supplies of the Request Form can be obtained by contacting the Renal laboratory on 01-8528633 (Dect phone)
- Packaging and transportation should comply with current UN legislation and the Transport of Dangerous Goods Act.
- The specimen should be dispatched so as to arrive at Beaumont Hospital <u>no later</u> than 16.00.
- Please note: name and contact of the referring nephrologist must be on the request form. This allows for tracking sample if not received within the timeframe.

Packages should be addressed to:

Consultant Renal Pathologist Renal Pathology/Electron Micrscopy/Histopathology, Histopathology Department, Beaumont Hospital, Dublin 9

NB Beaumont Hospital does not supply containers or fixative solutions for renal biopsies to external centres.

FOR REFERRING HOSPITALS IN THE DUBLIN AREA, if the sample can be transported to Beaumont Hospital within a couple of hours of excision, then place all of the tissue in normal saline in a 60 ml specimen jar or a universal container at least half full of liquid.

FOR REFERRALS FROM REGIONAL CENTRES, tissue can be examined and divided in the Histopathology Laboratory of the hospital prior to dispatch. Fresh tissue for immunofluorescence (0.3-0.4 cm of cortical tissue) should be placed in a transport medium suitable for preserving antigenic activity such as the Tissue Fixative available from Zeus Scientific Ltd. For best results, tissue should not spend any longer than 5 days in Zeus Tissue Fixative.

The remaining cores can be placed in Formalin. It is not necessary for external laboratories to make and keep a stock of glutaraldehyde. A piece of the core can be taken for EM from the Formalin fixed tissue on arrival at Beaumont Hospital Histopathology Department.

# 3.6.11 Urgent Renal Biopsies for Rapid Processing

If a renal biopsy result is required urgently, i.e. the day of biopsy, then rapid processing can be requested:

- You must contact the renal pathologist on duty to discuss the request, and when the request has been agreed, the Histopathology Laboratory should also be informed.
- The tissue must arrive in the Histopathology Laboratory by 12.30 pm at the latest. The tissue processor is then run for this single biopsy, and cannot be used until the process is completed. The surgical and biopsy specimens from that day's cut-up must be processed daily to maintain continuity of service to all other clinical specialities, so the processor must be available for use again at 5pm.

**Please note:** Renal biopsy cover: from time to time there may be an arrangement with Belfast. In terms of logistics, generally biopsies can be transferred up on the same day if we receive them by 11.15, after that they will go the following day.

Please liaise with the lab or indicate clearly on the form if a biopsy needs to be sent out or if it can wait for me to come back. It is vital that the lab is contacted regarding urgent biopsies to organise the most appropriate means of transferring the sampl. Renal laboratory personnel can be reached on 01 8528633 and Prof Declan O'Rourke can be contacted on 00447746648787.

### 3.6.12 *Electron Microscopy*

The Electron Microscopy (EM) Laboratory was initially set up to serve diagnostic Renal Pathology which comprises the bulk of the caseload but a small number of Neuropathology cases are also handled.

The Laboratory is equipped with a JEOL 1400 Plus Transmission Electron Microscope and an AMT XR50 4 megapixel Digital Camera system. Samples are batched and processed automatically once a week.

The EM Laboratory is not equipped or staffed to deal with Virological EM requests, and due to low frequency of request does not accept nasal brushings for analysis of Primary Ciliary Dyskinesia (PCD)*. This is a highly specialised investigation and requires expertise which cannot be gained in this hospital due the low volume of requests. Please contact the EM laboratory for instructions, request form and fixative. When the procedure has been carried out, the sample should be sent to the EM Laboratory from where it will be referred to the UK National Centre for PCD Analysis in Southampton.

*Specimens referred out from Beaumont Hospital - the results of these tests are not covered by the scope of Beaumont Hospital Histopathology Department ISO15189 accreditation.

# 3.6.13 Specimen Requirements for Neuropathology

Tissue Type		Comment
Specimen for uncent	Neuropathology Send fresh. Hand deliver	The Neuronathelegy
Specimen for urgent frozen section		The Neuropathology consultation form must include
rrozen section	immediately.	
		a bleep number or intercom
Mussla Diamery*		number to deliver the report
Muscle Biopsy*		Must be received during normal
	dampened in saline.	working hours unless
	Do <u>not</u> fix in formalin.	previously arranged.
	Hand deliver immediately.	
	See Section 3.6.10 for	
	requirements from external	
N. D.	centres.	
Nerve Biopsy		Must be received during normal
	dampened in saline.	working hours unless
	Do <u>not</u> fix in formalin.	previously arranged.
	Hand deliver immediately.	
	See Section 3.6.10 for	
	requirements from external	
	centres.	
Hippocampus &	Send fresh. Hand deliver	
Amygdala	immediately to the	
	laboratory.	
Temporal Lobe	Send fresh. Hand deliver	
(Epilepsy)	immediately to the	
	laboratory.	
Temporal Artery	Send in 10% Neutral	Send Immediately/ASAP
	Buffered Formalin.	, i
Laminectomy/Disc	Send in 10% Neutral	
	Buffered Formalin.	
Tumour fluid for	Hand delivery immediately.	Must be received during normal
cytology		working hours.
CSF for cytology	Hand delivery immediately.	Must be received during normal
		working hours.
CSF for RT-QuIC	CSF frozen at -70°C within	Must be received during normal
Analysis	30 minutes of aspiration and	
	transported to the	previously arranged.
	_	CJD Questionnaire must
		accompany specimen.
	ice.	accompany specimen.
	μου.	

Tissue Type	Means of Delivery to	Comment
	Neuropathology	
Autopsy & Biopsy	Hand delivery immediately.	Must be received during normal
tissue (e.g/ Brain /		working hours. Contact Rachel
Tonsil) for Prion		Howley 017977766
Protein Analysis		
All other tissue	Sent in 10% neutral	Must be received during normal
	buffered formalin indicating	working hours.
	volume.	

^{*} Specimens referred out from Beaumont Hospital - the results of these tests are not covered by the scope of Beaumont Hospital Histopathology Department ISO15189 accreditation.

#### REQUIREMENTS FOR EXTERNAL CENTRES

The responsibility for sending specimens lies with the external centre (Sender). Specimens must be pre-booked with the Neuropathology department (Tel. 8092633) in advance to enable the department to make arrangements should the sample arrive after hours. Ensure that packaging and transportation comply with current UN legislation.

Address the package to:

Neuropathology,

Beaumont Hospital,

Dublin 9

Include the Consignee address and telephone number. Record that the sample is an 'Urgent sample for Neuropathology'.

Confirm by contacting the Neuropathology department when the sample has been collected.

# **RESULTS**

<u>Muscle Biopsies:</u> Laboratory tests on muscle biopsies are performed on a weekly basis due to the complexity of the techniques involved. Results are generally available in the Neuropathology office on the Friday or Monday following receipt of the sample. Approximate turnaround time of 10 days

<u>CSF Samples for RT-QuIC Analysis</u>: There is an approximate turn around of 10-15 days from receipt of the sample to results.

Nerve Biopsies: Results are available 10 days weeks from specimen receipt.

# REQUIREMENTS / FACTORS AFFECTING MUSCLE BIOPSIES

# Requirements

All investigations are performed on unfixed frozen tissue. Samples must be delivered to the lab on gauze that is barely dampened with saline as excess causes swelling and separation of fibres. This makes interpretation difficult. A muscle having grade 3/5 on MRC strength scale is best. A fatty muscle ('end-stage' biopsy) may have insufficient fibres for diagnosis.

The department must be informed in advance if a sample is being delivered after hours. Ensure a requisition form is properly completed to include clinical details

### Specimen Size

An open biopsy is preferable to a needle biopsy especially if mitochondrial DNA (mtDNA) and protein analysis be required. A biopsy of at least 1.5 x 1x 1cm is ideal. This allows extra samples to be banked in case it is necessary to forward any to an external centre for further studies. Biopsies less than 0.5cu cm are insufficient for this purpose.

#### **CSF Samples for RT-QuIC Analysis**

#### Requirements

The sample should be sent to the Neuropathology lab immediately after aspiration for freezing as sub optimal sample storage may give unpredictable results. Alternatively the CSF sample must be frozen at -70°C within 30 minutes of aspiration and transported to the Neuropathology Dept, Beaumont Hospital on dry ice. All samples must be logged in with the Neuropathology Lab prior to sending. All samples must accompany a completed questionnaire (LF-NCJD-CSF Questions), copies of which are available from the Neuropathology Laboratory (Ext. 2633) or are available for download from www.cjd.ie.

The sample volume should be between 1-2mls and be clear and colourless (not blood stained) with a white cell count of <10x10^6/L and have a total protein concentration of <1 g/L1. Red blood cells (>1250 x 10^6/L) inhibit the RT-QuIC response resulting in false negatives. High CSF total protein concentrations of >1.0 g/L and raised white blood cell counts can result in false positives.

# **Safety Precautions**

CSF is considered to be a low risk sample for all types of Prion Disease. Take appropriate precautions when sampling..[see <a href="https://www.cjd.ie">www.cjd.ie</a>]

In the event of accidental leakage of the sample please contact the Neuropathology laboratory. There is no immediate hazard to health unless the sample is ingested or injected into the body. Disposable gloves must be worn before attempting to handle the material.

#### 3.6.13.1 Test Request Forms

Test request forms are available to download via the Beaumont Hospital Histopathology department website at <a href="http://www.beaumont.ie/index.jsp?p=105&n=349">http://www.beaumont.ie/index.jsp?p=105&n=349</a> or by contacting the laboratory.

## 3.6.13.2 Delivery of Specimens for Analysis

Courier Services Specimens can be delivered via courier directly to the Department of Histopathology.

#### 3.6.13.3 Oral Requests/Additional Requests

Requests for additional tests are made by the Consultant Histopathologists. Molecular testing (PDL1 and DDISH) is currently being performed by Poundbury Cancer Institute (PCI). Oral/Additional requests to the lab for these tests must be requested by email to the laboratory. The request form is available on the poundbury institute. The request form must be completed by the requesting clinician, scanned and emailed to the histology office on <a href="mailto:histology">histo@beaumont.ie</a> where send out of material to PCI will be arranged. Specimens submitted for Histology are retained in the department for 6 weeks and Cytology for 4 weeks. In addition, blocks and slides are retained indefinitely on all specimens processed. Contact the laboratory/Histology office for advice regarding additional examinations required.

#### **3.6.13.4 Test Results**

Despite our best efforts, it is possible that an error can occur. If you have concerns about a report please draw it to our attention without delay, and we will investigate immediately.

# 3.6.13.5 Specimen Referral

When we are unable to provide a request or required follow-on analysis, we will attempt to source a referral laboratory, to which specimens may be sent. We welcome input from interested clinicians in this process. The choice of laboratory is primarily based on quality grounds, with accredited laboratories being chosen preferentially. Other factors such as cost and turnaround times are also considered.

# 3.6.13.6 Details Required for All Specimens

Regardless of the specimen type, the minimum essential information and minimum criteria that must be supplied <u>legibly</u> include:

# On the specimen block/slide:

Histopathology block number

#### On the <u>request form</u>

- Name of patient
- Date of Birth
- Requesting Clinician/Pathologist
- Referring Hospital
- Relevant clinical details
- Specimen type

**Note:** Please send the pathology report relating to the sample to be tested and give *as much clinical information on the form / letter* as possible, as this will be required by the Pathologist when considering interpretations and advice. Specimens will not be accepted without a minimum of three forms of identification on the request form and will be returned to the source of origin to be completed / labelled correctly.

All hazard labels where appropriate must be used for the health and safety of the staff that will be handling the specimen. Turnaround Times for Results (TATs)

The turnaround time of specimens will vary depending on the nature of the specimen and the complexity of the investigations required. The following is an outline of estimated turn around times for different specimen types from time of receipt in the laboratory:

Histopathology IHC or ISH	5-10 days
HER2 IHC testing	10-15 days
Histopathology (referred to external institute)	20 days

#### **Notes**

- TATs refer to working days from receipt of specimen until report has been authorised. Time refers to 95% of referrals.
- Any request forms requesting a phoned report will be phoned to the Clinician or his/her Secretary.
- There is no time limit for requesting additional examinations but requests should be made by contacting the laboratory or the Pathologist dealing with the case.
- Urgent specimens will be "fast tracked". From receipt of specimen to interim report status can be performed in two days.

# 3.6.13.7 Reports

Reports are not available through the laboratory.

- Reports are sent to the Clinical Consultant or GP.
- Authorised Reports are sent to the clinician and additional requests for reports are sent via the Fortimail email encryption System. Please contact the

Histology admin office if you wish to receive reports by an alternative means or email histo@beaumont.ie

• Reports are available by phoning the Histology Office at (01) 8092632/2636/2678/2154/3919.

Neuropathology reports are available by phoning the Neuropathology results office at (01) 8092636/8092672

Renal pathology reports are available by phoning the Rena pathology results office at (01) 8092008.

- Only authorised reports are available through the office/PIPE
- If an interim report, clinical advice or result interpretation is required please contact the Consultant Histopathologist

Release of Information – As a participant of the NHQI programme Data Sharing Agreements are in line with the policy outlined in the NSQI Information Governance Policy (.https://www.healthatlasireland.ie). Only aggregate data will be shared by the NSQI Programmes. Aggregate data are anonymous and provide an overall summary of the findings from individual sites in relation to the different KQIs and targets.

#### 3.6.14 Autopsy Services (Post Mortems)

The Histopathology and Neuropathology Department provide an autopsy service. Autopsies may be performed at the request of the clinical staff responsible for the care of the patient or under the direction of the Coroner.

•

Written consent from the next of kin on the appropriate post-mortem examination consent form is required for non-Coroner cases (i.e. "Hospital" or "House" consent cases) before an autopsy is performed. This consent is the responsibility of the treating physician (LAB 358B6).

In Coroner's cases, including query CJD cases, the Coroner Autopsy Post Mortem Examination Form (LAB 357B) detailing the nature of the procedure and giving the name and number of a family member must be completed by the treating physician. Consent from the next of kin is not an option as the Coroner may, under the law, order a post mortem in certain situations to establish or clarify the cause of death".

#### 3.7 NHISSOT

#### 3.7.1 How to Order Tests

As per the EFI standard for sample acceptance, all samples received and accepted into the laboratory **must** have the patient's name, date of birth and sample date.

- The Histocompatibility Testing Request and Consent Form **must** have the name, date of birth, requesting clinician/consultant, centre and sample date.
- Samples that do not comply with this EFI standard will be rejected and repeat samples for H&I will be required.

**Note:** It is the responsibility of the requesting clinician to ensure that the patient has read and understood the permission statement on the consent form. This must be initialled by the patient. For more information on the permission statement please contact the laboratory.

**Note**: Patients for HLA antibody screening only (HLA antibodies) must meet the same standards of identification. An HLA antibody Screening request form must be completed and can be emailed to <a href="mailto:crossmatch@beaumont.ie">crossmatch@beaumont.ie</a> or posted with the samples to the H&I Department. This form is checked against the specimens received and the referring dialysis centre is notified if the samples are unsuitable and are rejected. For Beaumont Hosital patients the information is automatically generated on the specimen label by the Beaumont Hospital Information System

Request and Consent forms for HLA typing and HLA antibody screening are available from the H&I department. Please phone or email <a href="mailto:crossmatch@beaumont.ie">crossmatch@beaumont.ie</a> if a request form is required.

Revision 15

# 3.7.2 Repertoire of Tests

Test	Specimen Type	Minimum Volume
HLA typing of patients for solid organ transplants	Sodium Citrate	2.9ml
HLA antibody screening for solid organ transplants	Serum Clotted	Paeds: 3ml Adult: 5ml
<ul> <li>Pre transplant [3 monthly when on waiting list]</li> <li>Post Transplant [As per schedule]</li> <li>Urgent Request for suspected antibody mediated rejection [AMR]</li> </ul>		
Autocrossmatch [Only upon request from Laboratory]	Serum Clotted Sodium Citrate	5ml 40ml
ABO blood grouping [carried out by Beaumont Blood Transfusion Laboratory]	EDTA Blood	5ml
Potential Living Donor Assessment:		
These tests are only available via Beaumont Hospital Transplant Co-Ordinators		
transplantcoordina@beaumont.ie		

## 3.7.3 HLA Typing of Patients for Solid Organ Transplantation

Human Leucocyte Antigen (HLA) type is defined by the presence of different HLA antigens on the cell surface. These antigens enable the immune system to recognise foreign organisms and destroy them.

In solid organ transplantation the major HLA antigens involved are HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP.

Mismatches between donor and recipient HLA type are a major stimulus of the development of donor specific HLA antibodies leading to rejection of the transplanted organ.

Potential recipients are HLA typed by serology and low to medium resolution molecular techniques. These techniques use commercial sera and probes and primer sets selected according to the EFI standards for HLA typing.

**Note**: Specimens received for HLA typing have DNA isolated and stored, serum stored and a sample sent for blood grouping. When instructed by the Transplant Co-Ordinator, HLA typing and antibody screening will be carried out. A NHISSOT patient report will be issued prior to the patient's appointment at the renal and pancreas transplant clinics.

## Samples and tests required prior to a Renal Transplant Clinic appointment

- 1x 2.9ml Sodium Citrate citrated [HLA typing]
- 1x 5ml Serum Clotted sample [HLA Antibody Screening]
- 1x 5ml EDTA sample [ABO Blood Grouping]

Histocompatibility Testing Request and Consent Form [H&I-Form-509]

# MOLECULAR (DNA) TYPING

Patient's DNA is isolated from citrated blood and typed by molecular techniques:

- 1. PCR-SSP (sequence specific primers) these SSP primers consist of allele and group specific primers that are designed to anneal to specific sequences characteristic of a given allele or group of alleles. Amplified products of DNA are visualised by gel electrophoresis.
- 2. PCR-SSO (sequence specific oligonucleotides) After PCR amplification the amplicons are denatured to form single stranded DNA which are added to a microsphere or chip containing specific SSO probes. The amplicons then hybridise to those probes that contain a complementary target sequence. Assignment of a HLA type is based on the reaction patterns associated with published HLA gene sequences.

Revision 15

**Note:** Luminex® technology for SSO typing allows for multiplex, high throughput testing. This method is therefore particularly suited for the routine HLA typing of multiple DNA samples. SSO typing is not usually done outside of routine hours but it is a backup method if required for donors on call.

**Note:** DNA samples may be sent to the National Histocompatibility and Immunogenetics Reference Laboratory (NHIRL) for high resolution or sequencing for confirmation of rare HLA types.

**Note:** Patients are HLA typed on two separate samples taken on two different occasions.

## 3.7.4 Antibody Screening

Antibodies to HLA antigens can develop through pregnancy, transfusion, previous solid organ transplant or cardiac mechanical assist device placement. These antibodies can potentially react with a transplant organ causing graft rejection. All patients for solid organ transplantation are tested for HLA antibodies and these are recorded in the H&I database.

#### 3.7.4.1 ScreeningTests

#### **Luminex Single Antigen**

Microbeads coated with purified HLA antigens are used to detect HLA antibodies. The Luminex flow analyser detects the fluorescent emission from the beads and the amount of fluorescence can help to estimate the amount of antibody present.

# 3.7.4.2 Antibody Analysis and Identification

The antibody screening results are analysed and any HLA antibody identified is recorded in the patient's antibody profile as an unacceptable antigen. Therefore, if a donor is identified and a recipient list is generated, any potential recipient with an antibody to the potential donors's HLA antigens are excuded. This significantly reduces the liklihood of a positive crossmatch.

# 3.7.4.3 Pgen

## PGEN - GENERATED OR CALCULATED PRA

Using the H&I database of donor HLA types, we can calculate how many donors are unsuitable due to the presence of HLA antibody. This is referred to as generated PRA - Pgen. The Pgen value can be used as an indicator of how difficult it is to find a compatible graft.

# **Pgen example:**

HLA-A2 is present in approx 25% of Irish donor population. If a recipient has an antibody to HLA-A2, the Pgen is calculated at 25%. This tells us that 25% of donors in the Irish population are unsuitable for this recipient. The more antibodies the patient has, the higher the Pgen.

## 3.7.4.4 Specimen Requirements for Antibody Screening

# Renal/pancreatic patients who are active on the transplant waiting list:

- HLA antibody screening sample (clotted sample) every 90 days
- CAPD and pre-emptive patients can have the samples taken by their local GP and posted to the department -see section 3 for transport requirements
- Following a transfusion (blood products or platelets) a clotted sample is required 14 days post transfusion or as soon as possible thereafter. It is **vital** we receive these samples to monitor a patient for donor specific HLA antibodies.

Note: Routine 3 monthly samples are essential for screening and crossmatching patients on the waiting list. If we do not have a sample less than 90 days old, the patient will not be listed for transplant.

## Renal/pancreatic patients who are not yet on the transplant waiting list:

• All patients transfused (blood products or platelets) require a clotted sample 14 days post transfusion or as soon as possible thereafter. It is **vital** we receive these samples

## **Cardiothoracic patients**

- Patients identified as positive for HLA antibody Sample every month
- Patients with no identified HLA antibody Sample every 3 months

Due to time constraints in cardiothoracic transplants the following schedule applies to ensure that a sample within an acceptable time frame is available for crossmatch:

• Following a blood transfusion (blood products or platelets), we require a sample at week 2, 3 and 4

Cardiothoracic patients with cardiac mechanical assist device placement – Samples required every month unless otherwise notified.

# 3.7.5 Solid Organ Transplant Pools Work-Up

#### 3.7.5.1 Renal/Pancreatic Patients

If a patient is approved for the transplant waiting list at the transplant clinic by the Consultant Transplant Surgeon, the Transplant Co-ordinator will contact the laboratory by email to confirm patient's approval for activation. The patient will appear on the monthly transplant waiting list as 'NHISSOT workup'.

A Patient is 'activated' on the transplant list when all the documentation and immunological work is completed.

A letter is then issued from the H&I Department to the patient, their Consultant Nephrologist and Transplant Co-ordinator to confirm activation on the transplant list.

#### 3.7.5.2 Cardiothoracic Patients

On receipt of a request by email from the Cardiothoracic Transplant Co-ordinator, the patient is HLA typed and tested for HLA antibodies. The report issued will indicate if the patient will need a prospective crossmatch when listed for transplant.

Note: Additional samples are required on patients listed for lung transplant for auto crossmatch. These bloods will be requested by the Cardiothoracic Transplant Co-ordinators when the patient has been approved for the active lung transplant waiting list

#### 3.7.5.3 LIVER PATIENTS

On receipt of a request by email from the Liver Transplant Co-ordinator, a patient is HLA-B typed and ABO blood grouped. A Confirmatory HLA-B type is performed following transplantation.

# 3.7.6 Deceased Donor Work-up and Potential Recipient List Generation

The ODTI Transplant Co-ordinator (Organ Donation and Transplant Ireland) contacts the H&I Department when apotential donor is identified. Donor bloods are sent to the laboratory.

## On receipt

- Potential donor is HLA typed
- ABO blood group requested
- Match programme to identify suitable recipients is generated
- Potential recipient list is complied according to agreed criteria and contains information on the following:
- Priority Patients/Paediatric Patients/Acceptable Mismatched Patients
- Significantly Sensitised Patients (Highly Sensitised) PGen  $\geq 50$
- Favourable Match / Reasonable Match Patients

- Longest Waiting Patients
- HLA incompatiable patients (HLAi)
- Simultaneaous Pancreas and Kidney (SPK) Patients
- The list of immunological suitable recipients is sent to the Consultant Transplant Surgeon and the Renal Transplant Co-ordinator.

#### 3.7.7 Matchability Scores

A database of HLA types of previous deceased donors from the Irish population is used to calculate the chance of a patient getting a good match from our donor population.

This data is expressed as a percentage of the population and is made available to the referring clinicians on the monthly transplant waiting lists.

The ODT (Organisation for donation and transplantation in the UK)) define a favourable match as:

- 000, 100, 200, 010, 110, 210 (HLA -A, -B, -DR) Figures represent donor mismatched antigens
- These grafts show a definite survival advantage in most large studies. Additionally, for patients likely to require a further transplant the degree of sensitisation following a well matched graft is usually less than that following a poorly matched graft.

#### **DEFINING MATCHABILITY**

For patients of blood groups A and O:

Score	Reported
5% or under	Low
5.1-7.9%	Medium
8% and over	High

# 3.7.8 Living Donor Work-Up

# 3.7.8.1 What is living donation?

Living donation is where a living person donates an organ (or part of an organ) for transplantation to another person. Living Donation is only considered after thorough evaluation when the donor is healthy, where the loss of the organ or part of an organ is not deemed to place their longterm health at undue risk, and where the donor understands the process and freely consents to donation.

The following forms must accompany potential donor samples for work-up:

- HLA Request form for 1st Living Donor Workup
- Activation Request form for Living Donor Workup

Samples should be forwarded to the H&I Department, either directly from the transplant co-ordinator, or by post if from abroad. Only 2 potential donors per recipient will be processed by the laboratory at any one time. If either is deemed unsuitable, two further potential donors can be evaluated once a signed activation form has been received.

#### 3.7.8.2 What makes a Living Donor Suitable?

#### • Compatible blood group

The living donor and recipient blood groups should be compatible.

#### • Compatible HLA type

HLA antigens are inherited therefore blood relatives are more likely to have similar HLA type. A brother and sister have a one in four chance of having an identical type.

Those genetically unrelated can also be assessed for living donation. Any potential living donor is HLA typed to ensure that their HLA type is compatible with the potential recipient

HLA antigens assessed for matching are HLA-A, -B, -C, -DR, -DQ, -DP.

## • Compatible Antibody Profile

A potential living donor can be eliminated at the first stage of living donor workup, if the potential recipient has an antibody to the donor's HLA antigens. This antibody can pose a risk to the graft.

## 3.7.8.3 Summary of stages for Living Donor work-up

Note: Families who wish to donate **must** initially contact the Transplant Coordinators. Any samples received into the laboratory **will not be processed** without prior contact with the Transplant Co-ordinators.

**Note:** Samples required are listed in the repertoire of tests.

## <u>First living donor work-up – virtual crossmatch</u>

- Potential donor HLA type and blood group
- Risk assessment issued

#### **Second living donor work-up**

#### 2a Workup – virtual crossmatch

- Confirmatory HLA type and blood group
- Risk assessment issued

#### 2b Workup - 'wet' crossmatch

- Confirmatory HLA type and blood group
- Crossmatch using the potential donor cells and recipient sera
- Autocrossmatch of the potential recipient
- Risk assessment issued

# Final living donor work-up

- This final stage of the work-up takes place no more than one week pretransplant
- 'Wet' crossmatch
- Risk assessment issued

#### 3.7.8.4 Risk Assesment

Using antibody screening data, sensitisation history and crossmatch results the immunological risk for a donor/recipient pair is assigned by the Consultant Immunologist

#### 3.7.8.5 Reporting

Reports for the first and second work-up are issued to the Transplant Co-ordinator. The final work-up report is sent to the Consultant Surgeon and Transplant Co-ordinator.

Note: Results cannot be transmitted directly to the potential recipient's Nephrologist or dialysis centre.

## 3.7.9 Crossmatching for Solid Organ Transplantation

Transplanting an organ into a patient who has circulating antibodies to donor HLA antigens could result in hyperacute rejection and immediate organ loss.

The crossmatch prior to transplantation will detect any donor specific antibodies and thus prevent hyperacute rejection, greatly reduce acute rejection and the risk of graft loss.

A positive crossmatch is not necessarily a bar to transplant. A patient's sensitisation history and antibody screening profile is also taken into account for the risk assessment.

The crossmatch uses a selection of both current and historic sera:

- Detection of historic antibody can be an indication of prior sensitisation (exposure) of the patient to donor antigen and the presence of memory T and B cells. This can lead to a rapid immunological response if challenged with the same antigen.
- Detection of current antibody, if directed against HLA antigens present on the graft, can cause hyperacute rejection of the organ, or an acute rejection.
- A day of transplant (DoTX) sample is required for crossmatch where a patient has had a recent sensitising event, graft in situ, failed graft within 12 months or borderline donor specific reactivity against donor HLA antigen.

#### **Please note:**

• It must be stressed that all crossmatch interpretation should be done in consultation with the H&I staff and the Consultant Immunologist or designated Senior Medical Scientist

#### 3.7.9.1 Crossmatch tests

The crossmatch techniques used in the laboratory are flow cytometry and complement dependent cytotoxicity (CDC). They can detect both HLA class I and class II donor specific antibodies.

#### 3.7.9.2 Virtual crossmatching

In limited circumstances a patient may be suitable for transplant without a prospective crossmatch due to theatre time constraints.

Renal and Cardiothoracic patients who fulfil <u>certain</u> criteria are suitable for consideration for virtual crossmatch in discussion with the transplant team.

**Note:** If the patient has had transfusion/pregnancies or has a failing transplant they may not be suitable for a virtual crossmatch.

All patients transplanted using virtual crossmatching require a flow crossmatch retrospectively in accordance with EFI standards

#### 3.7.9.3 Autocrossmatch

This assay involves a crossmatch of the recipient's lymphocytes with autologous (own) serum. This can identify auto-reactive antibodies.

Knowledge of the presence and type of autoantibody can be helpful in interpreting positive crossmatches.

- Samples for autocrossmatches should reach the laboratory within 24 hours
- Please contact the H&I department to book in the samples for autocrossmatch

## 3.7.10 Post Transplant Monitoring

Antibody testing post transplant can detect the presence of donor specific antibodies (DSA) that may develop clinical and sub-clinical. Screening for DSA post transplant and early intervention could prevent graft rejection and improve graft outcomes.

# 3.7.10.1 Graft Rejection

Transplant rejection occurs when a transplanted organ is rejected by the recipient's immune system, which destroys the transplanted tissue.

Rejection of solid organ grafts is conventionally classified as hyperacute, acute and chronic.

 Hyperacute rejection causes rapid activation of complement, platelet aggregation, thrombosis and ischaemic necrosis. It is mediated by preformed antibodies that react with many different antigens expressed on the transplanted organ. The result of hyperacute rejection is rapid destruction of the transplanted organ which must be removed immediately to prevent a severe inflammatory response.

- Acute rejection usually occurs early following transplantation (typically within 4 weeks). It is a classical cell-mediated immune response involving presentation of foreign antigens to T cells by antigen presenting cells, proliferation and activation of T cell clones and destruction of the graft by cytoxic T cells.
- Chronic rejection occurs later (typically months or years after transplantation). It leads to a gradual deterioration of renal function with biopsy appearances of fibrous intimal thickening, interstitial fibrosis and tubular atrophy. The most consistent predisposing factor is that of previous episodes of acute rejection.

#### 3.7.10.2 Renal/Pancreatic Patients

#### **Specimen Requirements**

- Clotted sample weekly for the first month.
- Clotted sample monthly for the next two months.
- Clotted sample should then be sent at 6, 9 and 12 months post transplant.
- Clotted sample should then be sent on each subsequent anniversary of the transplant.
- Clotted sample should be sent when clinically indicated at biopsy, when there are concerns regarding graft function or a change to the immunosuppressive regimen.

**Note:** Samples are tested according to their post transplant testing schedule and a post transplant report sent to the requesting Clinican.

**Note:** Please email <u>posttransplant@beaumont.ie</u> or phone the H&I department when screening is clinically indicated. Please include any clinical indicators such as creatinine levels and a contact number for urgent results. If antibody mediated rejection is suspected, this should be discussed with a Senior Medical Scientist who will contact the Consultant Immunologist with patient clinical details.

#### 3.7.10.3 Cardiothoracic Patients

- Clotted sample weekly for the first month.
- Clotted sample monthly for the next two months.
- Clotted sample should then be sent at 6, 9 and 12 months post transplant.
- Clotted sample should then be sent on each subsequent anniversary of the transplant.
- Clotted sample should be sent when clinically indicated at biopsy, when there are concerns regarding graft function or a change to the immunosuppressive regimen.

**Note:** Samples are tested according to their post transplant testing schedule and a post transplant report sent to the requesting Clinican.

#### 3.7.10.4 Liver Patients

Graft versus Host Disease (GvHD) can pose significant risks to liver transplant patients. If GVHD is suspected, please contact the department with clinical details by phone or email posttransplantlab@beaumont.ie.

## 3.7.11 HLA Typing for Partners of Recipients

During pregnancy or birth the baby's cells can cross the placenta and expose the mother to paternal's HLA antigens.

Occasionally this can induce an immune response and the mother can subsequently develop HLA antibodies. These only become clinically relevant if the mother requires a transplant.

Paternal HLA typing is helpful to identify the antigens the mother may have been exposed to. This can aid antibody identification and help to build up an antibody profile on a patient.

#### 3.7.12 ABO blood group typing

Beaumont Hospital Blood Transfusion Department carries out all donor and recipient blood grouping on request.

## 3.7.13 Out of Hours services (On-Call)

The H&I department provides an out-of-hours service for solid organ transplantation.

The services available are:

- HLA typing and crossmatching all potential donors for solid organ transplantation.
- Urgent antibody screening for cardiothoracic patients.
- Urgent antibody screening for post transplant rejection episodes.

#### Note:

- All requests for urgent antibody screening **out of hours must be** done in consultation with the Medical Scientist on-call
- For clinical advice **out-of-hours**, the Consultant Immunologist on-call can be contacted through the switch board.

During normal working hours urgent requests must be discussed with a Senior Medical Scientist or e-mailed to one of following e-mail addresses:

- posttransplant@beaumont.ie
- <u>transplantlab@beaumont.ie</u>

#### 3.7.14 Data Protection Act and freedom of information

The H&I computer database is used to maintain patient data. A back-up paper copy is also retained. All data is stored in compliance with General Data Protection Regulation. .

Data can include the following:

- Name.
- Hospital chart numbers.
- Date of birth.
- Address.
- Phone number(s).
- Email address.
- Dates of dialysis.
- Type of dialysis.
- Dates of transfusions/transplants.
- Dates of sera samples received.
- Antibody screening information and results.
- HLA type.
- Molecular DNA typing information.
- Blood group.
- Number of pregnancies.
- Related donor information, where patients have been transplanted.
- Related family information, where a family study has been performed.Partner's HLA type where applicable.

# 3.7.15 Reports Issued/Expected Turn Around Times (TAT)

The following table lists the turn-around-times for H&I reports

TESTS	TURN AROUND TIMES
HLA typing for Solid Organ Transplant	3 weeks – <i>Urgent service available</i>
HLA Antibody Screening	2-4 weeks – <i>Urgent service available</i>
HLA Antibody Screening HLA typing	Same day service if requested
requests for emergency transplantation	
NHISSOT Patient report for the	4 weeks from request to issuing a
transplant clinic	report
Transplant pool work-up	2-6 weeks
Deceased donor work-up	6 hours
Potential donor recipient list	8 hours
Crossmatching for renal transplants	6 hours
Crossmatching for	6.5 hours for processing a single donor
pancreatic/cardiothoracic transplants.	with a standard workup of a maximum

TESTS	TURN AROUND TIMES
Time taken from receipt of bloods in	4 names. This time may change due to
H&I laboratory and potential names for	additional names or for technical
crossmatch given to the on-call scientist	issues. Users will be informed
Living donor work-up	1 st work-up 4 weeks
	2 nd work-up 3 weeks
	Final work-up 48 hours
Autocrossmatch	2-3 days
Post Transplant Monitoring	2 weeks.
Non Urgent.	
If contacted by the referring clinician for	
a more timely report the sample can be	
set on the next screen.	
Further testing/ typing	3 weeks
Post Transplant monitoring - Urgent	Same day service available if
antibody screening request for possible	magnined otherwise the semple is set
mine surjections and restrict bessies.	required, otherwise the sample is set
graft rejection	on the next screen.
	<u> </u>
graft rejection	<u> </u>
graft rejection  Requires discussion with Antibody	<u> </u>
graft rejection  Requires discussion with Antibody  Screening Senior. The level of urgency	<u> </u>
graft rejection Requires discussion with Antibody Screening Senior. The level of urgency must be stated by the referring clinician.	on the next screen.
graft rejection  Requires discussion with Antibody  Screening Senior. The level of urgency  must be stated by the referring clinician.  HLA typing for disease association	on the next screen.  4 weeks
graft rejection  Requires discussion with Antibody  Screening Senior. The level of urgency  must be stated by the referring clinician.  HLA typing for disease association	on the next screen.  4 weeks  2 weeks (unless awaiting further
graft rejection  Requires discussion with Antibody  Screening Senior. The level of urgency must be stated by the referring clinician.  HLA typing for disease association  HLA typing for BMT/HSCT	on the next screen.  4 weeks  2 weeks (unless awaiting further potential donors from overseas)

# 3.7.16 Abbreviations on H&I Reports and Printouts

#### **DIALYSIS CENTRES**

- AM Antrim Area Hospital
- BE Beacon Clinic Sandyford, Dublin
- BD Beacon Clinic Drogheda, Dublin
- BT Beacon Clinic Tallaght, Dublin
- BF Belfast City Hospital
- BH Beaumont Hospital, Dublin
- CA Cavan General Hospital
- CB Mayo General Hospital, Castlebar
- CO Cork University Hospital
- CR Our Lady's Hospital for Sick Children, Crumlin, Dublin
- EU Patients dialysing in hospitals overseas within the EU
- FR Fresensius Limerick
- GA Galway University Hospital
- GW Wellstone Clinic, Galway

Document Number: LP-GEN-0014

JA St. James's Hospital, DublinKK Wellstone Clinic, KilkennyLE Letterkenny General HospitalLI Limerick University Hospital

MA Mater Misericordiae University Hospital, Dublin

MK Merlin Park Hospital, Galway MW Midlands Wellstone Clinic NC Northern Cross Clinic, Dublin NE Daisy Hill Hospital, Newry OM Omagh General Hospital SL Sligo General Hospital

SV St. Vincent's University Hospital, Dublin TA Tallaght Hospital (AMNCH), Dublin

TE Children's University Hospital, Temple Street, Dublin

TR University Hospital KerryTU Tullamore General HospitalWA University Hospital Waterford

WW Wexford Wellstone

#### 3.7.17 RENAL/PANCREATIC TRANSPLANT POOL PRINTOUT

#### **ABBREVIATIONS**

Age Age in years
Blood Group
BMI Body Mass Index
Compno H&I computer number

Cyto Due Date Date a sample for antibody screening is required

Days Sample Number of days sample is due. Minus number indicates the

number of days the sample is outstanding.

Dial Cen Dialysis centre

Dial Dialysis type: P = CAPD/CCPD

H = Haemodialysis

KG Weight in kilos Match % Matchability score

PGen Generated PRA PGen4: calculated on 4 HLA loci

PGen10: calculated on 10 HLA loci

Prev Tx Previous transplant(s): Number is printed

Ref Hosp Referring Hospital

Urgent Highest urgency- ABO compatible kidney
Wait Length of time on transplant pool in months

#### 3.7.17.1 Crossmatch Codes

#### Potential deceased donor offer list

DoTx Day of transplant sample required

Std Standard – sample(s) available in the laboratory and suitable for crossmatch

VXM Suitable for virtual crossmatch